Patent Grant
11338140
The sympathetic nervous system (SNS) is a primarily involuntary bodily control system typically associated with stress responses. Fibers of the SNS innervate tissue in almost every organ system of the human body and can affect characteristics such as pupil diameter, gut motility, and urinary output. Such regulation can have adaptive utility in maintaining homeostasis or in preparing the body for rapid response to environmental factors. Chronic activation of the SNS, however, is a common maladaptive response that can drive the progression of many disease states. Excessive activation of the renal SNS in particular has been identified experimentally and in humans as a likely contributor to the complex pathophysiology of hypertension, states of volume overload (such as heart failure), and progressive renal disease. For example, radiotracer dilution has demonstrated increased renal norepinephrine (NE) spillover rates in patients with essential hypertension.
Cardio-renal sympathetic nerve hyperactivity can be particularly pronounced in patients with heart failure. For example, an exaggerated NE overflow from the heart and kidneys to plasma is often found in these patients. Heightened SNS activation commonly characterizes both chronic and end stage renal disease. In patients with end stage renal disease, NE plasma levels above the median have been demonstrated to be predictive for cardiovascular diseases and several causes of death. This is also true for patients suffering from diabetic or contrast nephropathy. Evidence suggests that sensory afferent signals originating from diseased kidneys are major contributors to initiating and sustaining elevated central sympathetic outflow.
The renal sympathetic nerves arise from T10-L2 and follow the renal artery to the kidney. The sympathetic nerves innervating the kidneys terminate in the blood vessels, the juxtaglomerular apparatus, and the renal tubules. Stimulation of renal efferent nerves results in increased renin release (and subsequent renin-angiotensin-aldosterone system (RAAS) activation) and sodium retention and decreased renal blood flow. These neural regulation components of renal function are considerably stimulated in disease states characterized by heightened sympathetic tone and likely contribute to increased blood pressure in hypertensive patients. The reduction of renal blood flow and glomerular filtration rate as a result of renal sympathetic efferent stimulation is likely a cornerstone of the loss of renal function in cardio-renal syndrome (i.e., renal dysfunction as a progressive complication of chronic heart failure). Pharmacologic strategies to thwart the consequences of renal efferent sympathetic stimulation include centrally acting sympatholytic drugs, beta blockers (intended to reduce renin release), angiotensin converting enzyme inhibitors and receptor blockers (intended to block the action of angiotensin II and aldosterone activation consequent to renin release), and diuretics (intended to counter the renal sympathetic mediated sodium and water retention). These pharmacologic strategies, however, have significant limitations including limited efficacy, compliance issues, side effects, and others.
The present technology is directed to methods, systems, devices, compositions, and kits for monitoring neuromodulation efficacy by detecting changes in the level or activity of one or more target biomarkers, as well as methods, systems, compositions, and kits for determining biomarker activity in a patient. Specific details of several embodiments of the technology are described below with reference to
Several current methods for neuromodulation would benefit from a process for rapid evaluation of success of the procedure. Examples of neuromodulation methods that may benefit from rapid evaluation methods include renal denervation, for example to treat clinical conditions characterized by increased overall and particularly renal sympathetic activity such as hypertension, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic end stage renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome, osteoporosis, and sudden death.
Efficacy of many current renal neuromodulation methods is evaluated after the procedure has been completed by monitoring blood pressure, but statistically meaningful changes in blood pressure may not be observed until about 2 weeks, 4 weeks, 3 months, 6 months, or more after completion. In the absence of real-time or at least relatively contemporaneous feedback (e.g., less than about 30 minutes), physicians may miss nerves (i.e., under ablate) with unconventional nerve anatomy or, alternatively, err on the side of over-ablation.
Disclosed herein are several embodiments of methods and processes for monitoring neuromodulation efficacy by detecting changes in the level or activity of one or more target biomarkers associated with neuromodulation, as well as methods and processes of performing neuromodulation that incorporate monitoring of neuromodulation efficacy based on changes in level or activity of one or more target biomarkers. In contrast with many conventional approaches, the disclosed methods are expected to allow for real-time or relatively contemporaneous monitoring of neuromodulation efficacy. In certain embodiments, these methods and processes are used to monitor the efficacy of renal neuromodulation. Also provided herein are methods of treating hypertension in a subject in need thereof using renal neuromodulation, wherein the methods include steps for monitoring the efficacy of the neuromodulation procedure by detecting changes in the level or activity of one or more target biomarkers associated with neuromodulation. Further provided herein are devices, compositions, and kits for use in conjunction with the disclosed methods.
“Neuromodulation” is the partial or complete incapacitation or effective disruption of one or more nerves. Such incapacitation or disruption can be long term (e.g., permanent or for periods of months or years) or short term (e.g., for periods of minutes, hours, days, or weeks). “Renal neuromodulation” is the partial or complete incapacitation or effective disruption of the nerves of the kidneys, including nerves terminating in the kidneys or in structures closely associated with the kidneys. Renal neuromodulation is expected to efficaciously treat several clinical conditions characterized by increased overall sympathetic activity, and, in particular, conditions associated with central sympathetic overstimulation such as hypertension, heart failure, acute myocardial infarction, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic and end stage renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome, osteoporosis, and sudden death, among others. The reduction of afferent neural signals typically contributes to the systemic reduction of sympathetic tone/drive, and renal neuromodulation is expected to be useful in treating several conditions associated with systemic sympathetic overactivity or hyperactivity.
Several embodiments of methods for monitoring neuromodulation efficacy by detecting changes in the level or activity of one or more target biomarkers in accordance with the present technology are described herein. In certain embodiments, these methods can be used to determine whether a neuromodulation procedure was successful, i.e., whether the procedure resulted in partial or complete incapacitation or effective disruption of one or more target nerves. In certain embodiments, these methods include (a) determining a baseline level or activity of one or more target biomarkers; (b) performing the neuromodulation procedure; (c) determining a post-neuromodulation level or activity for the target biomarker(s); and (d) comparing the post-neuromodulation level or activity to the baseline level or activity, wherein the neuromodulation procedure is classified as successful if the post-neuromodulation level or activity differs significantly from the baseline level or activity. In certain embodiments, a significant difference in level or activity means a difference of 1% or greater, for example 2% or greater, 3% or greater, 4% or greater, 5% or greater, 10% or greater, 20% or greater, or 50% or greater. In other embodiments, a significant difference in level or activity means a difference of 2-fold or greater, for example 3-fold or greater, 4-fold or greater, or 5-fold or greater. In other embodiments, these methods include (a) performing the neuromodulation procedure; (b) determining a post-neuromodulation level or activity for one or more target biomarkers; and (c) comparing the post-neuromodulation level or activity to a pre-determined threshold level or activity, wherein the neuromodulation procedure is classified as successful if the post-neuromodulation level or activity is greater than the pre-determined threshold level or activity. In still other embodiments, these methods include (a) performing the neuromodulation procedure; (b) determining a post-neuromodulation level or activity for one or more target biomarkers; and (c) comparing the post-neuromodulation level or activity to a pre-determined range of level or activity, wherein the neuromodulation procedure is classified as successful if the post-neuromodulation level or activity falls within the pre-determined range of level or activity. In certain embodiments, post-neuromodulation target biomarker level or activity is determined in an acute timeframe, e.g., within 30 minutes or less following denervation, thereby allowing neuromodulation efficacy to be assessed while a subject is still catheterized. In other embodiments, however, post-neuromodulation target biomarker level or activity may be measured in a chronic timeframe, e.g., within several hours, days, weeks, or months following denervation. In certain embodiments, the methods provided herein include (a) determining a baseline level or activity of one or more target biomarkers, (b) at least partially inhibiting sympathetic neural activity in a renal nerve of the subject via a neuromodulation assembly (discussed in more detail below), (c) determining a post-neuromodulation level or activity for the target biomarker(s), and (d) comparing the post-neuromodulation level or activity to the baseline level or activity, wherein the neuromodulation procedure is classified as successful if the post-neuromodulation level or activity differs significantly from the baseline level or activity.
Also described herein are several embodiments of methods for determining biomarker activity in a patient in accordance with the present technology. In certain of these embodiments, these methods include (a) transluminally positioning an energy delivery element of a catheter within a target blood vessel of a patient and adjacent to target neural fibers, (b) at least partially ablating the target neural fibers via the energy delivery element, (c) capturing a plurality of at least one type of biomarker in a capture compartment of the catheter, wherein the biomarker is secreted as a result of the ablation procedure, (d) sequestering the plurality of the at least one type of biomarker in the capture compartment to concentrate the biomarker, (e) binding the biomarker to at least one immobilized capture agent disposed on an inner surface of the capture compartment, and (f) detecting a concentration of the biomarker, wherein the concentration corresponds, at least in part, to a degree of ablation of the target neural fibers.
Target biomarker(s) for use in conjunction with the methods disclosed herein may be any biomolecule that exhibits a quantitative and detectable change in level or activity following neuromodulation in a desired manner. In certain embodiments, target biomarkers may be proteins or fragments thereof. In these embodiments, a change in protein level may refer to a change in expression (as measured by mRNA or protein level) or secretion. In other embodiments, target biomarkers may be small molecules, peptides, or other non-protein compounds. Provided in certain embodiments are compositions and kits comprising one or more target biomarkers for use in the methods disclosed herein.
In those embodiments that utilize protein target biomarkers, the target biomarkers may be one or more proteins implicated in a cell death, apoptosis, metabolic modulation, oxidative stress, or neuro-endothelial cross-talk pathway, or proteins involved in neuromodulation, hormone modulation, neuronal stress response, neuronal regeneration, endothelial vasodilation or vasoconstriction, modulation of efferent and afferent sympathetic activation, or regulation of catecholamine production. Specific classes of proteins that may be utilized as target biomarkers in conjunction with the methods disclosed herein include but are not limited to endothelins, neurotrophins, vasoconstrictive proteins, cell surface receptors, heatshock proteins or modified heatshock proteins, secreted inflammatory cytokines or chemokines, and proteins from the renin-angiotensin system. Protein target biomarkers for use in the present methods may be cell surface proteins, secreted proteins, or intracellular proteins. In certain of these embodiments, the protein can be a cell surface receptor expressed on a vessel wall, a secreted protein that exhibits increased or decreased secretion levels post-ablation, and/or an enzyme that exhibits increased or decreased activity post-ablation (see, e.g.,
In those embodiments that utilize non-protein target biomarkers, the target biomarkers may be small molecules such as catecholamines or other neurotransmitters (particularly those associated with sympathetic nervous activity) such as NE, neuropeptide Y (NPY) epinephrine, or dopamine, secreted hormonal or other soluble endocrine molecules, or secreted metabolites or cellular debris.
In certain embodiments of the methods disclosed herein, a change in target biomarker level or activity occurs at or near a neuromodulation site (e.g., at or near an ablation site). In these embodiments, the change can be measured at or near the neuromodulation site or in a biological sample obtained from at or near the neuromodulation site. For example, where neuromodulation is carried out at or near the kidney (e.g., in the renal artery), changes in target biomarker level or activity may be measured in a biological sample obtained from at or near the kidney. A “biological sample” as used herein may refer to any bodily fluid (e.g., blood, plasma, urine, etc.) or tissue that may contain one or more target biomarkers. Therefore, a biological sample obtained from at or near the kidney may be blood or tissue from the renal arteries, renal veins, or elsewhere in the renal system. A target biomarker associated with renal neuromodulation may exhibit changes in expression or activity at any or all of these locations. Alternatively or in addition to locally measurable changes in level or activity, in certain embodiments the target biomarkers may exhibit changes in level or activity at locations remote to the neuromodulation site. In these embodiments, target biomarker collection may take place systemically, for example by collecting a blood or urine sample. In certain embodiments, local target biomarker collection may be preferred to systemic collection because it provides a higher concentration of target biomarker and may allow for more rapid or accurate results than systemic collection. In other embodiments, there may be no preference between local and systemic collection, or systemic collection may be preferred, for example due to ease of collection.
Target biomarkers for use in the methods disclosed herein may exhibit a change in level or activity that correlates with nerve ablation and/or NE levels, for example nerve ablation and/or NE levels in the kidney. In certain embodiments, changes in the level or activity of a target biomarker may be a direct result of neuromodulation, e.g., a direct response to neuronal damage. In certain of these embodiments, the target biomarker may exhibit changes in activity or level as a result of vascular-neuronal cross-talk (see, e.g.,
In certain embodiments of the methods disclosed herein, neuromodulation efficacy is monitored by detecting changes in the level or activity of a single target biomarker. In other embodiments, efficacy is monitored by detecting changes in the level or activity of two or more target biomarkers. In certain of these embodiments, neuromodulation is classified as successful if each of the target biomarkers exhibits a change in level or activity. In other embodiments, neuromodulation is classified as successful if a threshold number or a specific subset or combination of target biomarkers exhibits a change in level or activity. In those embodiments that utilize two or more target biomarkers, the target biomarkers may be all proteins, all non-proteins, or a combination of proteins and non-proteins.
In certain embodiments of the methods disclosed herein, baseline level or activity of a target biomarker is derived from the subject undergoing neuromodulation. For example, target biomarker level or activity may be measured in the subject at one or more timepoints before neuromodulation. The baseline value may represent target biomarker level or activity at a specific timepoint before neuromodulation, or it may represent an average level or activity at two or more timepoints before neuromodulation. In certain preferred embodiments, a baseline value is based on target biomarker level or activity immediately before neuromodulation (i.e., after the subject has already been catheterized). Alternatively, a baseline value for a particular target biomarker may be derived from a standard value for that target biomarker across the population as a whole or across a particular subpopulation. In certain embodiments, the baseline level or activity of a target biomarker is determined using the same method that is subsequently used to determine the post-neuromodulation level or activity of the target biomarker. In certain embodiments, changes in target biomarker level or activity are calculated based on the difference between baseline level or activity and post-neuromodulation level or activity. For example, the differential (delta) in target biomarker expression levels can be the difference between target biomarker expression at a specific timepoint pre- and post-neuromodulation.
Target biomarkers for use in the methods disclosed herein may exhibit a two-fold or greater change in level or activity in response to neuromodulation. For example, a target biomarker may be a protein that exhibits a two-fold or greater increase or decrease in expression or secretion following neuromodulation. In certain of these embodiments, a target biomarker exhibits a three-fold or greater, five-fold or greater, or ten-fold or greater change in level or activity in response to neuromodulation.
In certain embodiments, target biomarkers for use in the methods disclosed herein exhibit a change in level or activity within a predetermined timeframe post-neuromodulation. In certain embodiments, the methods provided herein allow for real-time or relatively contemporaneous monitoring of neuromodulation efficacy. Accordingly, certain target biomarkers for use in the methods disclosed herein may exhibit a change in level or activity at the time of neuromodulation or relatively contemporaneous to neuromodulation. For example, in certain embodiments a target biomarker exhibits a change in level or activity within 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, or 30 minutes of neuromodulation. Accordingly, in certain embodiments, post-neuromodulation level or activity for a target biomarker is determined during neuromodulation or relatively contemporaneous to neuromodulation, i.e., within 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, or 30 minutes of neuromodulation. In preferred embodiments, post-neuromodulation level or activity for a target biomarker is determined in an acute timeframe, i.e., while the subject is still catheterized and/or under anesthesia. Alternatively or in addition to a change in level or activity at the time of neuromodulation or relatively contemporaneous to neuromodulation, a target biomarker may exhibit a change in level or activity at a later timepoint (e.g., at a chronic timepoint). For example, in certain embodiments a target biomarker exhibits a change in level or activity within 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 7 days, 14 days, one month, two months, four months, or one year of neuromodulation. Accordingly, in certain embodiments, post-neuromodulation level or activity for a target biomarker is determined 2 hours or more after neuromodulation, i.e., within 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 7 days, 14 days, one month, two months, four months, or one year of neuromodulation. In certain embodiments, changes in target biomarker level or activity at these later timepoints can be used to assess or classify a subject's response to neuromodulation. The resultant information can be used to develop predictive models for determining whether neuromodulation is likely to be effective in a particular subject or subpopulation.
The methods disclosed herein may be used to monitor the efficacy of neuromodulation carried out using a variety of suitable techniques. The neuromodulation, for example, may be electrically-induced, thermally-induced, chemically-induced, or induced in another suitable manner or combination of manners at one or more suitable treatment locations during a treatment procedure. For example, neuromodulation may be carried out by delivering monopolar or bipolar radio frequency (RF) energy, microwave energy, laser light or optical energy, magnetic, ultrasound energy (e.g., intravascularly delivered ultrasound, extracorporeal ultrasound, high frequency ultrasound (HIFU)), direct heat energy, and/or cryotherapeutic energy to target tissue at a treatment location to induce one or more desired effects at the treatment location. A treatment location may be a location proximate to one or more nerves being neuromodulated. In some embodiments, the treatment location is in or near a vessel or other body lumen. For example, a treatment location for renal neuromodulation may be at or near the renal artery. In certain embodiments, the identity of the target biomarkers may vary depending on the neuromodulation method being used. For example, neuromodulation using RF energy may result in changes in the level or activity of a different set of target biomarkers than cryotherapy. In other embodiments, a specific target biomarker or set of target biomarkers may be effective for monitoring efficacy across a range of neuromodulation techniques.
In certain embodiments, changes in target biomarker level or activity can be used in the prognosis of co-morbidities that are directly or indirectly benefited by neuromodulation. In other embodiments, changes in target biomarker level or activity can be used to predict a subject's response to neuromodulation.
Determination of baseline and/or post-neuromodulation target biomarker level or activity may be carried out using any previously known method and/or methods disclosed herein. In some embodiments, for example, determination of target biomarker level or activity utilizes a detection method that produces results in an acute timeframe following neuromodulation. Where a target biomarker is a secreted or cell surface biomolecule, determination of target biomarker level or activity may utilize one or more capture or detection agents. Where a target biomarker is an intracellular biomolecule, determination of target biomarker level or activity may utilize imaging/spectroscopy techniques that allow level or activity to be assessed in a non-invasive manner. In other embodiments, the level or activity of an intracellular target biomarker may require tissue sampling.
In certain embodiments, determination of baseline or post-neuromodulation level of a target biomarker may be carried out using one or more capture agents that specifically bind the target biomarker, such as an antibody or an epitope-binding fragment thereof (see, e.g.,
Determination of baseline or post-neuromodulation activity of a target biomarker may be carried out using a detection agent that has a functional interaction with the target biomarker, such as a substrate for the target biomarker or an enzyme or catalytic antibody for which the target biomarker is a substrate (see, e.g.,
Capture or detection agents for use in determining the activity of a target biomarker may be in solution, or they may be immobilized on a surface such as a bead, resin, or one or more surfaces of a neuromodulation or other treatment device, a component thereof, or a separate capture device. Examples of suitable resins include, for example, hydrophobic resins, cation/anion exchange resins (e.g., carboxymethyl, sulfopropyl/diethylamine), immobilized metal affinity chromatography (IMAC) resins, and polar chromatographic resins (e.g., silica gel). In those embodiments that utilize a surface such as a bead or resin, all capture agents on the surface may be specific for a single target biomarker. Alternatively, capture or detection agents for multiple target biomarkers may be present on a single surface, allowing for simultaneous detection and analysis of multiple target biomarkers. In those embodiments wherein capture or detection agents are immobilized on one or more surfaces of a treatment device, a component thereof, or a separate capture device, the capture or detection agents may be on the outside of the device, i.e., in direct contact with arterial blood or the artery wall. In other embodiments, the capture or detection agents may be on an internal surface, such as the interior of a catheter or a capture compartment.
In certain embodiments, binding of a target biomarker to a capture agent and/or interaction of the target biomarker with a detection agent results in a quantifiable signal. This quantifiable signal may be, for example, a colorimetric, fluorescent, heat, energy, or electric signal. In certain embodiments, this signal may be transduced to an external visual output device (see, e.g.,
In certain embodiments, binding of a target biomarker to a capture agent results in a signal that which can be transduced to an external monitoring device. For example, binding of a target biomarker to a capture or detection agent may be detected using a high sensitivity fluorescence technique such as a resonance energy transfer method (e.g., Forster resonance energy transfer, bioluminescence resonance energy transfer, or surface plasmon resonance energy transfer).
In certain embodiments of the methods disclosed herein, determination of baseline and/or post-neuromodulation target biomarker level or activity is carried out using any immunoassay-based method. For example, target biomarker levels may be determined using an electrochemical immunosensor (see, e.g.,
Determination of baseline and/or post-neuromodulation target biomarker level or activity may take place in vivo in some embodiments. For example, the determination may be carried out using the same device that is used to carry out neuromodulation or a component attached to the treatment device. Alternatively, determination of biomarker level or activity may be carried out using a separate device. In certain of these embodiments, the separate device can be delivered to the neuromodulation site via the same catheter used to deliver the treatment device. In other embodiments, however, determination of baseline and/or post-neuromodulation target biomarker level or activity takes place ex vivo.
In some embodiments, the interaction between a target biomarker and a capture or detection agent takes place at or near the neuromodulation site, e.g., near the renal artery. In certain of these embodiments, a target biomarker binds to a capture or detection agent in the bloodstream or at the surface of the arterial wall. In these embodiments, the capture or detection agent may be in solution (i.e., in the bloodstream) or immobilized to a surface that is in contact with the bloodstream and/or arterial wall. For example, a device or component thereof in which a capture or detection agent is integrated may be a balloon coated with one or more detection molecules that inflates to touch the ablated artery wall (see, e.g.,
In other embodiments, however, the interaction between a target biomarker and a capture or detection agent can take place away from the neuromodulation site. For example, target biomarkers may be removed from a neuromodulation site and sequestered in a capture compartment (see, e.g.,
A representative embodiment of a target biomarker detection method and device is set forth in
In certain embodiments, the methods provided herein produce a biofeedback score indicating to a practitioner the likelihood that a neuromodulation procedure was successful. For example, a biofeedback score falling within a certain range indicates that the procedure was likely successful, while a score falling outside this range indicates that the procedure was unsuccessful (see, e.g.,
For example, as disclosed in Example 1 below, a set of candidate protein target biomarkers was screened in vivo to identify proteins exhibiting a change in expression level in renal tissue at various timepoints following ablation. This resulted in the identification of a set of secreted, cell surface, and intracellular protein target biomarkers that showed increased or decreased expression levels at 10 minutes, 24 hours, and 7 days post-ablation.
Examples of secreted protein target biomarkers that were upregulated within 10 minutes of ablation include brain-derived neurotrophic factor (BDNF), calcitonin-related polypeptide beta (CALCB, CGRP), CD40L ligand (CD40L, CD40LG), clusterin (CLU), endothelin-3 (EDN3), interleukin 10 (IL-10), and kalakrein B1 (KLKB1). Examples of cell surface protein target biomarkers that were upregulated within 10 minutes of ablation include selectin E (SELE) and DnaJ (Hsp40) homolog superfamily A member 4 (DNAJA4). Examples of intracellular protein target biomarkers that were upregulated within 10 minutes of ablation include BTG2 family member 2 (BTG2), DNAJA4, DnaJ (Hsp40) homolog superfamily B member 1 (DNAJB1), FBJ murine osteosarcoma viral oncogene homolog (FOS), heat shock 27 kDa protein 1 (HSPB1), heat shock 60 kDa protein 1 (HSPD1), and heat shock 105 kDa/110 kDa protein 1 (HSPH1).
Examples of secreted protein target biomarkers that were upregulated within 24 hours of ablation include bone morphogenetic protein 7 (BMP7), IL-10, tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), and leukemia inhibitor factor (LIF). Examples of cell surface protein target biomarkers that were upregulated within 24 hours of ablation include ATPase/Na/K transporting alpha 1 polypeptide (ATP1A1), endothelin receptor type B (ETB, EDNRB), integrin alpha M (ITGAM, CD11b), solute carrier family 2 (facilitated glucose/fructose transporter) member 5 (SLC2A5/GLUT5), SELE, Toll-like receptor 4 (TLR4), and TNFRSF1B. Examples of surface protein target biomarkers that were downregulated within 24 hours of ablation include melanocortin 2 receptor (MC2R). Examples of intracellular protein target biomarkers that were upregulated within 24 hours of ablation include heme oxygenase (decycling) 1 (HMOX-1), heat shock 70 kDa protein 5 (HSPA5), HSPD1, HSPH1, ATP1A1, and superoxide dismutase 2 (SOD2).
Examples of secreted protein target biomarkers that were upregulated within 7 days of ablation include natriuretic peptide B (BNP), CD40L, CLU, Fas ligand (FASLG), IL-10, TNFRSF1B, and LIF. Examples of secreted protein target biomarkers that were downregulated within 7 days of ablation include neurotrophin 3 (NTF3). Examples of cell surface protein target biomarkers that were upregulated within 7 days of ablation include ATP1A1, EDNRB, ITGAM, purinergic receptor P2Y G-protein coupled 12 (P2RY12), SELE, SLC2A5/GLUT5, Toll-like receptor 3 (TLR3), TLR4, Toll-like receptor 7 (TLR7), and TNFRSF1B. Examples of cell surface protein target biomarkers that were downregulated within 7 days of ablation include adrenergic alpha 2B receptor (ADRA2b). Examples of intracellular protein target biomarkers that were upregulated within 7 days of ablation include CDKN2B (p15), HMOX-1, heat shock 70 kDa protein 14 (HSPA14), ATP1A1, and HSPD1. Examples of intracellular protein target biomarkers that were downregulated within 7 days of ablation include CDKN1B (p27).
As disclosed in Example 2 below, a set of candidate protein target biomarkers was screened in vitro to identify proteins exhibiting a change in expression or secretion level at 1, 5, and 10 minutes after exposure to heat, inflammation, or a combination thereof. This resulted in the identification of a set of protein target biomarkers that showed increased expression or secretion levels at 1, 5, or 10 minutes post-ablation. Examples of protein target biomarkers that exhibited an increase in expression include caspase 10 (CASP10), CCL13 (MCP4), CCND1, CD70, alpha B crystalline (CRYAB), CPS1, DNAJB1, DNAJB11, heat shock 70 kDa protein 1A (HSPA1A), heat shock 70 kDa protein 1B (HSPA1B), heat shock protein B6 (HSPB6), IL-10, KIT, lymphotoxin alpha (LTA), myosin light chain kinase 3 (MYLK3), NODAL, NPY1R, POU1F1, and TCP-1-alpha (TCP1). Examples of protein target biomarkers that exhibited an increase in secretion include actin, cytoplasmic (ACTA2), S100 calcium binding protein A6 (CACY/2A9), cofilin-1 (CFL1), protein cTAGE-2 (CTAG1A1/CTAG21), L-lactate dehydrogenase (LDHA), transmembrane protein 141 (MGC141/TMEM141), N-alpha-acetyltransferase 20 (NAA20/NAT5), nucleoside diphosphate kinase B (NM23B), phytanoyl-CoA deoxygenase, peroxisomal (PAHX/PHYH1), prefoldin subunit 1 (PFDN1), serine/threonine protein kinase (PLK-2), tubulin alpha-1B-chain (TUBA1B), and vimentin (VIM).
As further disclosed in Example 2, a set of candidate protein target biomarkers was screened by treating a set of neuronal cells with heat, inflammation, or a combination thereof, then treating a set of endothelial cells with the neuronal cell secretome, i.e., conditioned media from the heat/inflammation treated neuronal cells. This conditioned media contains neuronal protein and non-protein stress factors that exhibit increased secretion after heat/inflammation treatment. Alternatively, the endothelial cells were treated directly with recombinant factors including neurotropic factor or angiogenic growth factors (e.g., BDNF, FGF5). Examples of protein target biomarkers that exhibited an increase in expression in the second set of cells include synuclein alpha (SNCA), BDNF, ciliary neurotrophic factor (CNTF), fibroblast growth factor 2 (basic) (FGF2), glial cell-derived factor 2 (basic) (GDNF), beta nerve growth factor 2 (NGF2), neurotrophin-3 (NTF3), PF4, EDN2, ACE2, interferon gamma (IFN-γ), artemin (ARTN), LIF, cerebellin 1 precursor (CBLN1), neuregulin 1 (NRG1), neuregulin 2 (NRG2), neuregulin 4 (NRG4), persephin (PSPN), NTF4, and transforming growth factor alpha (TGFA).
As disclosed in Example 3 below, an additional set of protein and non-protein candidate target biomarkers will be screened in vivo to identify potential target biomarkers exhibiting a change in renal arterial or venous blood levels at various timepoints following ablation. As set forth in Example 3, an initial evaluation using this screen was carried out using NE and CFL1. Additional candidate target biomarkers that may be evaluated in this screen include NPY, DBN, Ca2+, renin, dopamine beta-hydroxylase (DBH), angiotensin (AGT), endothelin 1, 2, and 3, neurotensin (NTS), and amyloid beta (A4) precursor protein (APP).
In certain embodiments, the methods disclosed herein utilize one or more of the target biomarkers listed above from the in vivo and in vitro studies to evaluate the efficacy of renal neuromodulation. Provided herein in certain embodiments are compositions comprising capture or detection agents specific to one or more of these target biomarkers, as well as kits, panels, and arrays comprising such capture or detection agents.
The following examples are provided to better illustrate the disclosed technology and are not to be interpreted as limiting the scope of the technology. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the technology. It will be understood that many variations can be made in the procedures herein described while still remaining within the bounds of the present technology. It is the intention of the inventors that such variations are included within the scope of the technology.
Gene expression studies were conducted in renal artery tissue samples from domestic swine to identify candidate target biomarkers that exhibit a change in expression level at various time points after renal denervation/ablation.
Animals were broken into three groups of three animals each: naïve (no treatment), sham (catheterized but not ablated), and treated (subject to ablation at 65° C. and 90 seconds using a spiral ablation catheter device). Left and right renal arteries and surrounding tissue samples were obtained by sampling tissue in the area of ablation at 10 minutes (“day 0”), 7 days, or 24 hours post-treatment. Slices from the center of ablation sites were removed for histopathological analysis, and the ablation sites were cleaned up by removing any non-ablated tissue and pooled. Tissue was maintained during the dissection process using RNALater.
Pooled tissue samples were weighed and mixed under frozen conditions, and then added to round-bottomed tubes containing 2× stainless steel beads (5 mm diameter) at room temperature. 900 μL QIAzol lysis reagent was added to each tube, and the tissue was macerated using the TissueLyser II Adaptor Set with disruption at 30 Hz (3×2 minutes) to release RNA. An additional 300 μL of lysis buffer was added to each tube, and the disruption cycle was repeated (1×2 minutes at 30 Hz). Lysates were transferred to new Eppendorf tubes for mRNA isolation.
120 μl gDNA Eliminator Solution was added to each lysate sample, and tubes were shaken vigorously for 15 seconds. 180 μL of chloroform was added, and tubes were again shaken vigorously for 15 seconds. After 2-3 minutes at room temperature, tubes containing homogenate were centrifuged at 12,000×g for 15 minutes at 4° C. The centrifuge was warmed to room temperature, and the upper aqueous phase was transferred to a new Eppendorf tube. An equal volume of 70% ethanol was added to each tube with thorough mixing, and 700 μL of each sample was transferred to an RNeasy Mini spin column in a 2 mL collection tube. Samples were centrifuged for 15 seconds at >8000×g (>10,000 rpm) at room temperature and flow-thru was discarded. The ethanol mixing and RNeasy centrifugation steps were repeated until all sample was used up. 700 μL of Buffer RWT was added to each spin column, followed by centrifugation for 15 seconds at >8,000×g (>10,000 rpm) to wash the membrane. Flow-thru was discarded, and 500 μL Buffer RPE was added each spin column, followed by centrifugation for 15 seconds at >8,000×g (>10,000 rpm). Flow thru was discarded, and 500 μl Buffer RPE was again added to each spin column, followed by centrifugation for 2 minutes at >8,000×g (>10,000 rpm) to wash the membrane. RNeasy spin columns were placed in a new 2 mL collection tube and centrifuged at full speed for 1 minute. The spin column was placed in a new 1.5 mL collection tube, 50 μL RNase free water was added directly to the spin column membrane, and RNA eluted was eluted by centrifugation for 1 minute at >8,000×g (>10,000 rpm). This step was repeated using another 50 μL of RNase free water. To ensure significance, A260 readings were verified to be greater than 0.15. An absorbance of 1 unit at 260 nm corresponds to 44 μg of mRNA per mL (A260=1=44 μg/mL) at neutral pH.
ABI High Capacity cDNA kits were used to convert mRNA to cDNA for quantitative real-time PCR (qPCR). PCR was performed in optical 384-well plates, freshly prepared on the Eppendorf epMotion liquid handler. Final reaction volume was 20 μL (4 μL Taqman Assay+mixture of 6 μL cDNA (3 ng)+10 μL Universal Master Mix with UNG). Assays were performed to include+RT (reverse transcriptase) samples and, when appropriate, a-RT control. Endogenous controls (×2) were run in triplicate and animal samples were run only once for screening purposes. The real-time PCR protocol included an initial step of 50° C. (2 minutes) to activate the DNA polymerase, denaturation by a hot start at 95° C. for 10 minutes, and 40 cycles of a two-step program (denaturation at 95° C. for 15 seconds for primer annealing/extension at 60° C. for 1 minute). Fluorescence data was collected at 60° C. Fluorescence was quantified with the ABI PRISM 7900HT, and the resultant data was analyzed using SDS RQ Manager (1.2.1) Software (Sequence Detection System Software, Applied Biosystems). Each candidate target biomarker was checked, and threshold and baseline was adjusted to produce (in Δ Rn versus Cycle) an amplification curve of the type suggested by Applied Biosystems in their “Relative Quantification Using Comparative Ct Getting Started Guide.” A calibrator was selected for calculation of the RQ (relative quantification). The calibrator was based on an average of 6× figures from the three naïve animals, left & right arteries, resulting in a numerical result of 1 for the naïve RQ. For calculation of the RQ for the standard deviation (SD) of the naïves, any other experimental animal was used as a calibrator (generally the first animal for Day 0 treated). RQ averages of animals (×3) in the same treatment group were calculated for each point and for each candidate target biomarker individually, and plotted in bar graphs.
Renal NE and dopamine (DBN) levels in naïve, sham, and test animals were evaluated at 10 minutes, 24 hours, and 7 days. Average kidney NE production post-ablation is shown in
The initial screen was carried out using the 70 candidate target biomarkers set forth in Table 1. Shaded genes exhibited an increase or decrease in expression within 10 minutes, 24 hours, and/or 7 days of ablation. Preferred target biomarkers are those exhibiting at least a two-fold change in expression within 10 minutes of ablation. From the initial screen, this group included the genes BDNF, CALCB, CD40L, CLU, EDN3, IL-10, KLKB1, SELE, DNAJA4, BTG2, DNAJB1, FOS, HSPB1, HSPD1, and HSPH1. Of these, the most preferred biomarkers are the secreted proteins BDNF, CALCB, CD40L, CLU, EDN3, IL-10, and KLKB1. Additional screens may be carried out to evaluate candidate target biomarker expression at later time periods (e.g., 1 month, 6 months, or one year post-ablation) in order to validate efficacy as long-term target biomarkers and durability of changes in expression.
Additional screens will be carried out using genes associated with nerves in the renal pelvis, wherein a high percentage are afferent. Examples of such genes are set forth in Table 2.
Screens will also be carried out using various neuronal genes that are not necessarily associated with kidney afferent nerves. Examples of such genes are set forth in Table 3.
Additional screens will be carried out using a variety of secreted, surface, and intracellular genes. Examples of genes that may be included in such screens include those set forth in Table 4.
Additional screens may be carried out to evaluate changes in various non-protein candidate biomarkers such as NE, DBN, or other catecholamines in renal tissue.
Additional candidate target biomarkers were evaluated through in vitro screening of human vascular and neuronal cells. Target biomarkers were identified based on changes in expression and/or secretion levels in response to experimental conditions that imitate heat-based stress to neuronal and vascular cells, thereby mimicking in vivo intervention. Specifically, cells were exposed to inflammatory stimulation and/or heat to simulate arterial RF ablation and SNS denervation in vivo.
A first set of gene profiling and secretomics experiments were performed according to the protocol set forth in
Cells were lysed, and gene profiling was performed. This resulted in the identification of 19 proteins that exhibited an acute response to inflammation and heat. These proteins are listed in Table 5. Results for LTA, POU1F1, CPS1, NODAL, CCL13, and IL-10 are set forth in
The collected cell culture samples included cultured media from the treated cells (i.e., conditioned media) into which the cells can actively secrete proteins, peptides, and non-protein molecules in response to inflammation and heat. These cell culture samples were subjected to secretomics to identify proteins released into culture in response to inflammation and heat. Secretomics assays were performed using iTRAQ methodology (Wiśniewski Arch Pathol Lab Med 132:1566 (2008)). Samples were diluted, digested with trypsin, and iTRAQ labeled using 8-Plex reagent. The resultant complex protein digests were pooled together for MudPIT analysis. Each fraction was analyzed by LC-MS/MS, for acquisition of mass spectroscopy data with the inclusion of iTRAQ quantitation data. The 13 proteins listed in Table 6 exhibited increased secretion after exposure to inflammatory markers and heat. Results for cTAGE-2 are set forth in
Cell culture samples were further subjected to proteomics analysis using commercially available ELISA assays for proteins encoded by the genes identified in Tables 5 and 6.
A second set of gene profiling and secretomics experiments were performed according to the protocol set forth in
Proteomics detection studies are conducted using porcine blood collected from the renal artery to screen for protein and non-protein candidate target biomarkers that exhibit a change in secretion level at various time points after renal denervation/ablation.
Animals are broken into three groups of three animals each: naïve (no treatment), sham (catheterized but not ablated), and treated (subject to ablation at 65° C. and 90 seconds using a spiral ablation catheter device). Blood is collected using a multi-lumen OTW catheter designed to collect localized blood samples in the left or right renal artery (see U.S. Provisional Appl. No. 61/608,626 (C00002431.USP2)). Denervation is carried out using either a Symplicity™ catheter or an alternate catheter as described in U.S. patent application Ser. No. 13/281,361.
For renal artery blood collection, percutaneous vascular access is obtained through the right or left femoral artery and an introducer sheath is placed. Using fluoroscopic guidance, an appropriately sized angiographic catheter is inserted through the introducer sheath and advanced to each renal artery. One or more angiograms are performed for measurements of treated vessels.
Renal arterial blood samples are collected immediately following treatment with the RF catheter and at approximately 2, 5, and 10 minutes post-ablation using a specialized collection catheter that allows for concentration of secreted factors and collection of back flow (
An initial evaluation was carried out using NE and CFL1, with protein levels being assessed by ELISA. Results for NE are set forth in
This screening method may be used to evaluate one or more of the candidate target biomarkers set forth in Tables 1-7. Additional candidate biomarkers that may be evaluated include factors released in the kidney from stressed/denervated nerve ends such as neurotransmitters stored at the nerve ends (e.g., NPY), enzymes stored in nerve ends (e.g., DBH), ions released upon denervation (e.g., Ca2+), and factors released from renal artery endothelial cells and the kidney that may play a physiological role in response to stress or modulation of renal sympathetic system (e.g., Endothelin 1, 2, and 3). Examples of these additional potential candidate target biomarkers are set forth in Table 9. Additional screens may be carried out using other porcine biological samples such as urine.
Selected Embodiments of Renal Neuromodulation Systems and Devices
The system 100 can further include an analyzer 120 (e.g., a biosensor) configured to receive and analyze the biological sample collected by the neuromodulation and sampling assembly 102 for the level or activity of one or more target biomarkers. In certain embodiments, the analyzer may be configured to further analyze one or more additional biological parameters related to neuromodulation.
Upon receipt of the sample by the analyzer 120, detection and/or capture agents within the analyzer 120 can interact with target biomarkers of the collected sample, if present. In at least some cases, binding of a target biomarker to a capture agent and/or interaction of the target biomarker with a detection agent can result in a biomarker response (e.g., a change in color, formation of a reaction product, or another suitable response). The physicochemical transducer 122 can transform the biomarker response into a more easily measurable and quantifiable signal (e.g., a colorimetric, fluorescent, heat, energy, or electric signal) that can be sensed by or communicated to the processing device 124 for storage and/or analysis. The processing device 124 can be operably coupled to an indicator 126 carried by the handle 112. The indicator 126 can be configured to indicate suitable information related to processing the target biomarker (e.g., a sample date, a status of the target biomarker, and/or a status of nerve modulation based on a detected level or activity of the target biomarker). The indication can be auditory and/or visual. In some embodiments, the indicator 126 includes a suitable display component, such as a light emitting diode, an imaging display, and/or a graphical user interface.
In some embodiments, the analyzer 120 is integrated into the console 132 instead of the handle 112. In these embodiments, for example, the analyzer 120 can be configured to receive a biological sample directly from the treatment device 110 (e.g., via a fluid conduit (not shown) (e.g., polymer tubing) within or separate from the connector 130). The fluid conduit can extend between the treatment device 110 and the console 132 where an air or fluid pump (not shown) integrated with the analyzer 120 can draw a biological sample into a portion of the analyzer 120. Alternatively, the air or fluid pump can be housed in the handle 112 to transfer a biological sample to the analyzer 120 contained within the console. In these and other embodiments, the handle 112 can include a removable container (not shown) configured to receive a biological sample collected via the sampling port 108 and conveyed to the container via the shaft 116. For detection and/or analysis of a target biomarker within the sample, the removable container can be removed from the handle 112 and transferred to the analyzer 120 (e.g., when the analyzer 120 is a remote a standalone device or when the analyzer 120 integrated into the console 132, and/or in other embodiments in which the analyzer 120 is remote relative to the treatment device 110). The removable container may be reusable or disposable.
The console 132 can be configured to generate a selected form and/or magnitude of energy for delivery to the treatment site via the energy delivery element 104 of the neuromodulation and sampling assembly 102. For example, the console 132 can include an energy generator (not shown) configured to generate RF energy (monopolar or bipolar), pulsed RF energy, microwave energy, optical energy, ultrasound energy (e.g., intravascularly delivered ultrasound, extracorporeal ultrasound, high-intensity focused ultrasound (HIFU)), cryotherapeutic energy, direct heat energy, chemicals (e.g., drugs or other agents), radiation (e.g., infrared, visible, gamma), or another suitable type of energy. In some embodiments, neuromodulation may be achieved by chemical-based treatment including delivering one or more chemicals (e.g., guanethidine, ethanol, phenol, a neurotoxin (e.g., vincristine)), or another suitable agent selected to alter, damage, or disrupt nerves. In a particular embodiment, the console 132 includes a RF generator operably coupled to one or more energy delivery elements 104 of the neuromodulation and sampling assembly 102. Furthermore, the console 132 can be configured to control, monitor, supply, or otherwise support operation of the treatment device 110. For example, a control mechanism, such as foot pedal 144, may be connected (e.g., pneumatically connected or electrically connected) to the console 132 to allow an operator to initiate, terminate and/or adjust various operational characteristics of the energy generator, such as power delivery. In some embodiments, the console 132 may be configured to provide delivery of a monopolar electric field via the energy delivery element 104. In such embodiments, a neutral or dispersive electrode 142 may be electrically connected to the console 132 and attached to the exterior of the patient (not shown).
In some embodiments, the system 100 includes a remote control device (not shown) that can be configured to be sterilized to facilitate its use within a sterile field. The remote control device can be configured to control operation of the neuromodulation and sampling assembly 102, the console 132, and/or other suitable components of the system 100. For example, the remote control device can be configured to allow for selective activation of the neuromodulation and sampling assembly 102. In other embodiments, the remote control device may be omitted and its functionality may be incorporated into the handle 112 or console 132.
As shown in
The console 132 can be configured to communicate with the treatment device 110 (e.g., via the connector 130). For example, the neuromodulation and sampling assembly 102 and/or the shaft 116 can include a sensor 106 (e.g., a chemical sensor, a temperature sensor, a pressure sensor, or a flow rate sensor) and a sensor lead (not shown) (e.g., an electrical lead or a pressure lead) configured to carry a signal from the sensor 106 to the handle 112. The connector 130 can be configured to carry the signal from the handle 112 to the console 132. The processing device 146 of the console 132 can be configured to communicate with the processing device 124 of the analyzer 120 (e.g., via the connector 130, Bluetooth, wireless, or in another suitable manner when the analyzer 120 is within the handle 112 or otherwise remote relative to the console 132).
In some embodiments, the console 132 includes a vacuum 148 or other suitable negative pressure source (e.g., a syringe) operably coupled to the sampling port 108 of the neuromodulation and sampling assembly 102. In other embodiments, the vacuum 148 can be a standalone device separate from the console 132. The vacuum 148 can be in fluid connection with the sampling port 108 via the shaft 116. Negative pressure generated by the vacuum 148 can be used, for example, to draw a biological sample into the sampling port 108. In yet other embodiments, the treatment device 110 can include an adapter (not shown) (e.g., a luer lock) configured to be operably coupled to a syringe (not shown) and the syringe can be used to apply negative pressure to the shaft 116.
In some embodiments, the energy delivery elements 104 are formed from a suitable electrically conductive material (e.g., a metal, such as gold, platinum, alloys of platinum and iridium, etc.). The number, arrangement, shape (e.g., spiral and/or coil electrodes) and/or composition of the energy delivery elements 104 may vary. The individual energy delivery elements 104 can be electrically connected to the console 132 by a conductor or bifilar wire 300 extending through a lumen 302 of the shaft 116 and/or support structure 210. For example, the individual energy delivery elements 104 may be welded or otherwise electrically coupled to corresponding energy supply wires 300, and the wires 300 can extend through the elongated shaft 116 for the entire length of the shaft 116 such that proximal ends of the wires 300 are coupled to the handle 112 and/or to the console 132.
As shown in the enlarged cut-away view of
The sampling element 202 can further include an occlusion member 218 (e.g., a compliant, semi-compliant, or non-compliant balloon, an expandable basket, a stent-like structure, etc.) as part of the occlusion element 204. The occlusion member 218 can be configured to at least partially occlude a vessel (e.g., a renal artery) or lumen in which the neuromodulation and sampling assembly 102 is positioned. In some embodiments, the occlusion member 218 extends around a segment of the shaft 116 that includes an inflation opening 216. For example, the occlusion member 218 can be laser-bonded or adhered by other suitable methods to an outer surface of the shaft 116 at axially spaced apart locations distal and proximal, respectively, relative to the inflation opening 216.
The inflation opening 216 can connect to an inflation lumen 500 that extends proximally along the shaft 116 from the inflation opening 216 to the handle 112. Control of the occlusion element 204 and/or occlusion member 218 (e.g., control over inflation/expansion volume, inflation/expansion timing and/or deflation/collapse timing) can be manual or automatic (e.g., based on a pre-set schedule or algorithm). As shown in
Several embodiments of methods for utilizing the system 100 to provide real-time or relatively contemporaneous (e.g., less than 30 minutes) renal neuromodulation efficacy feedback in accordance with the present technology are described herein. In a particular embodiment, a method includes: (a) collecting a pre-neuromodulation biological sample at a treatment site via a sampling element 202 of a neuromodulation and sampling assembly 102; (b) determining a baseline or pre-neuromodulation level or activity of one or more target biomarkers within the pre-neuromodulation biological sample; (c) performing a neuromodulation procedure using a neuromodulation element 200 of the neuromodulation and sampling assembly 102; (d) expanding an occlusion member 218 to at least partially occlude a vessel or lumen in which the treatment site is located; (e) collecting a post-neuromodulation biological sample at the treatment site via the sampling element 202; (f) determining a post-neuromodulation level or activity for the target biomarker(s); and (g) comparing the post-neuromodulation level or activity to the baseline level or activity to provide neuromodulation efficacy feedback.
Referring to
Image guidance, e.g., computed tomography (CT), fluoroscopy, intravascular ultrasound (IVUS), optical coherence tomography (OCT), intracardiac echocardiography (ICE), or another suitable guidance modality, or combinations thereof, may be used to aid the clinician's positioning and manipulation of the neuromodulation and sampling assembly 102. For example, a fluoroscopy system (e.g., including a flat-panel detector, x-ray, or c-arm) can be rotated to accurately visualize and identify the target treatment site. In other embodiments, the treatment site can be located using IVUS, OCT, and/or other suitable image mapping modalities that can correlate the target treatment site with an identifiable anatomical structure (e.g., a spinal feature) and/or a radiopaque ruler (e.g., positioned under or on the patient) before delivering the treatment device 110. Further, in some embodiments, image guidance components (e.g., IVUS, OCT) may be integrated with the treatment device 110 and/or run in parallel with the treatment device 110 to provide image guidance during positioning of the neuromodulation and sampling assembly 102. For example, image guidance components (e.g., IVUS or OCT) can be coupled to a distal portion of the treatment device 110 to provide three-dimensional images of the vasculature proximate the target site to facilitate positioning or deploying the neuromodulation and sampling assembly 102 within the target renal blood vessel.
Once the neuromodulation and sampling assembly 102 is positioned at a treatment location, the guide wire 600 can be at least partially introduced (e.g., inserted) into or removed (e.g., withdrawn) from the neuromodulation and sampling assembly 102 to transform or otherwise move the neuromodulation and sampling assembly 102 to a deployed state. In the deployed state, for example, the energy delivery elements 104 of the neuromodulation and sampling assembly 102 can be positioned in stable contact with a wall of the vessel or lumen for delivering energy, as illustrated by
In some embodiments, the neuromodulation and sampling assembly 102 may be delivered to a treatment site within a guide sheath (not shown) with or without using the guidewire 600. When the neuromodulation and sampling assembly 102 is at the target site, the guide sheath may be at least partially withdrawn or retracted and the neuromodulation and sampling assembly 102 can be transformed into the deployed state. For example, at least a portion of the neuromodulation and sampling assembly 102 can have a shape memory corresponding to a deployed state and the sheath can prevent the neuromodulation and sampling assembly 102 from deploying in response to the shape memory before reaching the treatment location. In still other embodiments, the shaft 116 may be steerable itself such that the neuromodulation and sampling assembly 102 may be delivered to the treatment site without the aid of the guide wire 600 and/or guide sheath.
Examples of other suitable neuromodulation delivery configurations, deployment configurations and/or deployment mechanisms can be found in U.S. application Ser. No. 12/910,631, filed Oct. 22, 2010, entitled “APPARATUS, SYSTEMS, AND METHODS FOR ACHIEVING INTRAVASCULAR, THERMALLY-INDUCED RENAL NEUROMODULATION,” U.S. application Ser. No. 13/281,361, filed Oct. 25, 2011, entitled “CATHETER APPARATUSES HAVING MULTI-ELECTRODE ARRAYS FOR RENAL NEUROMODULATION AND ASSOCIATED SYSTEMS AND METHODS,” and U.S. Provisional Application No. 61/646,218, filed May 5, 2012, entitled “MULTI-ELECTRODE CATHETER ASSEMBLIES FOR RENAL NEUROMODULATION AND ASSOCIATED SYSTEMS AND METHODS,” which are all incorporated herein by reference in their entireties.
In the deployed state, at least a portion of the neuromodulation and sampling assembly 102 can be configured to contact an inner wall of the renal artery and to cause a fully-circumferential lesion without the need for repositioning. For example, the neuromodulation element 200 can be configured to form a lesion or series of lesions (e.g., a helical/spiral lesion or a discontinuous lesion) that is fully-circumferential overall, but generally non-circumferential at longitudinal segments of the treatment location. This can facilitate precise and efficient treatment with a low possibility of vessel stenosis. In other embodiments, the neuromodulation element 200 can be configured to form a partially-circumferential lesion or a fully-circumferential lesion at a single longitudinal segment of the treatment location. In some embodiments, the therapeutic element 502 can be configured to cause therapeutically-effective neuromodulation (e.g., using ultrasound energy) without contacting a vessel wall.
At one or more timepoints prior to neuromodulation, the sampling element 202 of the assembly 102 can collect a pre-neuromodulation biological sample at or near the treatment site to determine an initial, pre-neuromodulation level or activity of one or more target biomarkers. In some embodiments, the collected baseline sample can be conveyed directly from the sampling port 108 through the sampling lumen 400 to the analyzer 120 (e.g., when the analyzer 120 is incorporated into the handle 112). The analyzer 120 can be configured to analyze the pre-neuromodulation sample to detect a baseline level of one or more target biomarkers. In other embodiments, the collected baseline sample can be conveyed directly from the sampling port 108 through the sampling lumen 400 to the console 132 via the connector 130 and/or a separate collection connector (not shown) between the handle 112 and the console 132. As discussed below, the baseline level or value can be compared to a post-neuromodulation level to evaluate the efficacy of the neuromodulation. When the analysis is complete, the baseline data obtained by the analyzer 120 from the baseline analysis may be stored by memory of the analyzer 120, or in some embodiments, the baseline data can be communicated (e.g., via the connector 130 and/or wirelessly) to memory of the console 132 for storage and/or processing. In addition, the baseline data may be displayed by an analyzer display (not shown) on the handle 112 and/or the console display 136 (
After the neuromodulation and sampling assembly 102 is adequately positioned in the vessel or lumen, the neuromodulation element 200 can be used to purposefully apply or withdraw energy to or from the tissue to induce one or more desired neuromodulating effects on localized regions of the renal artery and adjacent regions of the renal plexus (RP), which lay intimately within, adjacent to, or in close proximity to the adventitia of the renal artery (RA). During and/or after the application of energy, the system 100 can detect changes in the level or activity of one or more target biomarkers associated with neuromodulation and provide real-time or relatively contemporaneous feedback of neuromodulation efficacy.
Before, during, and/or after the energy delivery or withdrawal, the occlusion member 218 carried by the occlusion element 204 of the neuromodulation and sampling assembly 102 can be inflated and/or expanded to at least partially occlude the vessel or lumen proximal to the treatment site, as shown in
In some embodiments, collection of the post-neuromodulation sample can include an iterative process of inflating and/or expanding the occlusion member 218, collecting a first quantity of the sample, partially deflating the occlusion member 218 to allow perfusion of the renal artery, then re-inflating and/or re-expanding the occlusion member 218 to collect a second quantity of the sample. Such an iterative process can be used to collect any desired number of sample quantities until a sufficient sample volume has been reached. As discussed above, inflation and deflation of the occlusion member 218 can be automatically or manually controlled to achieve a desired occlusion to perfusion ratio. In some embodiments, the therapeutic element 502 can be configured to radially expand into a deployed state 504 at the treatment location.
The devices, systems and methods for conveying the post-neuromodulation sample from the sampling port 108 to an analyzer 120 and for analyzing the post-neuromodulation sample can be the same as that described above with respect to the baseline or pre-neuromodulation sample. Once determining the post-neuromodulation target biomarker level or activity, the processing circuitry associated with the analyzer 120, handle 112, and/or console 132 can compare the post-neuromodulation biomarker level or activity to the baseline level or activity and provide real-time or relatively contemporaneous feedback (e.g., auditory or visual) to the practitioner as to the efficacy of the neuromodulation. For example, target biomarkers for use in the methods disclosed herein may exhibit a change (e.g., a two-fold or greater, a three-fold or greater, a five-fold or greater, or a ten-fold or greater change) in level or activity in response to neuromodulation. If the feedback indicates that a neuromodulation treatment has not been effective, the neuromodulation element 200 can be re-activated (e.g., shifted and then reactivated) to perform a second neuromodulation. Once the second neuromodulation treatment is complete, an additional post-neuromodulation sample can be collected and analyzed to determine whether or not to continue treatment. This process can be repeated until sufficient neuromodulation has been effectuated at the treatment site.
The following examples are illustrative of several embodiments of the present technology:
1. A method of monitoring the efficacy of a renal neuromodulation procedure in a human subject, the method comprising:
2. The method of example 1 wherein at least partially inhibiting sympathetic neural activity in a renal nerve of the subject comprises delivering energy to the renal nerve via the neuromodulation assembly to modulate the renal nerve.
3. The method of example 2 wherein the energy is radio frequency (RF) energy.
4. The method of example 2 wherein the energy is selected from the group consisting of pulsed RF energy, microwave energy, laser light energy, optical energy, ultrasound energy, high-intensity focused ultrasound energy, magnetic energy, direct heat energy, and cryotherapeutic energy.
5. The method of any one of examples 1 to 4 wherein at least partially inhibiting sympathetic neural activity in a renal nerve of the subject comprises delivering a chemical to the renal nerve via the neuromodulation assembly to modulate the renal nerve.
6. The method of any one of examples 1 to 5 wherein the neuromodulation assembly comprises an intravascularly positioned catheter carrying an energy delivery element positioned at least proximate to the renal nerve.
7. The method of any one of examples 1 to 6 wherein at least partially inhibiting sympathetic neural activity in a renal nerve of the subject comprises thermally modulating the renal nerve via the neuromodulation assembly from within a renal blood vessel of the subject.
8. The method of example 1 wherein at least partially inhibiting sympathetic neural activity in a renal nerve of the subject comprises delivering a chemical agent to tissue at a treatment location in the renal blood vessel in a manner that modulates sympathetic neural activity.
9. The method of any one of examples 1 to 8 wherein the one or more target biomarkers are selected from the group consisting of ADRA2b, ATP1A1, BDNF, BMP7, BNP, BTG2, CALCB, CD40L, CDKN1B, CDKN2B/p15, CLU, DNAJA4, DNAJB1, EDN3, ETB, FASLG, FOS, HMOX-1, HSPA5, HSPA14, HSPB1, HSPD1, HSPH1, IL-10, ITGAM, KLKB1, LIF, MC2R, NTF3, P2RY12, SELE, SLC2A5/GLUT5, SOD2, TLR3, TLR4, TLR7, and TNFRSF1B.
10. The method of any one of examples 1 to 8 wherein the one or more target biomarkers are selected from the group consisting of CASP10, CCL13, CCND1, CD70, CRYAB, CPS1, DNAJB1, DNAJB11, HSPA1A, HSPA1B, HSPB6, IL-10, KIT, LTA, MYLK3, NODAL, NPY1R, POU1F1, and TCP1.
11. The method of any one of examples 1 to 8 wherein the one or more target biomarkers are selected from the group consisting of ACTA2, CACY/2A9, CFL1, CTAG1A1/CTAG21, LDHA, MGC141/TMEM141, NAA20/NAT5, NM23B, PAHX/PHYH1, PFDN1, PLK-2, TUBA1B, and VIM.
12. The method of any one of examples 1 to 8 wherein the one or more target biomarkers are selected from the group consisting of SNCA, BDNF, CNTF, FGF2, GDNF, NGF2, NTF3, PF4, EDN2, ACE2, IFN-γ, ARTN, LIF, CBLN1, NRG1, NRG2, NRG4, PSPN, NTF4, and TGFA.
13. The method of any one of examples 1 to 8 wherein the one or more target biomarkers are selected from the group consisting of NE, CFL1, NPY, DBN, Ca2+, renin, DBH, AGT, endothelin 1, 2, and 3, NTS, and APP.
14. The method of any one of examples 1 to 13 wherein the post-neuromodulation level or activity of the target biomarker(s) is determined at 10 minutes, 24 hours, or 7 days post-denervation.
15. A method of performing a renal neuromodulation procedure in a human patient, the method comprising:
16. The method of example 15 wherein partially disrupting function of the renal nerve comprises reducing renal nerve hyperplasia in the patient.
17. The method of example 15 or example 16 wherein partially disrupting function of the renal nerve comprises reducing the total number of functioning renal nerves of the patient to levels at or near levels observed in normotensive patients.
18. The method of any one of examples 15 to 17 wherein the one or more target biomarkers are selected from the group consisting of ADRA2b, ATP1A1, BDNF, BMP7, BNP, BTG2, CALCB, CD40L, CDKN1B, CDKN2B/p15, CLU, DNAJA4, DNAJB1, EDN3, ETB, FASLG, FOS, HMOX-1, HSPA5, HSPA14, HSPB1, HSPD1, HSPH1, IL-10, ITGAM, KLKB1, LIF, MC2R, NTF3, P2RY12, SELE, SLC2A5/GLUT5, SOD2, TLR3, TLR4, TLR7, and TNFRSF1B.
19. The method of any one of examples 15 to 17 wherein the one or more target biomarkers are selected from the group consisting of CASP10, CCL13, CCND1, CD70, CRYAB, CPS1, DNAJB1, DNAJB11, HSPA1A, HSPA1B, HSPB6, IL-10, KIT, LTA, MYLK3, NODAL, NPY1R, POU1F1, and TCP1.
20. The method of any one of examples 15 to 17 wherein the one or more target biomarkers are selected from the group consisting of ACTA2, CACY/2A9, CFL1, CTAG1A1/CTAG21, LDHA, MGC141/TMEM141, NAA20/NAT5, NM23B, PAHX/PHYH1, PFDN1, PLK-2, TUBA1B, and VIM.
21. The method of any one of examples 15 to 17 wherein the one or more target biomarkers are selected from the group consisting of SNCA, BDNF, CNTF, FGF2, GDNF, NGF2, NTF3, PF4, EDN2, ACE2, IFN-γ, ARTN, LIF, CBLN1, NRG1, NRG2, NRG4, PSPN, NTF4, and TGFA.
22. The method of any one of examples 15 to 17 wherein the one or more target biomarkers are selected from the group consisting of NE, CFL1, NPY, DBN, Ca2+, renin, DBH, AGT, endothelin 1, 2, and 3, NTS, and APP.
23. A method of determining biomarker activity in a human patient, the method comprising:
24. The method of example 23 wherein the catheter further comprises a distal filter at a distal end of the capture compartment, and wherein capturing a plurality of at least one type of biomarker in a capture compartment of the catheter comprises allowing passage of the biomarker(s) through the distal filter into the capture compartment, while preventing passage of other biomolecules through the distal filter into the capture compartment.
25. The method of example 23 or example 24 wherein the catheter further comprises a proximal filter at a proximal end of the capture compartment, and wherein capturing a plurality of at least one type of biomarker in a capture compartment of the catheter comprises preventing passage of the biomarker(s) out of the capture compartment through the proximal filter, while allowing blood to flow through the proximal filter and out of the capture compartment.
26. The method of any one of examples 23 to 25 wherein the capture compartment of the catheter is located within the patient while capturing the biomarker(s).
27. The method of any one of examples 23 to 25 wherein the capture compartment of the catheter is located external to the patient while capturing the biomarker(s).
28. A method of monitoring the efficacy of a renal neuromodulation procedure in a human subject, the method comprising:
29. A device for carrying out the method of any one of examples 1 to 28.
The above detailed descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology, as those skilled in the relevant art will recognize. For example, while steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments. All references cited herein are incorporated by reference as if fully set forth herein.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.
Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application is a Continuation of and claims the benefit of U.S. patent application Ser. No. 15/296,925, filed Oct. 18, 2016, now U.S. Pat. No. 10,368,791, which is a Continuation of and claims the benefit of U.S. patent application Ser. No. 13/791,681, filed Mar. 8, 2013, now U.S. Pat. No. 9,510,777, which claims priority to U.S. Provisional Patent Application No. 61/608,625, filed Mar. 8, 2012, U.S. Provisional Patent No. 61/608,626, filed Mar. 8, 2012, and U.S. Provisional Patent Application No. 61/746,528, filed Dec. 27, 2012. All of the foregoing applications are incorporated herein by reference in their entireties. Further, components and features of embodiments disclosed in the applications incorporated by reference may be combined with various components and features disclosed and claimed in the present application. The following application is also incorporated herein by reference in its entirety: U.S. patent application Ser. No. 13/791,751, entitled “BIOMARKER SAMPLING IN THE CONTEXT OF NEUROMODULATION DEVICES, SYSTEMS, AND METHODS,” filed Mar. 8, 2013, now U.S. Pat. No. 9,597,018. As such, components and features of embodiments disclosed in this application may be combined with various components and features disclosed in the present application.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2130758 | Rose | Sep 1938 | A |
| 2276995 | Milinowski | Mar 1942 | A |
| 2276996 | Milinowski | Mar 1942 | A |
| 3043310 | Milinowski | Jul 1962 | A |
| 3127895 | Kendall et al. | Apr 1964 | A |
| 3181535 | Milinowski | May 1965 | A |
| 3270746 | Kendall et al. | Sep 1966 | A |
| 3329149 | Kendall et al. | Jul 1967 | A |
| 3522811 | Schwartz et al. | Aug 1970 | A |
| 3563246 | Puharich et al. | Feb 1971 | A |
| 3650277 | Sjostrand et al. | Mar 1972 | A |
| 3670737 | Pearo | Jun 1972 | A |
| 3760812 | Timm et al. | Sep 1973 | A |
| 3774620 | Hansjurgens et al. | Nov 1973 | A |
| 3794022 | Nawracaj et al. | Feb 1974 | A |
| 3800802 | Berry et al. | Apr 1974 | A |
| 3803463 | Cover | Apr 1974 | A |
| 3894532 | Morey | Jul 1975 | A |
| 3895639 | Rodler et al. | Jul 1975 | A |
| 3897789 | Blanchard | Aug 1975 | A |
| 3911930 | Hagfors et al. | Oct 1975 | A |
| 3952751 | Yarger | Apr 1976 | A |
| 3987790 | Eckenhoff et al. | Oct 1976 | A |
| 4011861 | Enger | Mar 1977 | A |
| 4026300 | DeLuca et al. | May 1977 | A |
| 4055190 | Tany et al. | Oct 1977 | A |
| 4071033 | Nawracaj et al. | Jan 1978 | A |
| 4105017 | Ryaby et al. | Aug 1978 | A |
| 4141365 | Fischell et al. | Feb 1979 | A |
| 4266532 | Ryaby et al. | May 1981 | A |
| 4266533 | Ryaby et al. | May 1981 | A |
| 4305115 | Armitage et al. | Dec 1981 | A |
| 4315503 | Ryaby et al. | Feb 1982 | A |
| 4360019 | Portner et al. | Nov 1982 | A |
| 4379462 | Borkan et al. | Apr 1983 | A |
| 4405305 | Stephen et al. | Sep 1983 | A |
| 4444203 | Engelman et al. | Apr 1984 | A |
| 4454883 | Fellus et al. | Jun 1984 | A |
| 4467808 | Brighton et al. | Aug 1984 | A |
| 4487603 | Harris | Dec 1984 | A |
| 4530840 | Tice et al. | Jul 1985 | A |
| 4587975 | Salo et al. | May 1986 | A |
| 4602624 | Naples et al. | Jul 1986 | A |
| 4608985 | Crish et al. | Sep 1986 | A |
| 4649936 | Ungar et al. | Mar 1987 | A |
| 4671286 | Renault et al. | Jun 1987 | A |
| 4674482 | Waltonen et al. | Jun 1987 | A |
| 4692147 | Duggan | Sep 1987 | A |
| 4709698 | Johnston et al. | Dec 1987 | A |
| 4715852 | Reinicke et al. | Dec 1987 | A |
| 4764504 | Johnson et al. | Aug 1988 | A |
| 4774967 | Zanakis et al. | Oct 1988 | A |
| 4791931 | Slate | Dec 1988 | A |
| 4816016 | Schulte et al. | Mar 1989 | A |
| 4852573 | Kennedy | Aug 1989 | A |
| 4865845 | Eckenhoff et al. | Sep 1989 | A |
| 4890623 | Cook et al. | Jan 1990 | A |
| 4976711 | Parins et al. | Dec 1990 | A |
| 4979511 | Terry, Jr. | Dec 1990 | A |
| 4981146 | Bertolucci | Jan 1991 | A |
| 4998532 | Griffith | Mar 1991 | A |
| 5006119 | Acker et al. | Apr 1991 | A |
| 5014699 | Pollack et al. | May 1991 | A |
| 5019034 | Weaver et al. | May 1991 | A |
| 5057318 | Magruder et al. | Oct 1991 | A |
| 5058584 | Bourgeois et al. | Oct 1991 | A |
| 5059423 | Magruder et al. | Oct 1991 | A |
| 5061492 | Okada et al. | Oct 1991 | A |
| 5094242 | Gleason et al. | Mar 1992 | A |
| 5111815 | Mower | May 1992 | A |
| 5112614 | Magruder et al. | May 1992 | A |
| 5125928 | Parins et al. | Jun 1992 | A |
| 5131409 | Lobarev et al. | Jul 1992 | A |
| 5137727 | Eckenhoff | Aug 1992 | A |
| 5188837 | Domb | Feb 1993 | A |
| 5193048 | Kaufman et al. | Mar 1993 | A |
| 5193539 | Schulman et al. | Mar 1993 | A |
| 5193540 | Schulman et al. | Mar 1993 | A |
| 5199428 | Obel et al. | Apr 1993 | A |
| 5203326 | Collins et al. | Apr 1993 | A |
| 5213098 | Bennett et al. | May 1993 | A |
| 5215086 | Terry, Jr. et al. | Jun 1993 | A |
| 5231988 | Wernicke et al. | Aug 1993 | A |
| 5234692 | Magruder et al. | Aug 1993 | A |
| 5234693 | Magruder et al. | Aug 1993 | A |
| 5251634 | Weinberg | Oct 1993 | A |
| 5251643 | Osypka et al. | Oct 1993 | A |
| 5263480 | Wernicke et al. | Nov 1993 | A |
| 5269303 | Wernicke et al. | Dec 1993 | A |
| 5282468 | Klepinski | Feb 1994 | A |
| 5282785 | Shapland et al. | Feb 1994 | A |
| 5286254 | Shapland et al. | Feb 1994 | A |
| 5299569 | Wernicke et al. | Apr 1994 | A |
| 5300068 | Rosar et al. | Apr 1994 | A |
| 5301683 | Durkan | Apr 1994 | A |
| 5304120 | Crandell et al. | Apr 1994 | A |
| 5304206 | Baker, Jr. et al. | Apr 1994 | A |
| 5317155 | King | May 1994 | A |
| 5324255 | Passafaro et al. | Jun 1994 | A |
| 5324316 | Schulman et al. | Jun 1994 | A |
| 5334193 | Nardella | Aug 1994 | A |
| 5335657 | Terry, Jr. et al. | Aug 1994 | A |
| 5338662 | Ri | Aug 1994 | A |
| 5351394 | Weinberg | Oct 1994 | A |
| 5358514 | Schulman et al. | Oct 1994 | A |
| 5368591 | Lennox et al. | Nov 1994 | A |
| 5370680 | Proctor | Dec 1994 | A |
| 5389069 | Weaver | Feb 1995 | A |
| 5397308 | Ellis et al. | Mar 1995 | A |
| 5397338 | Grey et al. | Mar 1995 | A |
| 5400784 | Durand et al. | Mar 1995 | A |
| 5405367 | Schulman et al. | Apr 1995 | A |
| 5423744 | Gencheff et al. | Jun 1995 | A |
| 5429634 | Narciso, Jr. | Jul 1995 | A |
| 5433739 | Sluijter et al. | Jul 1995 | A |
| 5439440 | Hofmann | Aug 1995 | A |
| 5454782 | Perkins | Oct 1995 | A |
| 5454809 | Janssen | Oct 1995 | A |
| 5458568 | Racchini et al. | Oct 1995 | A |
| 5458626 | Krause | Oct 1995 | A |
| 5458631 | Xavier | Oct 1995 | A |
| 5470352 | Rappaport | Nov 1995 | A |
| 5472406 | de la Torre et al. | Dec 1995 | A |
| 5478303 | Foley-Nolan et al. | Dec 1995 | A |
| 5484400 | Edwards et al. | Jan 1996 | A |
| 5494822 | Sadri | Feb 1996 | A |
| 5498238 | Shapland et al. | Mar 1996 | A |
| 5499971 | Shapland et al. | Mar 1996 | A |
| 5505700 | Leone et al. | Apr 1996 | A |
| 5507724 | Hofmann et al. | Apr 1996 | A |
| 5507791 | Sit'ko et al. | Apr 1996 | A |
| 5531778 | Maschino et al. | Jul 1996 | A |
| 5540730 | Terry, Jr. et al. | Jul 1996 | A |
| 5540734 | Zabara | Jul 1996 | A |
| 5553611 | Budd et al. | Sep 1996 | A |
| 5560360 | Filler et al. | Oct 1996 | A |
| 5569198 | Racchini | Oct 1996 | A |
| 5571147 | Sluijter et al. | Nov 1996 | A |
| 5571150 | Wernicke et al. | Nov 1996 | A |
| 5573552 | Hansjurgens et al. | Nov 1996 | A |
| 5584863 | Rauch et al. | Dec 1996 | A |
| 5588964 | Imran et al. | Dec 1996 | A |
| 5589192 | Okabe et al. | Dec 1996 | A |
| 5599345 | Edwards et al. | Feb 1997 | A |
| 5608519 | Gourley et al. | Mar 1997 | A |
| 5618563 | Berde et al. | Apr 1997 | A |
| 5626576 | Janssen | May 1997 | A |
| 5626862 | Brem et al. | May 1997 | A |
| 5628730 | Shapland et al. | May 1997 | A |
| 5634462 | Tyler et al. | Jun 1997 | A |
| 5634899 | Shapland et al. | Jun 1997 | A |
| 5672174 | Gough et al. | Sep 1997 | A |
| 5688266 | Edwards et al. | Nov 1997 | A |
| 5689877 | Grill, Jr. et al. | Nov 1997 | A |
| 5690691 | Chen et al. | Nov 1997 | A |
| 5700282 | Zabara | Dec 1997 | A |
| 5700485 | Berde et al. | Dec 1997 | A |
| 5704908 | Hofmann et al. | Jan 1998 | A |
| 5707400 | Terry, Jr. et al. | Jan 1998 | A |
| 5711326 | Thies et al. | Jan 1998 | A |
| 5713847 | Howard, III et al. | Feb 1998 | A |
| 5722401 | Pietroski et al. | Mar 1998 | A |
| 5723001 | Pilla et al. | Mar 1998 | A |
| 5725563 | Klotz et al. | Mar 1998 | A |
| 5728396 | Peery et al. | Mar 1998 | A |
| 5747060 | Sackler et al. | May 1998 | A |
| 5755750 | Petruska et al. | May 1998 | A |
| 5756115 | Moo-Young et al. | May 1998 | A |
| 5772590 | Webster, Jr. | Jun 1998 | A |
| 5792187 | Adams | Aug 1998 | A |
| 5800464 | Kieval | Sep 1998 | A |
| 5807306 | Shapland et al. | Sep 1998 | A |
| 5810802 | Panescu et al. | Sep 1998 | A |
| 5814079 | Kieval | Sep 1998 | A |
| 5824087 | Aspden et al. | Oct 1998 | A |
| 5836935 | Ashton et al. | Nov 1998 | A |
| RE35987 | Harris et al. | Dec 1998 | E |
| 5843069 | Butler et al. | Dec 1998 | A |
| 5860974 | Abele | Jan 1999 | A |
| 5861021 | Thome et al. | Jan 1999 | A |
| 5865787 | Shapland et al. | Feb 1999 | A |
| 5871449 | Brown | Feb 1999 | A |
| 5891181 | Zhu et al. | Apr 1999 | A |
| 5893885 | Webster et al. | Apr 1999 | A |
| 5906636 | Casscells, III et al. | May 1999 | A |
| 5906817 | Moullier et al. | May 1999 | A |
| 5913876 | Taylor et al. | Jun 1999 | A |
| 5916154 | Hobbs et al. | Jun 1999 | A |
| 5916239 | Geddes et al. | Jun 1999 | A |
| 5919187 | Guglielmi et al. | Jul 1999 | A |
| 5924997 | Campbell | Jul 1999 | A |
| 5928272 | Adkins et al. | Jul 1999 | A |
| 5935075 | Casscells et al. | Aug 1999 | A |
| 5944710 | Dev et al. | Aug 1999 | A |
| 5954719 | Chen et al. | Sep 1999 | A |
| 5983131 | Weaver et al. | Nov 1999 | A |
| 5983141 | Sluijter et al. | Nov 1999 | A |
| 6004269 | Crowley et al. | Dec 1999 | A |
| 6006134 | Hill et al. | Dec 1999 | A |
| 6009877 | Edwards | Jan 2000 | A |
| 6010613 | Walters et al. | Jan 2000 | A |
| 6024740 | Lesh et al. | Feb 2000 | A |
| 6026326 | Bardy | Feb 2000 | A |
| 6036687 | Laufer et al. | Mar 2000 | A |
| 6041252 | Walker et al. | Mar 2000 | A |
| 6051017 | Loeb et al. | Apr 2000 | A |
| 6058328 | Levine et al. | May 2000 | A |
| 6058331 | King | May 2000 | A |
| 6066134 | Eggers et al. | May 2000 | A |
| 6073048 | Kieval et al. | Jun 2000 | A |
| 6077227 | Miesel et al. | Jun 2000 | A |
| 6086527 | Talpade | Jul 2000 | A |
| 6091995 | Ingle et al. | Jul 2000 | A |
| 6099524 | Lipson et al. | Aug 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6122548 | Starkebaum et al. | Sep 2000 | A |
| 6123718 | Tu et al. | Sep 2000 | A |
| 6135999 | Fanton et al. | Oct 2000 | A |
| 6142993 | Whayne et al. | Nov 2000 | A |
| 6146380 | Racz et al. | Nov 2000 | A |
| 6149620 | Baker et al. | Nov 2000 | A |
| 6161048 | Sluijter et al. | Dec 2000 | A |
| 6171306 | Swanson et al. | Jan 2001 | B1 |
| 6178349 | Kieval | Jan 2001 | B1 |
| 6190353 | Makower et al. | Feb 2001 | B1 |
| 6192889 | Morrish | Feb 2001 | B1 |
| 6205361 | Kuzma et al. | Mar 2001 | B1 |
| 6208894 | Schulman et al. | Mar 2001 | B1 |
| 6214032 | Loeb et al. | Apr 2001 | B1 |
| 6219577 | Brown, III et al. | Apr 2001 | B1 |
| 6224592 | Eggers et al. | May 2001 | B1 |
| 6238702 | Berde et al. | May 2001 | B1 |
| 6245026 | Campbell et al. | Jun 2001 | B1 |
| 6246912 | Sluijter et al. | Jun 2001 | B1 |
| 6251130 | Dobak, III et al. | Jun 2001 | B1 |
| 6254598 | Edwards et al. | Jul 2001 | B1 |
| 6258087 | Edwards et al. | Jul 2001 | B1 |
| 6259952 | Sluijter et al. | Jul 2001 | B1 |
| 6269269 | Ottenhoff et al. | Jul 2001 | B1 |
| 6272377 | Sweeney et al. | Aug 2001 | B1 |
| 6272383 | Grey et al. | Aug 2001 | B1 |
| 6273886 | Edwards et al. | Aug 2001 | B1 |
| 6280377 | Talpade | Aug 2001 | B1 |
| 6283951 | Flaherty et al. | Sep 2001 | B1 |
| 6287304 | Eggers et al. | Sep 2001 | B1 |
| 6287608 | Levin et al. | Sep 2001 | B1 |
| 6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
| 6304777 | Ben-Haim et al. | Oct 2001 | B1 |
| 6304787 | Kuzma et al. | Oct 2001 | B1 |
| 6306423 | Donovan et al. | Oct 2001 | B1 |
| 6314325 | Fitz | Nov 2001 | B1 |
| 6322558 | Taylor et al. | Nov 2001 | B1 |
| 6322559 | Daulton et al. | Nov 2001 | B1 |
| 6326020 | Kohane et al. | Dec 2001 | B1 |
| 6326177 | Schoenbach et al. | Dec 2001 | B1 |
| 6328699 | Eigler et al. | Dec 2001 | B1 |
| 6334069 | George et al. | Dec 2001 | B1 |
| 6347247 | Dev et al. | Feb 2002 | B1 |
| 6353763 | George et al. | Mar 2002 | B1 |
| 6356786 | Rezai et al. | Mar 2002 | B1 |
| 6356787 | Rezai et al. | Mar 2002 | B1 |
| 6366808 | Schroeppel et al. | Apr 2002 | B1 |
| 6366815 | Haugland et al. | Apr 2002 | B1 |
| 6393324 | Gruzdowich et al. | May 2002 | B2 |
| 6400982 | Sweeney et al. | Jun 2002 | B2 |
| 6405079 | Ansarinia | Jun 2002 | B1 |
| 6405732 | Edwards et al. | Jun 2002 | B1 |
| 6413255 | Stern | Jul 2002 | B1 |
| 6415183 | Scheiner et al. | Jul 2002 | B1 |
| 6415187 | Kuzma et al. | Jul 2002 | B1 |
| 6438423 | Rezai et al. | Aug 2002 | B1 |
| 6442424 | Ben-Haim et al. | Aug 2002 | B1 |
| 6449507 | Hill et al. | Sep 2002 | B1 |
| 6450942 | Lapanashvili et al. | Sep 2002 | B1 |
| 6461314 | Pant et al. | Oct 2002 | B1 |
| 6464687 | Ishikawa et al. | Oct 2002 | B1 |
| 6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
| 6482619 | Rubinsky et al. | Nov 2002 | B1 |
| 6488679 | Swanson et al. | Dec 2002 | B1 |
| 6506189 | Rittman, III et al. | Jan 2003 | B1 |
| 6508774 | Acker et al. | Jan 2003 | B1 |
| 6514226 | Levin et al. | Feb 2003 | B1 |
| 6516211 | Acker et al. | Feb 2003 | B1 |
| 6517811 | John et al. | Feb 2003 | B2 |
| 6522926 | Kieval et al. | Feb 2003 | B1 |
| 6522932 | Kuzma et al. | Feb 2003 | B1 |
| 6524607 | Goldenheim et al. | Feb 2003 | B1 |
| 6534081 | Goldenheim et al. | Mar 2003 | B2 |
| 6536949 | Heuser | Mar 2003 | B1 |
| 6542781 | Koblish et al. | Apr 2003 | B1 |
| 6562034 | Edwards et al. | May 2003 | B2 |
| 6564096 | Mest | May 2003 | B2 |
| 6571127 | Ben-Haim et al. | May 2003 | B1 |
| 6592567 | Levin et al. | Jul 2003 | B1 |
| 6599256 | Acker et al. | Jul 2003 | B1 |
| 6600954 | Cohen et al. | Jul 2003 | B2 |
| 6600956 | Maschino et al. | Jul 2003 | B2 |
| 6601459 | Jenni et al. | Aug 2003 | B1 |
| 6605084 | Acker et al. | Aug 2003 | B2 |
| 6613045 | Laufer et al. | Sep 2003 | B1 |
| 6615071 | Casscells, III et al. | Sep 2003 | B1 |
| 6616624 | Kieval | Sep 2003 | B1 |
| 6620151 | Blischak et al. | Sep 2003 | B2 |
| 6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
| 6622731 | Daniel et al. | Sep 2003 | B2 |
| 6635054 | Fjield et al. | Oct 2003 | B2 |
| 6640120 | Swanson et al. | Oct 2003 | B1 |
| 6654636 | Dev et al. | Nov 2003 | B1 |
| 6666845 | Hooper et al. | Dec 2003 | B2 |
| 6669655 | Acker et al. | Dec 2003 | B1 |
| 6671556 | Osorio et al. | Dec 2003 | B2 |
| 6672312 | Acker | Jan 2004 | B2 |
| 6676657 | Wood | Jan 2004 | B2 |
| 6681136 | Schuler et al. | Jan 2004 | B2 |
| 6684105 | Cohen et al. | Jan 2004 | B2 |
| 6685648 | Flaherty et al. | Feb 2004 | B2 |
| 6690971 | Schauerte et al. | Feb 2004 | B2 |
| 6692738 | MacLaughlin et al. | Feb 2004 | B2 |
| 6697670 | Chomenky et al. | Feb 2004 | B2 |
| 6711444 | Koblish | Mar 2004 | B2 |
| 6718208 | Hill et al. | Apr 2004 | B2 |
| 6735471 | Hill et al. | May 2004 | B2 |
| 6736835 | Pellegrino et al. | May 2004 | B2 |
| 6738663 | Schroeppel et al. | May 2004 | B2 |
| 6749598 | Keren et al. | Jun 2004 | B1 |
| 6752805 | Maguire et al. | Jun 2004 | B2 |
| 6786904 | Doscher et al. | Sep 2004 | B2 |
| 6795728 | Chomenky et al. | Sep 2004 | B2 |
| 6845267 | Harrison et al. | Jan 2005 | B2 |
| 6850801 | Kieval et al. | Feb 2005 | B2 |
| 6862479 | Whitehurst et al. | Mar 2005 | B1 |
| 6865416 | Dev et al. | Mar 2005 | B2 |
| 6869431 | Maguire et al. | Mar 2005 | B2 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6893436 | Woodard et al. | May 2005 | B2 |
| 6916656 | Walters et al. | Jul 2005 | B2 |
| 6917834 | Koblish et al. | Jul 2005 | B2 |
| 6923808 | Taimisto | Aug 2005 | B2 |
| 6927049 | Rubinsky et al. | Aug 2005 | B2 |
| 6936047 | Nasab et al. | Aug 2005 | B2 |
| 6939345 | KenKnight et al. | Sep 2005 | B2 |
| 6939346 | Kannenberg et al. | Sep 2005 | B2 |
| 6949097 | Stewart et al. | Sep 2005 | B2 |
| 6958060 | Mathiesen et al. | Oct 2005 | B2 |
| 6969388 | Goldman et al. | Nov 2005 | B2 |
| 6972013 | Zhang et al. | Dec 2005 | B1 |
| 6978174 | Gelfand et al. | Dec 2005 | B2 |
| 6985774 | Kieval et al. | Jan 2006 | B2 |
| 6994700 | Elkins et al. | Feb 2006 | B2 |
| 6994706 | Chornenky et al. | Feb 2006 | B2 |
| 7004911 | Tu et al. | Feb 2006 | B1 |
| 7054685 | Dimmer et al. | May 2006 | B2 |
| 7063679 | Maguire et al. | Jun 2006 | B2 |
| 7081114 | Rashidi | Jul 2006 | B2 |
| 7081115 | Taimisto | Jul 2006 | B2 |
| 7083614 | Fjield et al. | Aug 2006 | B2 |
| 7122019 | Kesten et al. | Oct 2006 | B1 |
| 7149574 | Yun et al. | Dec 2006 | B2 |
| 7155284 | Whitehurst et al. | Dec 2006 | B1 |
| 7160296 | Pearson et al. | Jan 2007 | B2 |
| 7162303 | Levin et al. | Jan 2007 | B2 |
| 7191015 | Lamson et al. | Mar 2007 | B2 |
| 7221979 | Zhou et al. | May 2007 | B2 |
| 7373204 | Gelfand et al. | May 2008 | B2 |
| 7381200 | Katoh et al. | Jun 2008 | B2 |
| 7390894 | Weinshilboum et al. | Jun 2008 | B2 |
| 7444183 | Knudson et al. | Oct 2008 | B2 |
| 7617005 | Demarais et al. | Nov 2009 | B2 |
| 7620451 | Demarais et al. | Nov 2009 | B2 |
| 7647115 | Levin et al. | Jan 2010 | B2 |
| 7653438 | Deem et al. | Jan 2010 | B2 |
| 7717948 | Demarais et al. | May 2010 | B2 |
| 7756583 | Demarais et al. | Jul 2010 | B2 |
| 7778703 | Gross et al. | Aug 2010 | B2 |
| 8131371 | Demarais et al. | Mar 2012 | B2 |
| 8131372 | Levin et al. | Mar 2012 | B2 |
| 8140170 | Rezai et al. | Mar 2012 | B2 |
| 8145317 | Demarais et al. | Mar 2012 | B2 |
| 8150518 | Levin et al. | Apr 2012 | B2 |
| 8150519 | Demarais et al. | Apr 2012 | B2 |
| 8150520 | Demarais et al. | Apr 2012 | B2 |
| 8175711 | Demarais et al. | May 2012 | B2 |
| 8702619 | Wang | Apr 2014 | B2 |
| 8768470 | Deem et al. | Jul 2014 | B2 |
| 8888773 | Chang et al. | Nov 2014 | B2 |
| 8909316 | Ng | Dec 2014 | B2 |
| 8977359 | Rossing | Mar 2015 | B2 |
| 9002446 | Wenzel et al. | Apr 2015 | B2 |
| 9014809 | Wenzel et al. | Apr 2015 | B2 |
| 9014821 | Wang | Apr 2015 | B2 |
| 9022948 | Wang | May 2015 | B2 |
| 9119600 | Richardson et al. | Sep 2015 | B2 |
| 9168094 | Lee et al. | Oct 2015 | B2 |
| 9179973 | Nabutovsky et al. | Nov 2015 | B2 |
| 9186212 | Nabutovsky et al. | Nov 2015 | B2 |
| 9295842 | Ghaffari et al. | Mar 2016 | B2 |
| 9314300 | Nabutovsky et al. | Apr 2016 | B2 |
| 9375154 | Wang | Jun 2016 | B2 |
| 9427283 | Nabutovsky et al. | Aug 2016 | B2 |
| 9427579 | Fain et al. | Aug 2016 | B2 |
| 9554850 | Lee et al. | Jan 2017 | B2 |
| 9579030 | Scheuermann et al. | Feb 2017 | B2 |
| 10537734 | Zarins | Jan 2020 | B2 |
| 20010044596 | Jaafar | Nov 2001 | A1 |
| 20020002329 | Avitall | Jan 2002 | A1 |
| 20020026222 | Schauerte et al. | Feb 2002 | A1 |
| 20020026228 | Schauerte | Feb 2002 | A1 |
| 20020032468 | Hill et al. | Mar 2002 | A1 |
| 20020038137 | Stein | Mar 2002 | A1 |
| 20020040204 | Dev et al. | Apr 2002 | A1 |
| 20020045853 | Dev et al. | Apr 2002 | A1 |
| 20020065541 | Fredricks et al. | May 2002 | A1 |
| 20020072782 | Osorio et al. | Jun 2002 | A1 |
| 20020107553 | Hill et al. | Aug 2002 | A1 |
| 20020116030 | Rezai | Aug 2002 | A1 |
| 20020120304 | Mest | Aug 2002 | A1 |
| 20020139379 | Edwards et al. | Oct 2002 | A1 |
| 20020165532 | Hill et al. | Nov 2002 | A1 |
| 20020165586 | Hill et al. | Nov 2002 | A1 |
| 20020169413 | Keren et al. | Nov 2002 | A1 |
| 20020177846 | Muller et al. | Nov 2002 | A1 |
| 20020183682 | Darvish et al. | Dec 2002 | A1 |
| 20020183684 | Dev et al. | Dec 2002 | A1 |
| 20020188325 | Hill et al. | Dec 2002 | A1 |
| 20020198512 | Seward | Dec 2002 | A1 |
| 20030004549 | Hill et al. | Jan 2003 | A1 |
| 20030009145 | Struijker-Boudier et al. | Jan 2003 | A1 |
| 20030018367 | DiLorenzo | Jan 2003 | A1 |
| 20030040774 | Terry et al. | Feb 2003 | A1 |
| 20030045909 | Gross et al. | Mar 2003 | A1 |
| 20030050635 | Truckai et al. | Mar 2003 | A1 |
| 20030050681 | Pianca et al. | Mar 2003 | A1 |
| 20030060848 | Kieval et al. | Mar 2003 | A1 |
| 20030060857 | Perrson et al. | Mar 2003 | A1 |
| 20030060858 | Kieval et al. | Mar 2003 | A1 |
| 20030074039 | Puskas | Apr 2003 | A1 |
| 20030100924 | Foreman et al. | May 2003 | A1 |
| 20030120270 | Acker | Jun 2003 | A1 |
| 20030125790 | Fastovsky et al. | Jul 2003 | A1 |
| 20030150464 | Casscells | Aug 2003 | A1 |
| 20030158584 | Cates et al. | Aug 2003 | A1 |
| 20030181897 | Thomas et al. | Sep 2003 | A1 |
| 20030181963 | Pellegrino et al. | Sep 2003 | A1 |
| 20030199747 | Michlitsch et al. | Oct 2003 | A1 |
| 20030199767 | Cespedes et al. | Oct 2003 | A1 |
| 20030199768 | Cespedes et al. | Oct 2003 | A1 |
| 20030199806 | Kieval | Oct 2003 | A1 |
| 20030199863 | Swanson et al. | Oct 2003 | A1 |
| 20030204161 | Ferek-Petric | Oct 2003 | A1 |
| 20030216792 | Levin et al. | Nov 2003 | A1 |
| 20030220521 | Reitz et al. | Nov 2003 | A1 |
| 20030229340 | Sherry et al. | Dec 2003 | A1 |
| 20030233099 | Danaek et al. | Dec 2003 | A1 |
| 20030236443 | Cespedes et al. | Dec 2003 | A1 |
| 20040010289 | Biggs et al. | Jan 2004 | A1 |
| 20040010303 | Bolea et al. | Jan 2004 | A1 |
| 20040019364 | Kieval et al. | Jan 2004 | A1 |
| 20040019371 | Jaafar et al. | Jan 2004 | A1 |
| 20040064090 | Keren et al. | Apr 2004 | A1 |
| 20040064091 | Keren et al. | Apr 2004 | A1 |
| 20040065615 | Hooper et al. | Apr 2004 | A1 |
| 20040073238 | Makower | Apr 2004 | A1 |
| 20040082978 | Harrison et al. | Apr 2004 | A1 |
| 20040101523 | Reitz et al. | May 2004 | A1 |
| 20040106953 | Yomtov et al. | Jun 2004 | A1 |
| 20040111080 | Harper et al. | Jun 2004 | A1 |
| 20040116401 | Shah | Jun 2004 | A1 |
| 20040127942 | Yomtov et al. | Jul 2004 | A1 |
| 20040162590 | Whitehurst et al. | Aug 2004 | A1 |
| 20040163655 | Gelfand et al. | Aug 2004 | A1 |
| 20040167415 | Gelfand et al. | Aug 2004 | A1 |
| 20040176699 | Walker et al. | Sep 2004 | A1 |
| 20040176757 | Sinelnikov et al. | Sep 2004 | A1 |
| 20040193228 | Gerber | Sep 2004 | A1 |
| 20040215186 | Cornelius et al. | Oct 2004 | A1 |
| 20040220511 | Scott et al. | Nov 2004 | A1 |
| 20040243102 | Berg et al. | Dec 2004 | A1 |
| 20040243206 | Tadlock | Dec 2004 | A1 |
| 20040249416 | Yun et al. | Dec 2004 | A1 |
| 20040254616 | Rossing et al. | Dec 2004 | A1 |
| 20050010263 | Schauerte | Jan 2005 | A1 |
| 20050021092 | Yun et al. | Jan 2005 | A1 |
| 20050038409 | Segal et al. | Feb 2005 | A1 |
| 20050049542 | Sigg et al. | Mar 2005 | A1 |
| 20050065562 | Rezai | Mar 2005 | A1 |
| 20050065573 | Rezai | Mar 2005 | A1 |
| 20050065574 | Rezai | Mar 2005 | A1 |
| 20050075681 | Rezai et al. | Apr 2005 | A1 |
| 20050080409 | Young et al. | Apr 2005 | A1 |
| 20050080459 | Jacobson et al. | Apr 2005 | A1 |
| 20050096647 | Steinke et al. | May 2005 | A1 |
| 20050096710 | Kieval | May 2005 | A1 |
| 20050153379 | Hoon et al. | Jul 2005 | A1 |
| 20050153885 | Yun et al. | Jul 2005 | A1 |
| 20050154418 | Kieval et al. | Jul 2005 | A1 |
| 20050171523 | Rubinsky et al. | Aug 2005 | A1 |
| 20050171574 | Rubinsky et al. | Aug 2005 | A1 |
| 20050171575 | Dev et al. | Aug 2005 | A1 |
| 20050187579 | Danek et al. | Aug 2005 | A1 |
| 20050197624 | Goodson et al. | Sep 2005 | A1 |
| 20050209548 | Dev et al. | Sep 2005 | A1 |
| 20050209642 | Palti | Sep 2005 | A1 |
| 20050228460 | Levin et al. | Oct 2005 | A1 |
| 20050234523 | Levin et al. | Oct 2005 | A1 |
| 20050240126 | Foley et al. | Oct 2005 | A1 |
| 20050240173 | Palti | Oct 2005 | A1 |
| 20050240228 | Palti | Oct 2005 | A1 |
| 20050240241 | Yun et al. | Oct 2005 | A1 |
| 20050245882 | Elkins et al. | Nov 2005 | A1 |
| 20050245892 | Elkins et al. | Nov 2005 | A1 |
| 20050251212 | Kieval et al. | Nov 2005 | A1 |
| 20050261672 | Deem et al. | Nov 2005 | A1 |
| 20050267010 | Goodson et al. | Dec 2005 | A1 |
| 20050282284 | Rubinsky et al. | Dec 2005 | A1 |
| 20060004417 | Rossing et al. | Jan 2006 | A1 |
| 20060004430 | Rossing et al. | Jan 2006 | A1 |
| 20060025821 | Gelfand et al. | Feb 2006 | A1 |
| 20060030814 | Valencia et al. | Feb 2006 | A1 |
| 20060036218 | Goodson et al. | Feb 2006 | A1 |
| 20060041277 | Deem et al. | Feb 2006 | A1 |
| 20060041283 | Gelfand et al. | Feb 2006 | A1 |
| 20060067972 | Kesten et al. | Mar 2006 | A1 |
| 20060069323 | Elkins et al. | Mar 2006 | A1 |
| 20060074453 | Kieval et al. | Apr 2006 | A1 |
| 20060079859 | Elkins et al. | Apr 2006 | A1 |
| 20060085046 | Rezai et al. | Apr 2006 | A1 |
| 20060085054 | Zikorus et al. | Apr 2006 | A1 |
| 20060089674 | Walters et al. | Apr 2006 | A1 |
| 20060095029 | Young et al. | May 2006 | A1 |
| 20060100667 | Machado et al. | May 2006 | A1 |
| 20060106429 | Libbus et al. | May 2006 | A1 |
| 20060111754 | Rezai et al. | May 2006 | A1 |
| 20060116720 | Knoblich | Jun 2006 | A1 |
| 20060121016 | Lee | Jun 2006 | A1 |
| 20060121610 | Rubinsky et al. | Jun 2006 | A1 |
| 20060135998 | Libbus et al. | Jun 2006 | A1 |
| 20060136004 | Cowan et al. | Jun 2006 | A1 |
| 20060149350 | Patel et al. | Jul 2006 | A1 |
| 20060155344 | Rezai et al. | Jul 2006 | A1 |
| 20060167437 | Valencia | Jul 2006 | A1 |
| 20060167498 | DiLorenzo | Jul 2006 | A1 |
| 20060167499 | Palti | Jul 2006 | A1 |
| 20060189941 | Seward et al. | Aug 2006 | A1 |
| 20060189960 | Kesten et al. | Aug 2006 | A1 |
| 20060190044 | Libbus et al. | Aug 2006 | A1 |
| 20060206149 | Yun | Sep 2006 | A1 |
| 20060206150 | Demarais et al. | Sep 2006 | A1 |
| 20060212076 | Demarais et al. | Sep 2006 | A1 |
| 20060212078 | Demarais et al. | Sep 2006 | A1 |
| 20060229677 | Moffitt et al. | Oct 2006 | A1 |
| 20060235474 | Demarais | Oct 2006 | A1 |
| 20060265014 | Demarais et al. | Nov 2006 | A1 |
| 20060265015 | Demarais et al. | Nov 2006 | A1 |
| 20060271111 | Demarais et al. | Nov 2006 | A1 |
| 20060276852 | Demarais et al. | Dec 2006 | A1 |
| 20070066957 | Demarais et al. | Mar 2007 | A1 |
| 20070066972 | Ormsby et al. | Mar 2007 | A1 |
| 20070083239 | Demarais et al. | Apr 2007 | A1 |
| 20070128174 | Kleinsek | Jun 2007 | A1 |
| 20070129720 | Demarais et al. | Jun 2007 | A1 |
| 20070129760 | Demarais et al. | Jun 2007 | A1 |
| 20070129761 | Demarais et al. | Jun 2007 | A1 |
| 20070135875 | Demarais et al. | Jun 2007 | A1 |
| 20070142864 | Libbus et al. | Jun 2007 | A1 |
| 20070156200 | Kornet et al. | Jul 2007 | A1 |
| 20070173899 | Levin et al. | Jul 2007 | A1 |
| 20070208382 | Yun | Sep 2007 | A1 |
| 20070265687 | Deem et al. | Nov 2007 | A1 |
| 20070282376 | Shuros et al. | Dec 2007 | A1 |
| 20070288070 | Libbus et al. | Dec 2007 | A1 |
| 20080004673 | Rossing et al. | Jan 2008 | A1 |
| 20080015659 | Zhang et al. | Jan 2008 | A1 |
| 20080039904 | Bulkes et al. | Feb 2008 | A1 |
| 20080057590 | Urdea et al. | Mar 2008 | A1 |
| 20080091255 | Caparso et al. | Apr 2008 | A1 |
| 20080140150 | Zhou et al. | Jun 2008 | A1 |
| 20080213331 | Gelfand et al. | Sep 2008 | A1 |
| 20080255642 | Zarins et al. | Oct 2008 | A1 |
| 20080319513 | Pu et al. | Dec 2008 | A1 |
| 20090024195 | Rezai et al. | Jan 2009 | A1 |
| 20090036948 | Levin et al. | Feb 2009 | A1 |
| 20090062873 | Wu et al. | Mar 2009 | A1 |
| 20090076409 | Wu et al. | Mar 2009 | A1 |
| 20090105605 | Abreu | Apr 2009 | A1 |
| 20100010567 | Deem et al. | Jan 2010 | A1 |
| 20100057150 | Demarais et al. | Mar 2010 | A1 |
| 20100069888 | Solomon | Mar 2010 | A1 |
| 20100086948 | Gold et al. | Apr 2010 | A1 |
| 20100087716 | Nashed | Apr 2010 | A1 |
| 20100114244 | Manda et al. | May 2010 | A1 |
| 20100137860 | Demarais et al. | Jun 2010 | A1 |
| 20100137952 | Demarais et al. | Jun 2010 | A1 |
| 20100166739 | Chancellor et al. | Jul 2010 | A1 |
| 20100168731 | Wu et al. | Jul 2010 | A1 |
| 20100168739 | Wu et al. | Jul 2010 | A1 |
| 20100174282 | Demarais et al. | Jul 2010 | A1 |
| 20100191112 | Demarais et al. | Jul 2010 | A1 |
| 20100222851 | Deem et al. | Sep 2010 | A1 |
| 20100222854 | Demarais et al. | Sep 2010 | A1 |
| 20100249773 | Clark et al. | Sep 2010 | A1 |
| 20100268307 | Demarais et al. | Oct 2010 | A1 |
| 20100331833 | Maschke et al. | Dec 2010 | A1 |
| 20110060324 | Wu et al. | Mar 2011 | A1 |
| 20110086257 | Pitteloud et al. | Apr 2011 | A1 |
| 20110112400 | Emery et al. | May 2011 | A1 |
| 20110137298 | Nguyen et al. | Jun 2011 | A1 |
| 20110152759 | Clymer et al. | Jun 2011 | A1 |
| 20110160644 | Dacey, Jr. et al. | Jun 2011 | A1 |
| 20110178570 | Demarais | Jul 2011 | A1 |
| 20110184337 | Evans et al. | Jul 2011 | A1 |
| 20110200171 | Beetel et al. | Aug 2011 | A1 |
| 20110202098 | Demarais et al. | Aug 2011 | A1 |
| 20110208096 | Demarais et al. | Aug 2011 | A1 |
| 20110257564 | Demarais et al. | Oct 2011 | A1 |
| 20110264011 | Wu et al. | Oct 2011 | A1 |
| 20110264075 | Leung et al. | Oct 2011 | A1 |
| 20110270120 | McFarlin et al. | Nov 2011 | A1 |
| 20110306851 | Wang | Dec 2011 | A1 |
| 20120029504 | Alfonzo et al. | Feb 2012 | A1 |
| 20120116383 | Mauch | May 2012 | A1 |
| 20120123400 | Francischelli et al. | May 2012 | A1 |
| 20120130289 | Demarais et al. | May 2012 | A1 |
| 20120130345 | Levin et al. | May 2012 | A1 |
| 20120143097 | Pike, Jr. | Jun 2012 | A1 |
| 20120172680 | Gelfand | Jul 2012 | A1 |
| 20120172837 | Demarais et al. | Jul 2012 | A1 |
| 20120172870 | Jenson et al. | Jul 2012 | A1 |
| 20120191079 | Moll et al. | Jul 2012 | A1 |
| 20120296232 | Ng | Nov 2012 | A1 |
| 20120296329 | Ng | Nov 2012 | A1 |
| 20130085489 | Fain et al. | Apr 2013 | A1 |
| 20130123778 | Richardson et al. | May 2013 | A1 |
| 20130165764 | Scheuermann et al. | Jun 2013 | A1 |
| 20130172878 | Subramaniam et al. | Jul 2013 | A1 |
| 20130178750 | Sheehan et al. | Jul 2013 | A1 |
| 20130218029 | Cholette et al. | Aug 2013 | A1 |
| 20130237948 | Donders et al. | Sep 2013 | A1 |
| 20130274614 | Shimada et al. | Oct 2013 | A1 |
| 20130282001 | Hezi-Yamit et al. | Oct 2013 | A1 |
| 20140012133 | Sverdlik et al. | Jan 2014 | A1 |
| 20140012242 | Lee et al. | Jan 2014 | A1 |
| 20140066803 | Choi | Mar 2014 | A1 |
| 20140073903 | Weber et al. | Mar 2014 | A1 |
| 20140074089 | Nishii | Mar 2014 | A1 |
| 20140128865 | Gross | May 2014 | A1 |
| 20140194866 | Wang | Jul 2014 | A1 |
| 20140213873 | Wang | Jul 2014 | A1 |
| 20140221805 | Wang | Aug 2014 | A1 |
| 20140236137 | Tran et al. | Aug 2014 | A1 |
| 20140236138 | Tran et al. | Aug 2014 | A1 |
| 20140246465 | Peterson et al. | Sep 2014 | A1 |
| 20140249524 | Kocur | Sep 2014 | A1 |
| 20140266235 | Mathur | Sep 2014 | A1 |
| 20140275924 | Min et al. | Sep 2014 | A1 |
| 20140276124 | Cholette et al. | Sep 2014 | A1 |
| 20140276733 | VanScoy et al. | Sep 2014 | A1 |
| 20140276742 | Nabutovsky et al. | Sep 2014 | A1 |
| 20140276746 | Nabutovsky et al. | Sep 2014 | A1 |
| 20140276755 | Cao et al. | Sep 2014 | A1 |
| 20140276762 | Parsonage | Sep 2014 | A1 |
| 20140276766 | Brotz et al. | Sep 2014 | A1 |
| 20140276767 | Brotz et al. | Sep 2014 | A1 |
| 20140276773 | Brotz et al. | Sep 2014 | A1 |
| 20140316400 | Blix et al. | Oct 2014 | A1 |
| 20140316496 | Masson et al. | Oct 2014 | A1 |
| 20140330267 | Harrington | Nov 2014 | A1 |
| 20140336637 | Agrawal et al. | Nov 2014 | A1 |
| 20150005764 | Hanson et al. | Jan 2015 | A1 |
| 20150018656 | Min et al. | Jan 2015 | A1 |
| 20150025524 | Nabutovsky | Jan 2015 | A1 |
| 20150112329 | Ng | Apr 2015 | A1 |
| 20150119674 | Fischell et al. | Apr 2015 | A1 |
| 20150173673 | Toth et al. | Jun 2015 | A1 |
| 20150201997 | Osypka | Jul 2015 | A1 |
| 20150216590 | Wang et al. | Aug 2015 | A1 |
| 20150223877 | Behar et al. | Aug 2015 | A1 |
| 20150224326 | Toth et al. | Aug 2015 | A1 |
| 20150289770 | Wang | Oct 2015 | A1 |
| 20150289929 | Toth et al. | Oct 2015 | A1 |
| 20150366609 | Richardson et al. | Dec 2015 | A1 |
| 20160000345 | Kobayashi et al. | Jan 2016 | A1 |
| 20160015452 | Nabutovsky et al. | Jan 2016 | A1 |
| 20160029960 | Toth et al. | Feb 2016 | A1 |
| 20160038028 | Buelna et al. | Feb 2016 | A1 |
| 20160081744 | Wang | Mar 2016 | A1 |
| 20160095652 | Lee et al. | Apr 2016 | A1 |
| 20160106498 | Highsmith et al. | Apr 2016 | A1 |
| 20160184010 | Nabutovsky et al. | Jun 2016 | A1 |
| 20160213262 | Ghaffari et al. | Jul 2016 | A1 |
| 20160213424 | Ghaffari et al. | Jul 2016 | A1 |
| 20160324572 | Gross et al. | Nov 2016 | A1 |
| 20160331451 | Nabutovsky et al. | Nov 2016 | A1 |
| 20160331453 | Fain et al. | Nov 2016 | A1 |
| 20160374568 | Wang | Dec 2016 | A1 |
| 20170215950 | Gross et al. | Aug 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 101489624 | Jul 2009 | CN |
| 3151180 | Aug 1982 | DE |
| 0811395 | Dec 1997 | EP |
| 1169976 | Jan 2002 | EP |
| 2092957 | Aug 2009 | EP |
| 2316371 | May 2011 | EP |
| 2594193 | May 2013 | EP |
| 2613704 | Jul 2013 | EP |
| 2747691 | Jul 2014 | EP |
| 2852339 | Apr 2015 | EP |
| 2866645 | May 2015 | EP |
| 2887900 | Jul 2015 | EP |
| 2907464 | Aug 2015 | EP |
| 2914334 | Sep 2015 | EP |
| 2967383 | Jan 2016 | EP |
| 2978372 | Feb 2016 | EP |
| 3011899 | Apr 2016 | EP |
| 3028628 | Jun 2016 | EP |
| 3089686 | Nov 2016 | EP |
| 2709517 | Jan 2017 | EP |
| H08504531 | May 1996 | JP |
| H1071037 | Mar 1998 | JP |
| 2001518808 | Oct 2001 | JP |
| 2005278739 | Oct 2005 | JP |
| 2008515544 | May 2008 | JP |
| 2009539565 | Nov 2009 | JP |
| 2010162163 | Jul 2010 | JP |
| 2010533513 | Oct 2010 | JP |
| 2011505929 | Mar 2011 | JP |
| WO-1985001213 | Mar 1985 | WO |
| 2014091328 | Jul 1989 | WO |
| WO-1991004725 | Apr 1991 | WO |
| WO-1992020291 | Nov 1992 | WO |
| WO-1993002740 | Feb 1993 | WO |
| WO-1993007803 | Apr 1993 | WO |
| WO-1994000188 | Jan 1994 | WO |
| WO-1994007446 | Apr 1994 | WO |
| WO-1994011057 | May 1994 | WO |
| WO-1995025472 | Sep 1995 | WO |
| WO-1995031142 | Nov 1995 | WO |
| WO-1995033514 | Dec 1995 | WO |
| WO-1996000039 | Jan 1996 | WO |
| WO-1996004957 | Feb 1996 | WO |
| WO-1996011723 | Apr 1996 | WO |
| WO-1997013463 | Apr 1997 | WO |
| WO-1997013550 | Apr 1997 | WO |
| WO-1997036548 | Oct 1997 | WO |
| WO-1997049453 | Dec 1997 | WO |
| WO-1998037926 | Sep 1998 | WO |
| WO-1998042403 | Oct 1998 | WO |
| WO-1998043700 | Oct 1998 | WO |
| WO-1998043701 | Oct 1998 | WO |
| WO-1998048888 | Nov 1998 | WO |
| 1999000060 | Jan 1999 | WO |
| WO-1999000060 | Jan 1999 | WO |
| WO-1999033407 | Jul 1999 | WO |
| WO-1999051286 | Oct 1999 | WO |
| WO-1999052424 | Oct 1999 | WO |
| WO-2001022897 | Apr 2001 | WO |
| WO-2001026729 | Apr 2001 | WO |
| WO-2001070114 | Sep 2001 | WO |
| WO-2002009808 | Feb 2002 | WO |
| WO-2002026314 | Apr 2002 | WO |
| WO-2002053207 | Jul 2002 | WO |
| WO-2002070039 | Sep 2002 | WO |
| WO-2002070047 | Sep 2002 | WO |
| WO-2002085192 | Oct 2002 | WO |
| WO-2002085448 | Oct 2002 | WO |
| WO-2003018108 | Mar 2003 | WO |
| WO-2003022167 | Mar 2003 | WO |
| WO-2003028802 | Apr 2003 | WO |
| WO-2003063692 | Aug 2003 | WO |
| WO-2003071140 | Aug 2003 | WO |
| WO-2003076008 | Sep 2003 | WO |
| WO-2003082080 | Oct 2003 | WO |
| WO-2003082080 | Oct 2003 | WO |
| WO-2003082403 | Oct 2003 | WO |
| WO-2004026370 | Apr 2004 | WO |
| WO-2004026371 | Apr 2004 | WO |
| WO-2004026374 | Apr 2004 | WO |
| WO-2004030718 | Apr 2004 | WO |
| WO-2004032791 | Apr 2004 | WO |
| WO-2004107965 | Dec 2004 | WO |
| WO-2005014100 | Feb 2005 | WO |
| WO-2005016165 | Feb 2005 | WO |
| WO-2005032646 | Apr 2005 | WO |
| WO-2005030072 | Apr 2005 | WO |
| WO-2005041748 | May 2005 | WO |
| WO-2005065284 | Jul 2005 | WO |
| WO-2005084389 | Sep 2005 | WO |
| WO-2005097256 | Oct 2005 | WO |
| WO-2005110528 | Nov 2005 | WO |
| WO-2005123183 | Dec 2005 | WO |
| WO-2006007048 | Jan 2006 | WO |
| WO-2006018528 | Feb 2006 | WO |
| WO-2006022790 | Mar 2006 | WO |
| WO-2006031899 | Mar 2006 | WO |
| WO-2006041847 | Apr 2006 | WO |
| WO-2006041881 | Apr 2006 | WO |
| WO-2006105121 | Oct 2006 | WO |
| WO-2007008954 | Jan 2007 | WO |
| WO-2007035537 | Mar 2007 | WO |
| WO-2007078997 | Jul 2007 | WO |
| WO-2007086965 | Aug 2007 | WO |
| WO-2007103879 | Sep 2007 | WO |
| WO-2007103881 | Sep 2007 | WO |
| WO-2007121309 | Oct 2007 | WO |
| WO-2007146834 | Dec 2007 | WO |
| 2008003058 | Jan 2008 | WO |
| WO-2008003058 | Jan 2008 | WO |
| WO-2008049084 | Apr 2008 | WO |
| WO-2008061150 | May 2008 | WO |
| WO-2008061152 | May 2008 | WO |
| WO-2008070413 | Jun 2008 | WO |
| WO-2010078175 | Jul 2010 | WO |
| 2011089935 | Jul 2011 | WO |
| 2012024543 | Feb 2012 | WO |
| 2012068471 | May 2012 | WO |
| 2013030743 | Mar 2013 | WO |
| 2013112844 | Aug 2013 | WO |
| 2014012282 | Jan 2014 | WO |
| 2014029355 | Feb 2014 | WO |
| 2014059165 | Apr 2014 | WO |
| 2014068577 | May 2014 | WO |
| 2014091401 | Jun 2014 | WO |
| 2014149550 | Sep 2014 | WO |
| 2014149552 | Sep 2014 | WO |
| 2014149553 | Sep 2014 | WO |
| 2014149690 | Sep 2014 | WO |
| 2014150425 | Sep 2014 | WO |
| 2014150432 | Sep 2014 | WO |
| 2014150441 | Sep 2014 | WO |
| 2014150455 | Sep 2014 | WO |
| 2014158708 | Oct 2014 | WO |
| 2014158713 | Oct 2014 | WO |
| 2014163990 | Oct 2014 | WO |
| 2014179768 | Nov 2014 | WO |
| 2014182946 | Nov 2014 | WO |
| Entry |
|---|
| Allen, E.V., Sympathectomy for essential hypertension, Circulation, 1952, 6:131-140. |
| Bello-Reuss, E. et al., “Effects of Acute Unilateral Renal Denervation in the Rat,” Journal of Clinical Investigation, vol. 56, Jul. 1975, pp. 208-217. |
| Bello-Reuss, E. et al., “Effects of Renal Sympathetic Nerve Stimulation on Proximal Water and Sodium Reabsorption,” Journal of Clinical Investigation, vol. 57, Apr. 1976, pp. 1104-1107. |
| Bhandari, A. and Ellias, M., “Loin Pain Hematuria Syndrome: Pain Control with RFA to the Splanchanic Plexus,” The Pain Cline, 2000, vol. 12, No. 4, pp. 323-327. |
| Curtis, John J. et al., “Surgical Therapy for Persistent Hypertension After Renal Transplantation” Transplantation, 31:125-128 (1981). |
| Dibona, Gerald F. et al., “Neural Control of Renal Function,” Physiological Reviews, vol. 77, No. 1, Jan. 1997, The American Physiological Society 1997, pp. 75-197. |
| Dibona, Gerald F., “Neural Control of the Kidney—Past, Present and Future,” Nov. 4, 2002, Novartis Lecture, Hypertension 2003, 41 part 2, 2002 American Heart Association, Inc., pp. 621-624. |
| Janssen, Ben J.A. et al., “Effects of Complete Renal Denervation and Selective Afferent Renal Denervation on the Hypertension Induced by Intrarenal Norepinephrine Infusion in Conscious Rats”, Journal of Hypertension 1989, 7: 447-455. |
| Katholi, Richard E., “Renal Nerves in the Pathogenesis of Hypertension in Experimental Animals and Humans,” Am J. Physiol. Vol. 245, 1983, the American Physiological Society 1983, pp. F1-F14. |
| Krum, Henry et al., “Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Mulitcentre Safety and Proof-of Principle Cohort Study,” Lancet 2009; 373:1275-81. |
| Krum, et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension.” New England Journal of Med, Aug. 2009, 361; 9, 3 pages. |
| Luippold, Gerd et al., “Chronic Renal Denervation Prevents Glomerular Hyperfiltration in Diabetic Rats”, Nephrol Dial Transplant, vol. 19, No. 2, 2004, pp. 342-347. |
| Mahfoud et al. “Treatment strategies for resistant arterial hypertension” Dtsch Arztebl Int. 2011;108:725-731. |
| Osborn, et al., “Effect of Renal Nerve Stimulation on Renal Blood Flow Autoregulation and Antinatriuresis During Reductions in Renal Perfusion Pressure,” Proceedings of the Society for Experimental Biology and Medicine, vol. 168, 77-81, 1981. |
| Page, I.H. et al., “The Effect of Renal Denervation on Patients Suffering From Nephritis,” Feb. 27, 1935;443-458. |
| Page, I.H. et al., “The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension,” J. Clin Invest. 1934;14:27-30. |
| Rocha-Singh, “Catheter-Based Sympathetic Renal Denervation,” Endovascular Today, Aug. 2009, 4 pages. |
| Schlaich, M.P. et al., “Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept,” Hypertension, 2009; 54:1195-1201. |
| Schlaich, M.P. et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension,” N Engl J Med 2009; 361(9): 932-934. |
| Smithwick, R.H. et al., “Splanchnicectomy for Essential Hypertension,” Journal Am Med Assn, 1953; 152:1501-1504. |
| Symplicity HTN-1 Investigators; Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-917. |
| Symplicity HTN-2 Investigators, “Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial”; Lancet, Dec. 4, 2010, vol. 376, pp. 1903-1909. |
| United States Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003, 593 pages. |
| Valente, John F. et al., “Laparoscopic Renal Denervation for Intractable ADPKD-Related Pain”, Nephrol Dial Transplant (2001) 16: 1 page. |
| Wagner, C.D. et al., “Very Low Frequency Oscillations in Arterial Blood Pressure After Autonomic Blockade in Conscious Dogs,” Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, 1997 the American Physiological Society, pp. 2034-2039. |
| Ahmed, Humera et al., Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension, JACC Cardiovascular Interventions, vol. 5, No. 7, 2012, pp. 758-765. |
| Avitall et al., “The creation of linear contiguous lesions in the atria with an expandable loop catheter,” Journal of the American College of Cardiology, 1999; 33; pp. 972-984. |
| Beale et al., “Minimally Invasive Treatment for Varicose Veins: A Review of Endovenous Laser Treatment and Radiofrequency Ablation”. Lower Extremity Wounds 3(4), 2004, 10 pages. |
| Blessing, Erwin et al., Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements, JACC Cardiovascular Interventions, vol. 6, No. 3, 2013, 1 page. |
| ClinicalTrials.gov, Renal Denervation in Patients with uncontrolled Hypertension in Chinese (2011), 6pages. www.clinicaltrials.gov/ct2/show/NCT01390831. |
| Dodge, et al., “Lumen Diameter of Normal Human Coronary Arteries Influence of Age, Sex, Anatomic Variation, and Left Ventricular Hypertrophy or Dilation”, Circulation, 1992, vol. 86 (1), pp. 232-246. |
| Excerpt of Operator's Manual of Boston Scientific's EPT-1000 XP Cardiac Ablation Controller & Accessories, Version of Apr. 2003, (6 pages). |
| Excerpt of Operator's Manual of Boston Scientific's Maestro 30000 Cardiac Ablation System, Version of Oct. 17, 2005 , (4 pages). |
| Holmes et al., Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation: Clinical Spectrum and Interventional Considerations, JACC: Cardiovascular Interventions, 2: 4, 2009, 10 pages. |
| Kandarpa, Krishna et al., “Handbook of Interventional Radiologic Procedures”, Third Edition, pp. 194-210 (2002). |
| Mount Sinai School of Medicine clinical trial for Impact of Renal Sympathetic Denervation of Chronic Hypertension, Mar. 2013, 11 pages. http://clinicaltrials.gov/ct2/show/NCT01628198. |
| Opposition to European Patent No. 2465470, Granted Oct. 28, 2015, Date of Opposition Jul. 27, 2016, 34 pp. |
| Opposition to European Patent No. EP1802370, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 20 pages. |
| Opposition to European Patent No. EP2037840, Granted Dec. 7, 2011, Date of Opposition Sep. 7, 2012, 25 pages. |
| Opposition to European Patent No. EP2092957, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 26 pages. |
| Oz, Mehmet, Pressure Relief, TIME, Jan. 9, 2012, 2 pages. <www.time.come/time/printout/0,8816,2103278,00.html>. |
| Papademetriou, Vasilios, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, Int. Journal of Hypertension, 2011, 8 pages. |
| Pieper, et al., “Design and Implementation of a New Computerized System for Intraoperative Cardiac Mapping” Journal of Applied Physiology, 1991, vol. 71 (4), pp. 1529-1539. |
| Prochnau, Dirk et al., Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter; Euro Intervention 2012, vol. 7, pp. 1077-1080. |
| Purerfellner, Helmut et al., Incidence, Management, and Outcome in Significant Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation, Am. J. Cardiol , 93, Jun. 1, 2004, 4 pages. |
| Purerfellner, Helmut et al., Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation, Curr. Opin. Cardio. 20 :484-490, 2005. |
| Remo, et al., “Safety and Efficacy of Renal Denervation as a Novel Treatment of Ventricular Tachycardia Storm in Patients with Cardiomyopathy” Heart Rhythm, 2014, 11(4), pp. 541-546. |
| Schneider, Peter A., “Endovascular Skills—Guidewire and Catheter Skills for Endovascular Surgery,” Second Edition Revised and Expanded, 10 pages, (2003). |
| ThermoCool Irrigated Catheter and Integrated Ablation System, Biosense Webster (2006), 6 pages. |
| Tsao, Hsuan-Ming, Evaluation of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation, Cardiac Electrophysiology Review, 6, 2002, 4 pages. |
| U.S. Appl. No. 11/363,867, filed Feb. 27, 2006, 70 pp. |
| U.S. Appl. No. 60/813,589, filed Dec. 29, 2005, 62 pgs. |
| U.S. Appl. No. 60/852,787, filed Oct. 18, 2006, 112 pgs. |
| Ureter, https://en.wikipedia.org/wiki/Ureter, Jun. 2016, 6 pgs. |
| Wittkampf et al., “Control of radiofrequency lesion size by power regulation,” Journal of the American Heart Associate, 1989, 80: pp. 962-968. |
| Zheng et al., “Comparison of the temperature profile and pathological effect at unipolar, bipolar and phased radiofrequency current configurations,” Journal of Interventional Cardiac Electrophysiology, 2001, pp. 401-410. |
| U.S. Appl. No. 95/002,110, filed Aug. 29, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,209, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,233, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,243, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,253, filed Sep. 13, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,255, filed Sep. 13, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,292, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,327, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,335, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,336, filed Sep. 14, 2012, Levin et al. |
| U.S. Appl. No. 95/002,356, filed Sep. 14, 2012, Demarais et al. |
| “2011 Edison Award Winners.” Edison Awards: Honoring Innovations & Innovators, 2011, 6 pages, <http://www.edisonawards.com/BestNewProduct_2011.php>. |
| “2012 top 10 advances in heart disease and stroke research: American Heart Association/America Stroke Association Top 10 Research Report.” American Heart Association, Dec. 17, 2012, 5 pages, <http://newsroom.heart.org/news/2012-top-10-advances-in-heart-241901>. |
| “Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension.” PR Newswire, Jun. 3, 2010, 2 pages, <http://www.prnewswire.com/news-releases/ardianr-receives-2010-europcr-innovation-award-and-demonstrates-further-durability-of-renal-denervation-treatment-for-hypertension-95545014.html>. |
| “Boston Scientific to Acquire Vessix Vascular, Inc.: Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology.” Boston Scientific: Advancing science for life-Investor Relations, Nov. 8, 2012, 2 pages, <http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-newsArticle&id=1756108>. |
| “Cleveland Clinic Unveils Top 10 Medical Innovations for 2012: Experts Predict Ten Emerging Technologies that will Shape Health Care Next Year.” Cleveland Clinic, Oct. 6, 2011,2 pages, <http://my.clevelandclinic.org/media_relations/library/2011/2011-10-6-cleveland-clinic-unveils-top-10-medical-innovations-for-2012.aspx>. |
| “Does renal denervation represent a new treatment option for resistant hypertension?” Interventional News, Aug. 3, 2010, 2 pages, <http://www.cxvascular.com/in-latest-news/interventional-news---latest-news/does-renal-denervation-represent-a-new-treatment-option-for-resistant-hypertension>. |
| “Iberis—Renal Sympathetic Denervation System: Turning innovation into quality care.” [Brochure], Terumo Europe N.V., 2013, Europe, 3 pages. |
| “Neurotech Reports Announces Winners of Gold Electrode Awards.” Neurotech business report, 2009.1 page, <http://www.neurotechreports.com/pages/goldelectrodes09.html>. |
| “Quick. Consistent. Controlled. OneShot renal Denervation System” [Brochure], Covidien: positive results for life, 2013, (n.l.), 4 pages. |
| “Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million.” Vessix Vascular Pharmaceutical Intelligence: A blog specializing in Pharmaceutical Intelligence and Analytics, Nov. 8, 2012, 21 pages, <http://pharmaceuticalintelligence.com/tag/vessix-vascular/>. |
| “The Edison Awards™” Edison Awards: Honoring Innovations & Innovators, 2013, 2 pages, <http://www.edisonawards.com/Awards.php>. |
| “The Future of Renal denervation for the Treatment of Resistant Hypertension.” St. Jude Medical, Inc., 2012, 12 pages. |
| “Vessix Renal Denervation System: So Advanced It's Simple.” [Brochure], Boston Scientific: Advancing science for life, 2013, 6 pages. |
| Asbell, Penny, “Conductive Keratoplasty for the Correction of Hyperopia.” Tr Am Ophth Soc, 2001, vol. 99, 10 pages. |
| Badger, Emilio, “Cardiacafferents play the dominant role in renal nerve inhibition elicited by volume expansion in the rabbit.” Am J Physiol Regul Integr Comp Physiol, vol. 274, 1998, 7 pages. |
| Bengel, Frank, “Serial Assessment of Sympathetic Reinnervation After Orthotopic Heart Transplantation: A longitudinal Study Using PET and C-11 Hydroxyephedrine.” Circulation, vol. 99, 1999,7 pages. |
| Benito, F., et al. “Radiofrequency catheter ablation of accessory pathways in infants.” Heart, 78:160-162 (1997). |
| Bettmann, Michael, Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association, Circulation, vol. 97, 1998, 4 pages. |
| Bohm, Michael et al., “Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Brosky, John, “EuroPCR 2013: CE-approved devices line up for renal denervation approval.” Medical Device Daily, May 28, 2013, 3 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=83002>. |
| Davis, Mark et al., “Effectiveness of Renal Denervation Therapy for Resistant Hypertension.” Journal ofthe American College of Cardiology, vol. 62, No. 3, 2013, 11 pages. |
| Dubuc, M., et al., “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter.” J Interv Cardiac Electrophysiol, 2:285-292 (1998). |
| Final Office Action; U.S. Appl. No. 12/827,700; dated Feb. 5, 2013, 61 pages. |
| Geisler, Benjamin et al., “Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension.” Journal of the American College of Cardiology, col. 60, No. 14, 2012, 7 pages. |
| Gelfand, M., et al., “Treatment of renal failure and hypertension.” U.S. Appl. No. 60/442,970, filed Jan. 29, 2003, 23 pages. |
| Gertner, Jon, “Meet the Tech Duo That's Revitalizing The Medical Device Industry.” Fast Company, Apr. 15, 2013, 6:00 AM, 17 pages, <http://www.fastcompany.com/3007845/meet-tech-duo-thats-revitalizing-medical-device-industry>. |
| Golwyn, D. H., Jr., et al. “Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease.” JVIR, 8: 527-533 (1997). |
| Hall, W. H., et al. “Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor.” Am. J. Roentgenol,174: 1592-1594 (2000). |
| Han, Y.-M, et al., “Renal artery embolization with diluted hot contrast medium: An experimental study.” J Vasc Interv Radiol, 12: 862-868 (2001). |
| Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin. Sci, 87: 13-19 (1994). |
| Hendee, W. R. et al. “Use of Animals in Biomedical Research: The Challenge and Response.” American Medical Association White Paper (1988) 39 pages. |
| Hering, Dagmara et al., “Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Imimdtanz, “Medtronic awarded industry's highest honor for renal denervation system.” The official blog of Medtronic Australasia, Nov. 12, 2012, 2 pages, <http://97waterlooroad.wordpress.com/2012/11/12/medtronic-awarded-industrys-highest-honour-for-renal-denervation-system/>. |
| Kaiser, Chris, AHA Lists Year's Big Advances in CV Research, medpage Today, Dec. 18, 2012, 4 pages, <http://www.medpagetoday.com/Cardiology/PCI/36509>. |
| Kompanowska, E., et al., “Early Effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow.” J Physiol, 531. 2:527-534 (2001). |
| Lee, S. J., et al. “Ultrasonic energy in endoscopic surgery.” Yonsei Med J, 40:545-549 (1999). |
| Linz, Dominik et al., “Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs.” Heart Rhythm, vol. 0, No. 0, 2013, 6 pages. |
| Lustgarten, D. L., et al., “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias.” Progr Cardiovasc Dis, 41:481-498 (1999). |
| Mabin, Tom et al., “First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.” EuroIntervention, vol. 8, 2012, 5 pages. |
| Mahfoud, Felix et al., “Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Circulation, 2013, 25 pages. |
| Mahfoud, Felix et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.” European Heart Journal, 2013, 9 pages. |
| Mahfoud, Felix et al., “Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension.” Hypertension, 2012, 6 pages. |
| Medical-Dictionary.com, Definition of “Animal Model,” http://medical-dictionary.com (search “Animal Model”), 2005, 1 page. |
| Medtronic, Inc., Annual Report (Form 10-K) (Jun. 28, 2011) 44 pages. |
| Millard, F. C., et al., “Renal Embolization for ablation of function in renal failure and hypertension.” Postgraduate Medical Journal, 65, 729-734, (1989). |
| Oliveira, V., et al., “Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats.” Hypertension, 19:II-17-II-21 (1992). |
| Ong, K. L., et al. “Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004.” Hypertension, 49: 69-75 (2007) (originally published online Dec. 11, 2006). |
| Ormiston, John et al., “First-in-human use of the OneShot™ renal denervation system from Covidien.” EuroIntervention, vol. 8, 2013, 4 pages. |
| Ormiston, John et al., “Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial.” EuroIntervention, vol. 9, 2013, 5 pages. |
| Pedersen, Amanda, “TCT 2012: Renal denervation device makers play show and tell.” Medical Device Daily, Oct. 26, 2012, 2 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=80880>. |
| Peet, M., “Hypertension and its Surgical Treatment by bilateral supradiaphragmatic splanchnicectomy” Am J Surgery (1948) pp. 48-68. |
| Renal Denervation (RDN), Symplicity RDN System Common Q&A (2011), 4 pages, http://www.medtronic.com/rdn/mediakit/RDN%20FAQ.pdf. |
| Schlaich, Markus et al., “Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects.” Curr Hypertens Rep, vol. 14, 2012, 7 pages. |
| Schmid, Axel et al., “Does Renal Artery Supply Indicate Treatment Success of Renal Denervation.” Cardiovasc Intervent Radiol, vol. 36, 2013, 5 pages. |
| Schmieder, Roland E. et al., “Updated ESH position paper on interventional therapy of resistant hypertension.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Sievert, Horst, “Novelty Award EuroPCR 2010.” Euro PCR, 2010, 15 pages. |
| Stella, A., et al., “Effects of reversible renal denervation on haemodynamic and excretory functions on the ipsilateral and contralateral kidney in the cat.” Hypertension, 4:181-188 (1986). |
| Stouffer, G. A. et al., “Catheter-based renal denervation in the treatment of resistant hypertension.” Journal of Molecular and Cellular Cardiology, vol. 62, 2013, 6 pages. |
| Swartz, J. F., et al., “Radiofrequency endocardial catheter ablation of accessory atrioventricular pathway atrial insertion sites.” Circulation, 87: 487-499 (1993). |
| Uchida, F., et al., “Effect of radiofrequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites.” PACE, 21:2517-2521 (1998). |
| Verloop, W. L. et al., “Renal denervation: a new treatment option in resistant arterial hypertension.” Neth Heart J., Nov. 30, 2012, 6 pages, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547427/>. |
| Weinstock, M., et al., “Renal denervation prevents sodium retention and hypertension in salt sensitive rabbits with genetic baroreflex impairment.” Clinical Science, 90:287-293 (1996). |
| Wilcox, Josiah N., Scientific Basis Behind Renal Denervation for the Control of Hypertension, ICI 2012, Dec. 5-6, 2012. 38 pages. |
| Worthley, Stephen et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.” European Heart Journal, vol. 34, 2013, 9 pages. |
| Worthley, Stephen, “The St. Jude Renal Denervation System Technology and Clinical Review.” The University of Adelaide Australia, 2012, 24 pages. |
| Zuern, Christine S., “Impaired Cardiac Baroflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Journal of the American College of Cardiology, 2013, doi: 10.1016/j.jacc.2013.07.046, 24 pages. |
| Miller, Reed, “Finding a Future dor Renal Denervation With Better Controlled Trials.” Pharma & Medtech Business Intelligence, Article# 01141006003, Oct. 6, 2014, 4 pages. |
| Papademetriou, Vasilios, “Renal Denervation and Symplicity HTN-3: “Dubium Sapientiae Initium” (Doubt is the Beginning of Wisdom)”, Circulation Research, 2014; 115: 211-214. |
| Papademetriou, Vasilios et al., “Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions.” Circulation. 2014; 129:1440-1450. |
| Papademetriou, Vasilios et al., “Catheter-Based Renal Denervation for Resistant Hypertension: 12-Month Results ofthe EnligHTN I First-in-Human Study Using a Multielectrode Ablation System.” Hypertension. 2014; 64: 565-572. |
| Doumas, Michael et al., “Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled.” The Journal of Clinical Hypertension. 2014; vol. 16, No. 6, 2 pages. |
| Messerli, Franz H. et al. “Renal Denervation for Resistant Hypertension: Dead or Alive?” Healio: Cardiology today's Intervention, May/Jun. 2014, 2 pages. |
| 2003 European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension, Guidelines Committee, Journal of Hypertension 2003, vol. 21, No. 6, pp. 1011-1053. |
| Aars, H. and S. Akre, Reflex Changes in Sympathetic Activity and Arterial Blood Pressure Evoked by Afferent Stimulation of the Renal Nerve, Feb. 26, 1999, Acta physiol. Scand., vol. 78, 1970, pp. 184-188. |
| Abramov, G.S. et al., Alteration in sensory nerve function following electrical shock, Burns vol. 22, No. 8, 1996 Elsevier Science Ltd., pp. 602-606. |
| Achar, Suraj, M.D., and Suriti Kundu, M.D., Principles of Office Anesthesia: Part I. Infiltrative Anesthesia, Office Procedures, American Family Physician, Jul. 1, 2002, vol. 66, No. 1, pp. 91-94. |
| Advanced Neuromodulation Systems' Comparison Chart, Dec. 16, 2008, pp. 1. |
| Advances in the role of the sympathetic nervous system in cardiovascular medicine, 2001 SNS Report, No. 3, Springer, Published with an educational grant from Servier, pp. 1-8. |
| Aggarwal, A. et al., Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension. 2003;41:553-7. |
| Agnew, William F. et al., Evolution and Resolution of Stimulation-Induced Axonal Injury in Peripheral Nerve, May 21, 1999, Muscle & Nerve, vol. 22, Oct. 1999, John Wiley & Sons, Inc. 1999, pp. 1393-1402. |
| Ahadian, Farshad M., M.D., Pulsed Radiofrequency Neurotomy: Advances in Pain Medicine, Current Pain and Headache Reports 2004, vol. 8, 2004 Current Science Inc., pp. 34-40. |
| Alexander, B.T. et al., Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion, Hypertension, 2005; 45 (part 2): pp. 754-758. |
| Alford, J. Winslow, M.D. and Paul D. Fadale, M.D., Evaluation of Postoperative Bupivacaine Infusion for Pain Management After Anterior Cruciate Ligament Reconstruction, The Journal of Arthroscopic and Related Surgery, vol. 19, No. 8, Oct. 2003 Arthroscopy Association of North America, pp. 855-861. |
| Amersham Health. Hypaque-Cysto, 2003, 6 pages. |
| Andrews, B.T. et al., The use of surgical sympathectomy in the treatment of chronic renal pain. Br J Urol. 1997; 80: 6-10. |
| Antman, Elliott M. and Eugene Braunwald, Chapter 37—Acute Myocardial Infarction, Heart Disease—A Textbook of Cardiovascular Medicine, 5th Edition, vol. 2, 1997, Edited by Eugene Braunwald, pp. 1184-1288. |
| Archer, Steffen et al., Cell Reactions to Dielectrophoretic Manipulation, Mar. 1, 1999, Biochemical and Biophysical Research Communications, 1999 Academic Press, pp. 687-698. |
| Arentz, T. et al., Incidence of pulmonary vein stenosis 2 years after radiofrequency catheter ablation of refractory atrial fibrillation. European Heart Journal. 2003. 24; pp. 963-969. |
| Arias, M.D., Manuel J., Percutaneous Radio-Frequency Thermocoagulation with Low Temperature in the Treatment of Essential Glossopharyngeal Neuralgia, Surg. Neurol. 1986, vol. 25, 1986 Elsevier Science Publishing Co., Inc., pp. 94-96. |
| Aronofsky, David H., D.D.S., Reduction of dental postsurgical symptoms using nonthermal pulsed high-peak-power electromagnetic energy, Oral Surg., Nov. 1971, vol. 32, No. 5, pp. 688-696. |
| Aspelin, Peter, M.D., Ph.D. et al., Nephrotoxic Effects in High-Risk Patients Undergoing Angiography, Feb. 6, 2003, New England Journal of Medicine 2003, vol. 348, No. 6, 2003 Massachusetts Medical Society, pp. 491-499. |
| Atrial Fibrillation Heart and Vascular Health on Yahoo! Health. 2 pgs. <URL: http://health.yahoo.com/topic/heart/overview/article/healthwise/hw160872;_ylt=AiBT43Ey74HQ7ft3jAb4C.sPu7cF> Feb. 21, 2006. |
| Augustyniak, Robert A. et al., Sympathetic Overactivity as a Cause of Hypertension in Chronic Renal Failure, Aug. 14, 2001, Journal of Hypertension 2002, vol. 20, 2002 Lippincott Williams & Wilkins, pp. 3-9. |
| Awwad, Ziad M., FRCS and Bashir A. Atiyat, GBA, JBA, Pain relief using continuous bupivacaine infusion in the paravertebral space after loin incision, May 15, 2004, Saudi Med J 2004, vol. 25 (10), pp. 1369-1373. |
| Badyal, D. K., H. Lata and A.P. Dadhich, Animal Models of Hypertension and Effect of Drugs, Aug. 19, 2003, Indian Journal of Pharmacology 2003, vol. 35, pp. 349-362. |
| Baker, Carol E. et al., Effect of pH of Bupivacaine on Duration of Repeated Sciatic Nerve Blocks in the Albino Rat, Anesth Analg, 1991, vol. 72, The International Anesthesia Research Society 1991, pp. 773-778. |
| Balazs, Tibor, Development of Tissue Resistance to Toxic Effects of Chemicals, Jan. 26, 1974, Toxicology, 2 (1974), Elsevier/North-Holland, Amsterdam, pp. 247-255. |
| Barajas, L. Innervation of the renal cortex. Fex Proc. 1978;37:1192-201. |
| Barrett, Carolyn J. et al., Long-term control of renal blood flow: what is the role of the renal nerves?, Jan. 4, 2001, Am J Physiol Regulatory Integrative Comp Physiol 280, 2001, the American Physiological Society 2001, pp. R1534-R1545. |
| Barrett, Carolyn J. et al., What Sets the Long-Term Level of Renal Sympathetic Nerve Activity, May 12, 2003, Integrative Physiology, Circ Res. 2003, vol. 92, 2003 American Heart Association, pp. 1330-1336. |
| Bassett, C. Andrew L. et al., Augmentation of Bone Repair by Inductively Coupled Electromagnetic Fields, May 3, 1974, Science, vol. 184, pp. 575-577. |
| Bassett, C. Andrew L., Fundamental and Practical Aspects of Therapeutic Uses of Pulsed Electromagnetic Fields (PEMFs), Critical Reviews in Biomedical Engineering, vol. 17, Issue 5, 1989, pp. 451-514. |
| Beebe, Stephen J. et al., Nanosecond pulsed electric fields modulate cell function through intracellular signal transduction mechanisms, Apr. 8, 2004, Physiol. Meas. 25, 2004, IOP Publishing Ltd. 2004, pp. 1077-1093. |
| Beebe, Stephen J., et al., Nanosecond Pulsed Electric Field (nsPEF) Effects on Cells and Tissues: Apoptosis Induction and Tumor Growth Inhibition, Oct. 11, 2001, IEEE Transactions on Plasma Science, vol. 30, No. 1, Feb. 2002, IEEE 2002, pp. 286-292. |
| Bello-Reuss, E. et al., Acute unilateral renal denervation in rats with extracellular volume expansion, Departments of Medicine and Physiology, University of North Carolina School of Medicine. F26-F32 Jul. 1975. |
| Bello-Reuss, E. et al., Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption, J Clin Invest, 1976;57:1104-1107. |
| Bello-Reuss, E. et al., Effects of Acute Unilateral Renal Denervation in the Rat, J Clin Invest, 1975;56:208-217. |
| Berde, C. et al., Local Anesthetics, Anesthesia, Chapter 13, 5th addition, Churchill-Livingston, Philadelphia 2000, pp. 491-521. |
| Bhadra, Niloy and Kevin L. Kilgore, Direct Current Electrical Conduction Block of Peripheral Nerve, Feb. 25, 2004, IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. 12, No. 3, Sep. 2004, pp. 313-324. |
| Bhandari, A. and Ellias, M., Loin pain hematuria syndrome: Pain control with RFA to the Splanchanic plexus, The Pain Clinic, 2000, vol. 12, No. 4, pp. 323-327. |
| Bhatt, Deepak L. et al., Rhabdomyolysis Due to Pulsed Electric Fields, May 11, 1989, Plastic and Reconstructive Surgery Jul. 1990, pp. 1-11. |
| Bichet, D., et al., Renal intracortical blood flow and renin secretion after denervation by 6-hydroxydopamine. Can J Physiol Pharmacol. 1982;60:184-92. |
| Bigler, D. et al., Tachyphylaxis during postoperative epidural analgesia—new insights, Apr. 15, 1987, Letter to the Editor, Acta Anaesthesiol Scand. 1987, vol. 31, pp. 664-665. |
| Binder, Allan et al., Pulsed Electromagnetic Field Therapy of Persistent Rotator Cuff Tendinitis, The Lancet, Saturday Mar. 31, 1984, The Lancet Ltd., pp. 695-698. |
| Black, M.D., Henry R., Resistant Hypertension 2004, presentation at Rush University Medical Center, Jul. 15, 2004, 40 pages. |
| Blad, B., et al., An Electrical Impedance index to Assess Electroporation in Tissue, Tissue and Organ (Therapy), 2001, Oslo, www.bl.uk<http://www.bl.uk> British Library, pp. 31-34. |
| Blair, M. L. et al., Sympathetic activation cannot fully account for increased plasma renin levels during water deprivation, Sep. 23, 1996, Am. J. Physiol., vol. 272, 1997, the American Physiological Society 1997, pp. R1197-R1203. |
| Blomberg, S.G., M.D., PhD, Long-Term Home Self-Treatment with High Thoracic Epidural Anesthesia in Patients with Severe Coronary Artery Disease, Mar. 29, 1994, Anesth Analg 1994, vol. 79, 1994 International Anesthesia Research Society, pp. 413-421. |
| Boehmer, J.P., Resynchronization Therapy for Chronic CHF: Indications, Devices and Outcomes. Penn State College of Medicine: Penn State Heart and Vascular Institute. Transcatheter Cardiovascular Therapeutics 2005, 31 slides. |
| Bourge, R.C., Heart Failure Monitoring Devices: Rationale and Status 28 pages, Feb. 2001. |
| Braunwald, E., Heart Disease, A Textbook of Cardiovascular Medicine, 5th Ed., vol. 2, 1997, pp. 480-481, 824-825, 1184-1288 and 1923-1925, W.B. Saunders Company. |
| Bravo, E.L., et al., Renal denervation for resistant hypertension, American Journal of Kidney Diseases, 2009, 3 pgs. |
| Bunch, Jared T. et al. Mechanisms of Phrenic Nerve Injury During Radiofrequency Ablation at the Pulmonary Vein Orifice. Journal of Cardiovascular Electrophysiclody. vol. 16, No. 12. pp. 1318-1325. Dec. 2005. |
| Burkhoff, D., Interventional Device-Based Therapy for CHF Will Redefine Current Treatment Paradigms. Columbia University. 2004. 32 slides. |
| Burns, J. et al., Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999-2005. |
| Cahana, A. et al., Acute Differential Modulation of Synaptic Transmission and Cell Survival During Exposure to Pulsed and Continuous Radiofrequency Energy, May 2003, The Journal of Pain, vol. 4, No. 4, © 2003 by the American Pain Society, pp. 197-202. |
| Cahana, Alex, M.D., Pulsed Radiofrequency: A Neurobiologic and Clinical Reality, May 17, 2005, Anesthesiology 2005, vol. 103, No. 6, Dec. 2005, 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., p. 1311. |
| Calaresu, F.R. et al., Haemodynamic Responses and Renin Release During Stimulation of Afferent Renal Nerves in the Cat, Aug. 12, 1975, J. Physiol. 1976, vol. 255, pp. 687-700. |
| Cameron, Tracy. Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muscles and Limbs. IEEE Transactions on Biomedical Engineering, vol. 44, No. 9, Sep. 1997. pp. 781-790. |
| Campese, V.M. et al., Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878-82. |
| Campese, V.M. et al., Renal Afferent Denervation Prevents the Progression of Renal Disease in the Renal Ablation Model of Chronic Renal Failure in the Rat, Am J Kidney Dis. 1995;26:861-5. |
| Campese, V.M., A new model of neurogenic hypertension caused by renal injury: pathophysiology and therapeutic implications, Clin Exp Nephrol (2003) 7: 167-171, Japanese Society of Nephrology 2003. |
| Campese, V.M., Neurogenic factors and hypertension in chronic renal failure, Journal of Nephrology, vol. 10, No. 4, 1997, Societa Italiana di Nefrologia, pp. 184-187. |
| Campese, V.M., Neurogenic factors and hypertension in renal disease. Kidney Int. 2000;57 Suppl 75:S2-3. |
| Canbaz, S. et al., Electrophysiological evaluation of phrenic nerve injury during cardiac surgery—a prospective, controlled clinical study. BioMed Central. 5 pgs. 2004. |
| Cardiac Glycosides, Heart Disease—A Textbook of Cardiovascular Medicine vol. 2, Edited by Eugene Braunwald, 5th Edition, 1997 WB Saunders Company, pp. 480-481. |
| Carls, G. et al., Electrical and magnetic stimulation of the intercostal nerves: a comparative study, Electromyogr, clin. Neurophysiol. 1997, vol. 37, pp. 509-512. |
| Carlson, Scott H. and J. Michael Wyss, e-Hypertension—Opening New Vistas, Introductory Commentary, Hypertension 2000, vol. 35, American Heart Association, Inc. 2000, p. 538. |
| Carson, P., Device-based Treatment For Chronic Heart Failure: Electrical Modulation of Myocardial Contractility. Transcatheter Cardiovascular Therapeutics 2005, 21 slides. |
| Chang, Donald C., Cell poration and cell fusion using an oscillating electric field, Biophysical Journal, vol. 56, Oct. 1989, Biophysical Society, pp. 641-652. |
| Chen, S.A. et al., Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablataion, Circulation, 1999, 100:1879-1886. |
| Chin, J.L. et al., Renal autotransplantation for the loin pain-hematuria syndrome: long term follow up of 26 cases, J Urol, 1998, vol. 160, pp. 1232-1236. |
| Chiou, C.W. et al., Efferent Vagal Innervation of the Canine Atria and Sinus and Atrioventricular Nodes. Circulation. Jun. 1997. 95(11):2573-2584. Abstract only. 2 pgs. |
| Chobanian, Aram V. et al., Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Nov. 6, 2003, Hypertension 2003, vol. 42, 2003 American Heart Association, Inc., pp. 1206-1252. |
| Clinical Trials in Hypertension and Renal Diseases, Slide Source, www.hypertensiononline.org, 33 pages Aug. 13, 2001. |
| Conradi, E. and Ines Helen Pages, Effects of Continous and Pulsed Microwave Irradiation on Distribution of Heat in the Gluteal Region of Minipigs, Scand J Rehab Med, vol. 21, 1989, pp. 59-62. |
| Converse, R.L., Jr. et al., Sympathetic Overactivity in Patients with Chronic Renal Failure, N Engl J Med. Dec. 31, 1992, vol. 327 (27), pp. 1912-1918. |
| Cosman, E.R., Jr et al., Electric and Thermal Field Effects in Tissue Around Radiofrequency Electrodes, Pain Medicine, vol. 6, No. 6, 2005, American Academy of Pain Medicine, pp. 405-424. |
| Cosman, E.R., Ph.D., A Comment on the History of the Pulsed Radiofrequency Technique for Pain Therapy, Anesthesiology Dec. 2005, vol. 103, No. 6, 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., p. 1312. |
| Crawford, William H. et al., Pulsed Radio Frequency Therapy of Experimentally Induced Arthritis in Ponies, Dec. 18, 1989, Can. J. Vet. Res. 1991, vol. 55, pp. 76-85. |
| Curtis, J.J. et al., Surgical therapy for persistent hypertension after renal transplantation, Transplantation, 1981, 31(2):125-128. |
| Dahm, Peter et al., Efficacy and Technical Complications of Long-Term Continuous Intraspinal Infusions of Opioid and/or Bupivacaine in Refractory Nonmalignant Pain . . . , Oct. 6, 1997, The Clinical Journal of Pain, vol. 14, No. 1, 1998, Lippincott-Raven Publishers 1998, pp. 4-16. |
| Dahm, Peter O. et al., Long-Term Intrathecal Infusion of Opioid and/or Bupivacaine in the Prophylaxis and Treatment of Phantom Limb Pain, Neuromodulation, vol. 1, No. 3, 1998, International Neuromodulation Society 1998, pp. 111-128. |
| Dang, Nicholas C. et al., A Novel Approach to Increase Total Urine Output in Heart Failure: Renal Nerve Blockade, ACC 2005 poster; 1 page. |
| Daniel, Alan and Honig, Carl R. Does Histamine Influence Vasodilation Caused by Prolonged Arterial Occlusion or Heavy Exercise? The Journal of Pharmacology and Experimental Therapeutics. vol. 215 No. 2. Aug. 21, 1980. pp. 533-538. |
| Davalos, R. et al., Electrical Impedance Tomography for Imaging Tissue Electroporation, Jul. 25, 2003, IEEE Transactions on Biomedical Engineering, vol. 51, No. 5, May 2004, IEEE 2004, pp. 761-767. |
| Davalos, R.V. et al., Tissue Ablation with Irreversible Electroporation, Sep. 7, 2004, Annals of Biomedical Engineering, Feb. 2005, vol. 33, No. 2, 2005 Biomedical Engineering Society, pp. 223-231. |
| De Leeuw, Peter W. et al., Renal Vascular Tachyphylaxis to Angiotensin II: Specificity of the Response for Angiotensin, Dec. 28, 1981, Life Sciences, vol. 30, 1982 Pergamon Press Ltd., pp. 813-819. |
| Deng, Jingdong et al., The Effects of Intense Submicrosecond Electrical Pulses on Cells, Nov. 26, 2002, Biophysical Journal, vol. 84, Apr. 2003, Biophysical Society 2003, pp. 2709-2714. |
| Denton, Kate M. et al., Differential Neural Control of Glomerular Ultrafiltration, Jan. 30, 2004, Proceedings of the Australian Physiological and Pharmacological Society Symposium: Hormonal, Metabolic and Neural Control of the Kidney, Clinical and Experimental Pharmacology and Physiology (2004) 31, pp. 380-386. |
| Dev, Nagendu B., Ph.D. et al., Intravascular Electroporation Markedly Attenuates Neointima Formation After Balloon Injury of the Carotid Artery in the Rat, Journal of Interventional Cardiology, vol. 13, No. 5, 2000, pp. 331-338. |
| Dev, Nagendu B., Ph.D et al., Sustained Local Delivery of Heparin to the Rabbit Arterial Wall with an Electroporation Catheter, May 5, 1998, Catheterization and Cardiovascular Diagnosis, vol. 45, 1998, Wiley-Liss, Inc. 1998, pp. 337-345. |
| Devereaux, R.B. et al., Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial, Circulation, 2004, vol. 110, pp. 1456-1462. |
| Dibona, Gerald F. and Linda L. Sawin, Role of renal nerves in sodium retention of cirrhosis and congestive heart failure, Sep. 27, 1990, Am. J. Physiol. 1991, vol. 260, 1991 the American Physiological Society, pp. R298-R305. |
| Dibona, Gerald F. and Susan Y. Jones, Dynamic Analysis of Renal Nerve Activity Responses to Baroreceptor Denervation in Hypertensive Rats, Sep. 19, 2000, Hypertension Apr. 2001, American Heart Association, Inc. 2001, pp. 1153-1163. |
| Dibona, Gerald F. and Ulla C. Kopp, Neural Control of Renal Function, Physiological Reviews, vol. 77, No. 1, Jan. 1997, the American Physiological Society 1997, pp. 75-197. |
| Dibona, Gerald F. and Ulla C. Kopp, Role of the Renal Sympathetic Nerves in Pathophysiological States, Neural Control of Renal Function, vol. 77, pp. 142-197 Jan. 1997. |
| Dibona, Gerald F., Functionally Specific Renal Sympathetic Nerve Fibers: Role in Cardiovascular Regulation, Mar. 6, 2001, American Journal of Hypertension, 2001, vol. 14, 2001 American Journal of Hypertension, Ltd. Published by Elsevier Science Inc., pp. 163S-170S. |
| Dibona, Gerald F., L.L. Sawin, Effect of renal nerve stimulation on NaCl and H2O transport in Henle's loop of the rat,: 1982, American Physiological Society, F576-F580, 5 pgs. |
| Dibona, Gerald F., Nervous Kidney—Interaction Between Renal Sympathetic Nerves and the Renin-Angiotensin System in the Control of Renal Function, Jun. 21, 2000, Hypertension 2000, vol. 36, 2000 American Heart Association, Inc., pp. 1083-1088. |
| Dibona, Gerald F., Neural Control of the Kidney: Functionally Specific Renal Sympathetic Nerve Fibers, Starling Lecture, Am J Physiol Regulatory Integrative Comp Physiol, 2000, 279, 2000 The American Physiological Society, pp. R1517-R1524. |
| Dibona, Gerald F., Peripheral and Central Interactions between the Renin-Angiotensin System and the Renal Sympathetic Nerves in Control of Renal Function, Annals New York Academy of Sciences, pp. 395-406 Jan. 25, 2006. |
| Dibona, Gerald F., Renal Innervation and Denervation: Lessons from Renal Transplantation Reconsidered, Artificial Organs, vol. 11, No. 6, Raven Press, Ltd., 1987 International Society for Artificial Organs, pp. 457-462. |
| Dibona, Gerald F., Sympathetic Nervous System and the Kidney in Hypertension, Current Opinion in Nephrology and Hypertension 2002, vol. 11,2002 Lippincott Williams & Wilkins, pp. 197-200. |
| Dibona, Gerald F., The Sympathetic Nervous System and Hypertension, Dec. 4, 2003, Hypertension Highlights, Hypertension Feb. 2004, vol. 43, 2004 American Heart Association, Inc., pp. 147-150. |
| Dibona, Gerald, LL Sawin, Effect of renal denervation on dynamic autoregulation of renal blood flow, Feb. 12, 2004, AmJ Physiol Renal Physiol 286, pp. F1209-1218. |
| Dong, Jun et al. Incidence and Predictors of Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation Using the Anatomic Pulmonary Vein Ablation Approach: Results from Paired Magnetic Resonance Imaging. Journal of Cardiovascular Electrophysiology. vol. 16, No. 8, Aug. 2005. pp. 845-852. |
| Dorros, Gerald, M.D., Renal Artery Stenting State of the Art, presentation, TCT, Washington D.C., Sep. 2003, 27 pages. |
| Dueck, Ron, M.D., Noninvasive Cardiac Output Monitoring, The Cardiopulmonary and Critical Care Journal, Chest, vol. 120, sec. 2, Aug. 2001, American College of Chest Physicians 2005, pp. 339-341, 5 pages. |
| Dunn, Matthew D. et al., Laparoscopic Nephrectomy in Patients With End-Stage Renal Disease and Autosomal Dominant Polycystic Kidney Disease,Oct. 25, 1999, American Journal of Kidney Diseases, vol. 35, No. 4 Apr. 2000, National Kidney Foundation, Inc. 2000, pp. 720-725. |
| Durand, D.M., Electric Field Effects in Hyperexcitable Neural Tissue: A Review, Radiation Protection Dosimetry, vol. 106, No. 4, 2003 Nuclear Technology Publishing, pp. 325-331. |
| Effects of Renal Failure on the Cardiovascular System, 5th Edition Heart Disease, A Textbook of Cardiovascular Medicine, vol. 2, Edited by Eugene Braunwald, 1997, W.B. Saunders Company, pp. 1923-1925. |
| Electrical Stimulation for the Treatment of Chronic Wounds, Radiation Protection Standard, Maximum Exposure Levels to Radiofrequency Fields—3 KHz to 300 GHz, Radiation Protection Series No. 3, Australian Radiation Protection and Nuclear Safety Agency, Apr. 1996, 322 pgs. |
| Electropermeabilization (Electroporation), Cyto Pulse Sciences, Inc., http://www.cytopulse.com/electroporation.html (last accessed Mar. 3, 2005), 3 pgs. |
| Electroporation based Technologies and Treatments, ESPE Newsletter No. 6, QLK 02002-2003, Jan. 2005, www.cliniporator.com, 4 pgs. |
| End-stage renal disease payment policies in traditional Medicare, Chapter 8, Report to the Congress: Medicare Payment Policy, Mar. 2001, Medpac, pp. 123-138. |
| Epidemiology of Renal Disease in Hypertension, slide presentation by hypertensiononline.org, 21 pages Mar. 30, 2001. |
| Erdine, Serap and Alev Arat-Ozkan, Resistant Hypertension, European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2003, vol. 4, No. 15, 2 pages. |
| Esler, M. et al., Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol. 1986;8:S39-43. |
| Esler, M. et al., Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens. 1989; 2:140S-146S. |
| Esler, M. et al., Sympathetic nerve biology in essential hypertension, Clin and Exp Pharmacology and Physiology, 2001, 28:986-989. |
| European Examination Report; European Patent Application No. 07799148.7; Applicant: Ardian, Inc.; dated Jan. 19, 2010, 4 pgs. |
| European Examination Report; European Patent Application No. 09156661.2; Applicant: Ardian, Inc.; dated Jan. 19, 2010, 6 pgs. |
| European Search Report; European Patent Application No. 05806045.0; Applicant: Ardian, Inc.; dated Sep. 22, 2009, 8 pgs. |
| European Search Report; European Patent Application No. 05811851.4; Applicant: Ardian, Inc.; dated Oct. 1, 2009, 7 pgs. |
| European Search Report; European Patent Application No. 06847926.0; Applicant: Ardian, Inc.; dated Feb. 10, 2010, 6 pgs. |
| European Search Report; European Patent Application No. 07757925.8; Applicant: Ardian, Inc.; dated Apr. 29, 2010, 9 pgs. |
| European Search Report; European Patent Application No. 07798341.9; Applicant: Ardian, Inc.; dated Aug. 4, 2011; 6 pgs. |
| European Search Report; European Patent Application No. 07799148.7; Applicant: Ardian, Inc.; dated Jul. 23, 2009, 6 pgs. |
| European Search Report; European Patent Application No. 07868755.5; Applicant: Ardian, Inc.; dated Jul. 28, 2010, 7 pgs. |
| European Search Report; European Patent Application No. 09156661.2; Applicant: Ardian, Inc.; dated Jul. 23, 2009, 6 pgs. |
| European Search Report; European Patent Application No. 09167937.3; Applicant: Ardian, Inc.; dated Nov. 11, 2009, 6 pgs. |
| European Search Report; European Patent Application No. 09168202.1; Applicant: Ardian, Inc.; dated Nov. 11, 2009, 5 pgs. |
| European Search Report; European Patent Application No. 09168204.7; Applicant: Ardian, Inc.; dated Nov. 19, 2009, 6 pgs. |
| Evelyn, K.A. et al., Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension, Am J Med, 1960;28:188-221. |
| Ex parte Quayle Office Action; U.S. Appl. No. 11/144,173; dated May 28, 2009, 4 pgs. |
| Fact Book Fiscal Year 2003, National Institutes of Health National Heart, Lung, and Blood Institute, Feb. 2004, 197 pgs. |
| Fajardo, J. et al., Effect of chemical sympathectomy on renal hydroelectrolytic handling in dogs with chronic caval constriction. Clin Physiol Biochem. 1986;4:252-6. |
| Fareed, Jawed, Ph.D. et al., Some Objective Considerations for the Use of Heparins and Recombinant Hirudin in Percutaneous Transluminal Coronary Angoplasty, Seminars in Thrombosis and Hemostasis 1991, vol. 17, No. 4, 1991 by Thieme Medical Publishers, Inc., pp. 455-470. |
| Ferguson, D.R. et al., Responses of the pig isolated renal artery to transmural electrical stimulation and drugs, Dec. 7, 1984, Br. J. Pharmac. 1985, vol. 84, The Macmillan Press Ltd. 1985, pp. 879-882. |
| Fernandez-Ortiz, Antonio, et al., A New Approach for Local Intravascular Drug Delivery—Iontophoretic Balloon, Intravascular Iontophoretic Local Delivery, Circulation, vol. 89, No. 4, Apr. 1994, pp. 1518-1522. |
| Fields, Larry E. et al., The Burden of Adult Hypertension in the United States 1999 to 2000—A Rising Tide, May 18, 2004, American Heart Association 2004, Hypertension Oct. 2004, pp. 1-7. |
| Final Office Action; U.S. Appl. No. 11/233,814; dated Jan. 29, 2009, 11 pgs. |
| Final Office Action; U.S. Appl. No. 11/266,993; dated Jan. 8, 2010, 7 pgs. |
| Final Office Action; U.S. Appl. No. 11/363,867; dated May 1, 2009, 8 pgs. |
| Final Office Action; U.S. Appl. No. 11/451,728; dated Jan. 13, 2009, 7 pgs. |
| Final Office Action; U.S. Appl. No. 11/599,649; dated Jan. 15, 2009, 10 pgs. |
| Final Office Action; U.S. Appl. No. 11/599,723; dated Apr. 5, 2010, 17 pgs. |
| Final Office Action; U.S. Appl. No. 11/599,890; dated Apr. 29, 2009, 9 pgs. |
| Fischell, Tim A. et al., Ultrasonic Energy: Effects on Vascular Function and Integrity, Circulation: Journal of the American Heart Association. 1991. 84;pp. 1783-1795. |
| Freeman, Scott A. et al., Theory of Electroporation of Planar Bilayer Membranes: Predictions of the Aqueous Area, Change in Capacitance, and Pore-Pore Separation, Feb. 23, 1994, Biophysical Journal, Jul. 1994, vol. 67, 1994 by the Biophysical Society, pp. 42-56. |
| Fukuoka, Yuko et al., Imaging of neural conduction block by neuromagnetic recording, Oct. 16, 2002, Clinical Neurophysiology, vol. 113, 2002, Elsevier Science Ireland Ltd. 2002, pp. 1985-1992. |
| Fuster, Valentin et al. ACC/AHA/ESC Practice Guidelines: ACA/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. JACC vol. 48, No. 4, Aug. 15, 2006. |
| Gami, Apoor S., M.D. and Vesna D. Garovic, M.D., Contrast Nephropathy After Coronary Angiography, Mayo Clin Proc. 2004, vol. 79, 2004 Mayo Foundation for Medical Education and Research, pp. 211-219. |
| Gattone II, Vincent H. et al., Contribution of Renal Innervation to Hypertension in Polycystic Kidney Disease in the Rat, University of Chicago Section of Urology, 16 pages. Mar. 17, 2008. |
| Gaylor, D.C. et al., Significance of Cell Size and Tissue Structure in Electrical Trauma, Jan. 26, 1988, J.theor. Biol. 1988, vol. 133, 1988 Academic Press Limited, pp. 223-237. |
| Gazdar, A.F. and G.J. Dammin, Neural degeneration and regeneration in human renal transplants, NEJM, Jul. 30, 1970, 283:222-244. |
| Gehl, Julie et al., In Vivo Electroporation of Skeletal Muscle: Threshold, Efficacy and Relation to Electric Field Distribution, Biochimica et Biophysica Acta, 1428, 1999, Elsevier Science B.V. 1999, pp. 233-240, www.elsevier.com/locate/bba<http:www.elsevier.com/locate/bba>. |
| Getts, R.T. et al., Regression of left ventricular hypertrophy after bilateral nephrectomy, Nephrol Dial Transplant, 2006, vol. 21, pp. 1089-1091. |
| Ghoname, El-sayed A. et al., Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica, Apr. 26, 1999, Pain 1999, vol. 83, 1999 International Association for the Study of Pain / Published by Elsevier Science B.V., pp. 193-199. |
| Gimple, M.D., Lawrence et al., Effect of Chronic Subcutaneous or Intramural Administration of Heparin on Femoral Artery Restenosis After Balloon Angioplasty in Hypercholesterolemic Rabbits, Laboratory Investigation, Circulation, vol. 86, No. 5, Nov. 1992, pp. 1536-1546. |
| Goldberger, Jeffrey J. et al., New technique for vagal nerve stimulation, Jun. 2, 1999, Journal of Neuroscience Methods 91, 1999, Elsevier Science B.V. 1999, pp. 109-114. |
| Gorbunov, F.E et al., The Use of Pulsed and Continuous Short Wave Diathermy (Electric Field) in Medical Rehabilitation of the Patients with Guillan-Barre Syndrome and Other Peripheral Myelinopathies, May 6, 1994, 5 pages (most of article in Russian language). |
| Gottschalk, C.W., Renal nerves and sodium excretion, Ann. Rev. Physiol., 1979, 41:229-240. |
| Greenwell, T.J. et al., The outcome of renal denervation for managing loin pain haematuria syndrome. BJU International, 2004; 4 pgs. |
| Gruberg, Luis, M.D. et al., The Prognostic Implications of Further Renal Function Deterioration Within 48 h of Interventional Coronary Procedures in Patients with Pre-existent Chronic Renal Insufficiency, Jun. 19, 2000, Journal of the American College of Cardiology 2000, vol. 36, No. 5, 2000 by the American College of Cardiology, pp. 1542-1548. |
| Guimaraes, Sarfim. Vascular Adrenoceptors: An Update, pp. 319-356, Jun. 1, 2001. |
| Haissaguerre, M. et al., Spontaneous initiation of atrial fibrillation by ectopic beats orginating in the pulmonary veins, New England Journal of Medicine, 1998, 339: 659-666. |
| Hajjar, Ihab, M.D., M.S. and Theodore A. Kotchen, M.D., Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000, JAMA, Jul. 9, 2003, vol. 290, No. 2, pp. 199-206. |
| Hammer, Leah W. Differential Inhibition of Functional Dilation of Small Arterioles by Indomethacin and Glibenclamide. Hypertension. Feb. 2001 Part II. pp. 599-603. |
| Hampers, C.L. et al., A hemodynamic evaluation of bilateral nephrectomy and hemodialysis in hypertensive man, Circulation. 1967;35:272-288. |
| Hamza, M.D., Mohamed A et al., Effect of the Duration of Electrical Stimulation on the Analgesic Response in Patients with Low Back Pain, Anesthesiology, vol. 91, No. 6, Dec. 1999, American Society of Anesthesiologists, Inc. 1999, pp. 1622-1627. |
| Han, Hyo-Kyung and Gordon L. Amidon, Targeted Prodrug Design to Optimize Drug Delivery, Mar. 21, 2000, AAPS Pharmsci 2000, 2 (1) article 6, pp. 1-11. |
| Hansen, J.M. et al., The transplanted human kidney does not achieve functional reinnervation, Clin Science, 1994, vol. 87, pp. 13-20. |
| Hasking, G.J. et al., Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-21. |
| Hausberg, M. et al., Sympathetic nerve activity in end-stage renal disease, Circulation, 2002, 106: 1974-1979. |
| Heart Arrhythmia Heart and Vascular Health on Yahoo! Health. 13 pgs. <URL: http://health.yahoo.com/topic/heart/overview/article/mayoclinic/21BBE2B0-128D-4AA2-A5CE215065586678;_ylt=Aqd9M5rNyHD0sbPOmHXFhLcPu7cF> Feb. 16, 2005. |
| Heart Disease and Stroke Statistics—2004 Update, American Heart Association, American Stroke Association, Dallas, Texas, 2003 American Heart Association, 52 pgs. |
| Heida, Tjitske, et al., Investigating Membrane Breakdown of Neuronal Cells Exposed to Nonuniform Electric Fields by Finite-Element Modeling and Experiments, May 9, 2002, IEEE Transactions on Biomedical Engineering, vol. 49, No. 10, Oct. 2002, IEEE 2002, pp. 1195-1203. |
| Heuer, G.J., The surgical treatment of essential hypertension, Annals of Surgery, 1936; 104 (4): 771-786. |
| Higuchi, Yoshinori, M.D., Ph.D et al., Exposure of the Dorsal Root Ganglion in Rats to Pulsed Radiofrequency Currents Activates Dorsal Horn Lamina I and II Neurons, Dec. 4, 2001, Experimental Studies, Neurosurgery, vol. 50, No. 4, Apr. 2002, pp. 850-856. |
| Hildebrand, Keith R., D.V.M., Ph.D. et al., Stability, Compatibility, and Safety of Intrathecal Bupivacaine Administered Chronically via an Implantable Delivery System, May 18, 2001, The Clinical Journal of Pain, vol. 17, No. 3, 2001 Lippincott Williams & Wilkins, Inc., pp. 239-244. |
| Hing, Esther, M.P.H. and Kimberly Middleton, B.S.N., M.P.H., National Hospital Ambulatory Medical Care Survey: 2001 Outpatient Department Summary, Aug. 5, 2003, Advance Data from Vital and Health Statistics, No. 338, CDC, 32 pages. |
| Hodgkin, Douglas D. et al., Electrophysiologic Characteristics of a Pulsed Iontophoretic Drug-Delivery System in Coronary Arteries, Journal of Cardiovascular Pharmacology. 29(1):pp. 39-44, Jan. 1997, Abstract, 2 pgs. |
| Hopp, F.A. et al., Respiratory Responses to Selective Blockade of Carotid Sinus Baroreceptors in the Dog, Jun. 22, 2005, Am J Physiol Regul Integr Comp Physiol 1998, vol. 275, 2005 American Physiological Society, pp. R10-R18. |
| Hortobagyi, Gabriel N., Randomized Trial of High-Dose Chemotherapy and Blood Cell Autographs for High-Risk Primary Breast Carcinoma, Journal of the National Cancer Institute, vol. 92, No. 3, Feb. 2, 2000, pp. 225-233. |
| Horwich, Tamara, M.D., New Advances in the Diagnosis and Management of Acute Decompensated Heart Failure, the heart.org satellite program, Rapid Review, CME Symposium presented on Nov. 8, 2004 at the Sheraton New Orleans Hotel, 4 pages. |
| Huang, Wann-Chu et al. Renal Denervation Prevents and Reverses Hyperinsulinemia-Induced Hypertension in Rats, Mar. 25, 1998, Hypertension 1998, vol. 32, 1998 American Heart Association, pp. 249-254. |
| Huang, Yifei et al., Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural and cellular responses, Jan. 8, 2004, Am J Physiol. Heart Circ. Physiol. 2004, vol. 286, 2004 the American Physiological Society, pp. H2141-H2150. |
| Hughes, Gordon B., M.D. et al., A Comparative Study of Neuropathologic Changes Following Pulsed and Direct Current Stimulation of the Mouse Sciatic Nerve, Jun. 27, 1980, American Journal of Otolaryngology, Nov. 1980, vol. 1, No. 5, pp. 378-384. |
| Hypertension and Renal Disease: Mechanisms, Slide Show by www.hypertensiononline.org, 22 pages Mar. 30, 2001. |
| Hypertension Incidence and Prevalence, Age-Specific Rates, By Gender, B.C., 2001/2002, Graph, Chronic Disease Management, May 2003, British Columbia Ministry of Health Services, 1 page. |
| Implantable Neurostimulation Systems, Medtronic Neurological, http://medtronic.com/neuro/paintherapies/pain_treatment_ladder/pdf/implantable_brochure.pdf; 1999, 6 pages. |
| Implantable Pump—The Medtronic MiniMed 2007 Implantable Insulin Pump System, Medtronic MiniMed, 2006, 5 pgs. |
| International Search Report and Written Opinion for PCT/US2009/069334; Applicant: Ardian, Inc.; dated Mar. 1, 2010, 10 pgs. |
| International Search Report and Written Opinion, PCT/US05/35693, dated Mar. 8, 2006, Applicant: Ardian, Inc., 29 pgs. |
| International Search Report and Written Opinion, PCT/US05/35757, dated Dec. 27, 2006, Applicant: Ardian, Inc., 8 pgs. |
| International Search Report and Written Opinion, PCT/US06/36120, dated Jun. 25, 2008, Applicant: Ardian, Inc., 10 pgs. |
| International Search Report and Written Opinion, PCT/US06/41889, dated Oct. 20, 2008, Applicant: Ardian, Inc., 7 pgs. |
| International Search Report and Written Opinion, PCT/US06/48822, dated Aug. 15, 2008, Applicant: Ardian, Inc., 12 pgs. |
| International Search Report and Written Opinion, PCT/US07/63322, dated Mar. 3, 2008, Applicant: Ardian, Inc., 10 pgs. |
| International Search Report and Written Opinion, PCT/US07/63324, dated Oct. 10, 2008, Applicant: Ardian, Inc., 10 pgs. |
| International Search Report and Written Opinion, PCT/US07/66539, dated Jan. 28, 2008, Applicant: Ardian, Inc., 6 pgs. |
| International Search Report and Written Opinion, PCT/US07/70799, dated Jul. 2, 2008, Applicant: Ardian, Inc., 7 pgs. |
| International Search Report and Written Opinion, PCT/US07/72396, dated Aug. 27, 2008, Applicant: Ardian, Inc., 9 pgs. |
| International Search Report and Written Opinion, PCT/US07/84701, dated Aug. 21, 2008, Applicant: Ardian, Inc., 11 pgs. |
| International Search Report and Written Opinion, PCT/US07/84705, dated Jul. 28, 2008, Applicant: Ardian, Inc., 12 pgs. |
| International Search Report and Written Opinion, PCT/US07/84708, dated Aug. 11, 2008, Applicant: Ardian, Inc., 9 pgs. |
| International Search Report, PCT/US02/0039, dated Sep. 11, 2002, Applicant: Advanced Neuromodulation Systems, Inc. |
| International Search Report, PCT/US02/25712, dated Apr. 23, 2003, Applicant: Cyberonics, Inc. |
| International Search Report, PCT/US03/08014, dated Sep. 23, 2003, Applicant: The General Hospital Corporation. |
| International Search Report, PCT/US03/09764, dated Oct. 28, 2003, Applicant: CVRX, Inc. |
| International Search Report, PCT/US04/38498, dated Feb. 18, 2005, Applicant: G & L Consulting, LLC, 4 pgs. |
| Introduction to Autonomic Pharmacology, Chapter 3, Part 2 Autonomic Pharmacology, pp. 18-26, May 24, 2002. |
| Isovue: Data Sheet. Regional Health Limited. 8 pgs. Mar. 11, 2003. |
| Israili, Z.H., Clinical pharmacokinetics of angiotensin II (AT) receptor blockers in hypertension, Journal of Human Hypertension, 2000, Macmillan Publishers Ltd., vol. 14, pp. S73-S86. |
| Janda, J., Impact of the electrical stimulation apparatus rebox on the course of ischemic renal damage in rats, British Library—The world's knowledge pp. 252-254 (translated and untranslated versions) 1996. |
| Janssen, Ben J.A. et al., Effects of complete renal denervation and selective afferent renal denervation on the hypertension induced by intrarenal norepinephrine infusion in conscious rats, Jan. 4, 1989, Journal of Hypertension 1989, vol. 7, No. 6, Current Science Ltd, pp. 447-455. |
| Jia, Jianping et al., Cold injury to nerves is not due to ischaemia alone, Brain. 121;pp. 989-1001. 1998. |
| Jia, Jianping et al.., The pathogenesis of non-freezing cold nerve injury: Observations in the rat, Brain. 120; pp. 631-646. 1997. |
| Jin, Yuanzhe et al., Pulmonary Vein Stenosis and Remodeling After Electrical Isolation for Treatment of Atrial Fibrillation: Short- and Medium-Term Follow-Up, PACE, vol. 27., Oct. 2004, pp. 1362-1370. |
| Johansson, Bjorn, Electrical Membrane Breakdown, A Possible Mediator of the Actions of Electroconvulsive Therapy, Medical Hypotheses 1987, vol. 24, Longman Group UK Ltd 1987, pp. 313-324. |
| Joles, J.A. et al., Causes and Consequences of Increased Sympathetic Activity in Renal Disease. Hypertension. 2004;43:699-706. |
| Jorgensen, William A. et al., Electrochemical Therapy of Pelvic Pain: Effects of Pulsed Electromagnetic Fields (PEMF) on Tissue Trauma, Eur J Surg 1994, Suppl 574, vol. 160, 1994 Scandinavian University Press, pp. 83-86. |
| Joshi, R. P. and K. H. Schoenbach, Mechanism for membrane electroporation irreversibility under high-intensity, ultrashort electrical pulse conditions, Nov. 11, 2002, Physical Review E 66, 2002, The American Physical Society 2002, p. 052901-1-052901-4. |
| Joshi, R. P. et al., Improved energy model for membrane electroporation in biological cells subjected to electrical pulses, Apr. 9, 2002, Physical Review E, vol. 65, 041920-1,2002 The American Physical Society, 8 pages. |
| Joshi, R. P. et al., Self-consistent simulations of electroporation dynamics in biological cells subjected to ultrashort electrical pulses, Jun. 21, 2001, Physical Review E, vol. 64, 011913, 2001 The American Physcial Society, pp. 1-10. |
| Kanduser, Masa et al., Effect of surfactant polyoxyethylene glycol (C12E8) on electroporation of cell line DC3F, Aug. 20, 2002, Colloids and Surfaces A: Physicochem. Eng. Aspects 214, 2003, Elsevier Science B.V. 2002, pp. 205-217. |
| Kassab, S. et al., Renal denervation attenuates the sodium retention and hypertension associated with obesity, Hypertension, 1995, 25:893-897. |
| Katholi, R.E. et al., Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension, Hypertension, 1982, 4 (suppl II): II-166-II-174. |
| Katholi, R.E. et al., Role of the renal nerves in the pathogenesis of one-kidney renal hypertension in the rat, Hypertension, 1981,3(4) 404-409. |
| Katholi, R.E., Renal nerves and hypertension: an update, Fed Proc., 1985, 44:2846-2850. |
| Kaye, D.M. et al., Functional and neurochemical evidence for partial cardiac sympathetic reinnervation after cardiac transplantation in humans, Circulation, 1993, vol. 88, pp. 1101-1109. |
| Kelleher, Catherine L. et al., Characteristics of Hypertension in Young Adults with Autosomal Dominant Polycystic Kidney Disease Compared with the General U.S. Population, Jun. 9, 2004, American Journal of Hypertension 2004, pp. 1029-1034. |
| King, Ronald W. P., Nerves in a Human Body Exposed to Low-Frequency Electromagnetic Fields, Jun. 7, 1999, IEEE Transactions on Biomedical Engineering, vol. 46, No. 12, Dec. 1999, IEEE 1999, pp. 1426-1431. |
| Kinney, Brian M., M.D., High-Tech Healing—The evolution of therapeutic electromagnetic fields in plastic surgery, Plastic Surgery Products, Jun. 2004, pp. 32-36, 3 pages. |
| Kirchheim, H. et al., Sympathetic modulation of renal hemodynamics, renin release and sodium excretion, Klin Wochenschr, 1989, 67:858-864. |
| Klein, K. et al., Impaired autofeedback regulation of hypothalamic norepinephrine release in experimental uremia. J Am Soc Nephrol. 2005;16:2081-7. |
| Knot, H. J. et al., Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure. The Journal of Physiology. 1998. 508; pp. 199-209. |
| Kok, Lai Chow et al. Effect of Heating on Pulmonary Veins: How to Avoid Pulmonary Vein Stenosis. Journal of Cardiovascular Electrophysiology. vol. 14, No. 3, Mar. 2003. pp. 250-254. |
| Kok, R. J. et al., Specific Delivery of Captopril to the Kidney with the Prodrug Captopril-Lysozyme, Aug. 16, 1998, Journal of Pharmacology and Experimental Therapeutics, vol. 288, No. 1, 1999 by The American Society for Pharmacology and Experimental Therapeutics, pp. 281-285. |
| Kon, V. Neural Control of Renal Circulation, Miner Electrolyte Metab. 1989;15:33-43. |
| Koomans, H.A., et al., Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524-37. |
| Kopp, U. et al., Dietary sodium loading increases arterial pressure in afferent renal-denervated rats, Hypertension, 2003, 42:968-973. |
| Kopp, U.C. et al., Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alphal- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1561-72. |
| Koyama, Shozo et al., Relative Contribution of Renal Nerve and Adrenal Gland to Renal Vascular Tone During Prolonged Canine Hemorrhagic Hypotension, Sep. 24, 1992, Circulatory Shock 1993, vol. 39, Wiley-Liss, Inc. 1993, pp. 269-274. |
| Kozak, Lola Jean, Ph.D et al., National Hospital Discharge Survey: 2001 Annual Summary with Detailed Diagnosis and Procedure Data, Vital and Health Statistics, Serices 13 No. 156, Jun. 2004, CDC, 206 pages. |
| Kumagai, K. et al. New Approach to Pulmonary Vein Isolation for Atrial Fibrillation Using a Multielectrode Basket Catheter. Circulation Journal. 2006;70:88-93. |
| Lafayette, Richard A., M.D., How Does Knocking Out Angiotensin II Activity Reduce Renal Injury in Mice?, Jun. 14, 1999, Journal Club, American Journal of Kidney Diseases, vol. 35, No. 1, Jan. 2000, National Kidney Foundation, Inc. 2000, pp. 166-172. |
| Lavie, Peretz, Ph.D. and Victor Hoffstein, M.D., Sleep Apnea Syndrome: A Possible Contributing Factor to Resistant Hypertension, Jun. 2001, SLEEP 2001, vol. 24, No. 6, pp. 721-725. |
| Le Noble, J.L. et al., Pharmacological evidence for rapid destruction of efferent renal nerves in rats by intrarenal infusion of 6-hydroxydopamine. J Hypertens Suppl. 1985;3:S137-40. |
| Lee, Michael A. (editor). SPORTSMed. Connecticut State Medical Society Committee on the Medical Aspects of Sports. Fall/Winter 2005. 10 pgs. |
| Lee, Raphael C. et al., Biophysical Injury Mechanisms in Electronic Shock Trauma, Annu. Rev. Biomed. Eng., 2000, vol. 2, Copyright ©2000 by Annual Reviews, pp. 477-509. |
| Lee, Raphael C. et al., Clinical Sequelae Manifested in Electrical Shock Survivors, Presentation by the Electrical Trauma Research Program, The University of Chicago, 37 pages Dec. 24, 2004. |
| Lee, Raphael C. et al., Membrane Biology and Biophysics, Chapter 25, Surgical Research, 2001 Academic Press, pp. 297-305. |
| Lee, Raphael C., M.D., Sc.D. and Michael S. Kolodney, S.B., Electrical Injury Mechanisms: Electrical Breakdown of Cell Membranes, Oct. 1, 1986, Plastic and Reconstructive Surgery, Nov. 1987, vol. 80, No. 5, pp. 672-679. |
| Lenoble, L.M. et al., Selective efferent chemical sympathectomy of rat kidneys. Am J Physiol. 1985;249:R496-501. |
| Ligtenberg, Gerry M.D. et al., Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure, Apr. 29, 1999, New England Journal of Medicine 1999, vol. 340, No. 17, 1999 Massachusetts Medical Society, pp. 1321-1328. |
| Lin, Vernon W. H. et al., High intensity magnetic stimulation over the lumbosacral spine evokes antinociception in rats, Apr. 16, 2002, Clinical Neurophysiology, vol. 113, 2002 Elsevier Science Ireland Ltd., pp. 1006-1012. |
| Lipfert, Peter, M.D. et al., Tachyphylaxis to Local Anesthetics Does Not Result form Reduced Drug Effectiveness at the Nerve Itself, Aug. 3, 1988, Anesthesiology 1989, vol. 70, pp. 71-75. |
| Lohmeier, Thomas E. and Drew A. Hildebrandt, Renal Nerves Promote Sodium Excretion in Angiotensin-Induced Hypertension, Oct. 20, 1997, Hypertension 1998, vol. 31, part 2, 1998 American Heart Association, Inc., pp. 429-434. |
| Lohmeier, Thomas E. et al., Prolonged Activation of the Baroreflex Produces Sustained Hypotension, Harry Goldblatt Award, Nov. 26, 2003, Hypertension 2004, vol. 43, Part 2, 2004 American Heart Association, Inc., pp. 306-311. |
| Lohmeier, Thomas E. et al., Renal Nerves Promote Sodium Excretion During Long-Term Increases in Salt Intake, Oct. 23, 1998, Hypertension 1999, vol. 33, part II, 1999 American Heart Association, Inc., pp. 487-492. |
| Lohmeier, Thomas E. et al., Sustained influence of the renal nerves to attenuate sodium retention in angiotensin hypertension, Apr. 13, 2001, Am J Physiol Regulatory Integrative Comp Physiol, vol. 281, 2001 the American Physiological Society, pp. R434-R443. |
| Lohmeier, Thomas E., et al., Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension, American Journal Physiol Regulatory Integrative Comp Physiol, vol. 279, 2000 the American Physiological Society, pp. R1437-R1448. |
| Lohmeier, Thomas E., Interactions Between Angiotensin II and Baroreflexes in Long-Term Regulation of Renal Sympathetic Nerve Activity, Circulation Research, Jun. 27, 2003, American Heart Association, Inc.2003, pp. 1282-1284. |
| Luff, S.E. et al., Two types of sympathetic axon innervating the juxtaglomerular arterioles of the rabbit and rat kidney differ structurally from those supplying other arteries, May 1, 1991, Journal of Neurocytology 1991, vol. 20, 1991 Chapman and Hall Ltd., pp. 781-795. |
| Luippold, G. et al., Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats, Nephrol Dial Transplant (2004) 19:342-347. |
| Lundborg, C. et al., Clinical experience using intrathecal (IT) bupivacaine infusion in three patients with complex regional pain syndrome type I (CRPS-I), Acta Anaesthesiol Scand 1999, vol. 43, pp. 667-678. |
| Maeder, Micha, M.D. et al., Contrast Nephropathy: Review Focusing on Prevention, Jun. 22, 2004, Journal of the American College of Cardiology Nov. 2, 2004, vol. 44, No. 9, 2004 by the American College of Cardiology Foundation, pp. 1763-1771. |
| Malpas, Simon C., What sets the long-term level of sympathetic nerve activity: is there a role for arterial baroreceptors?, Invited Review, Am J Physiol Regul Integr Comp Physiol 2004, vol. 286, 2004 the American Physiological Society, pp. R1-R12. |
| Mancia, G Grassi, G Giannattasio, C Seravalle, G Sympathetic actrivation of pathogenesis of hypertension and progression of organ damage, Hypertension 1999, 34 (4 Pt?): 724-728. |
| Marenzi, Giancarlo, M.D et al., The Prevention of Radiocontrast-Agent-Induced Nephropathy by Hemofiltration, New England Journal of Medicine, Oct. 2, 2003, vol. 349 (14), 2003 Massachusetts Medical Society, pp. 1333-1340. |
| Market for infusion pumps grows with an aging population, NWL 97-01, The BBI Newsletter, vol. 20, No. 2, Feb. 1, 1997, American Health Consultants, Inc., pp. 6. |
| Martin, Jason B. et al., Gene Transfer to Intact Mesenteric Arteries by Electroporation, Mar. 27, 2000, Journal of Vascular Research 2000, vol. 37, 2000 S. Karger AG, Basel, pp. 372-380. |
| McCreery, Douglas B. et al., Charge Density and Charge Per Phase as Cofactors in Neural Injury Induced by Electrical Stimulation, IEEE Transactions on Biomedical Engineering, vol. 17, No. 10, Oct. 1990, pp. 996-1000. |
| McCullough, Peter A., M.D., MPH et al., Acute Renal Failure after Coronary Intervention: Incidence, Risk Factors and Relationship to Mortality, Apr. 14, 1997, Am J Med. 1997, vol. 103, 1997 Excerpta Medica, Inc., pp. 368-375. |
| McMurray, John J.V., M.D. and Eileen O'Meara, M.D., Treatment of Heart Failure with Spironolactone—Trial and Tribulations, Aug. 5, 2004, New England Journal of Medicine, vol. 351, No. 6, 2004 Massachusetts Medical Society, pp. 526-528. |
| McRobbie, D. and M.A. Foster, Thresholds for biological effects of time-varying magnetic fields, Dec. 16, 1983, Clin. Phys. Physiol. Meas. 1984, vol. 5, No. 2, 1984 the Institute of Physics, pp. 67-78. |
| Medtronic Neurostimulation Systems, Expanding the Array of Pain Control Solutions, informational pamphlet, 1999 Medtronic, Inc., 6 pages. |
| Medtronic, Spinal Cord Stimulation, Patient Management Guidelines for Clinicians, Medtronic, Inc. 1999, 115 pages. |
| Medtronic, SynchroMed Infusion System—Clinical Reference Guide for Pain Therapy, Medtronic, Inc. 1998, 198 pages. |
| Mehran, Roxana, Renal insufficiency and contrast nephropathy: The most common, least understood risk factor, Cardiovascular Research Foundation, Columbia University Medical Center, 2005, 86 slides. |
| Mess, Sarah A., M.D et al., Implantable Baclofen Pump as an Adjuvant in Treatment of Pressure Sores, Mar. 1, 2003, Annals of Plastic Surgery, vol. 51, No. 5, Nov. 2003, Lippincott Williams & Wilkins 2003, pp. 465-467. |
| Micro ETS Hyperhidrosis USA Hyperhidrosis USA. 2 pgs. <URL: http://www.hyperhidrosis-usa.com/Index.html>. Nov. 6, 2006. |
| Mihran, Richard T. et al., Temporally-Specific Modification of Myelinated Axon Excitability in Vitro Following a Single Ultrasound Pulse, Sep. 25, 1989, Ultrasound in Med. & Biol. 1990, vol. 16, No. 3, pp. 297-309. |
| Miklav{hacek over (c)}i{hacek over (c)}, D. et al., A Validated Model of in Vivo Electric Field Distribution in Tissues for Electrochemotherapy and for DNA Electrotransfer for Gene Therapy, Biochimica et Biophysica Acta, 1523, 2000, pp. 73-83, <http:www.elsevier.com/locate/bba>. |
| Mitchell, G. A. G., The Nerve Supply of the Kidneys, Aug. 20, 1949, Acta Anatomica, vol. X, Fasc. ½, 1950, pp. 1-37. |
| Morrisey, D.M. et al., Sympathectomy in the treatment of hypertension: Review of 122 cases, Lancet. 1953;1:403-408. |
| Moss, Nicholas G., Renal function and renal afferent and efferent nerve activity, Am. J. Physiol. 1982, vol. 243, 1982 the American Physiological Society, pp. F425-F433. |
| Munglani, Rajesh, The longer term effect of pulsed radiofrequency for neuropathic pain, Jun. 8, 1998, Pain 80, 1999, International Association for the Study of Pain 1999, Published by Elsevier Science B.V., pp. 437-439. |
| Naropin (ropivacaine HCI) Injection, RX only Description, AstraZeneca 2001, 3 pages. |
| National High Blood Pressure Education Program, 1995 Update of the Working Group Reports on Chronic Renal Failure and Renovascular Hypertension, presentation, 13 pages. |
| National Kidney Foundation, Are You at Increased Risk for Chronic Kidney Disease?, 2002 National Kidney Foundation, Inc., 14 pages. |
| Nelson, L. et al., Neurogenic Control of Renal Function in Response to Graded Nonhypotensive Hemorrahage in Conscious Dogs, Sep. 13, 1992, Am J. Physiol. 264, 1993, American Physiological Society 1993, pp. R661-R667. |
| Nikolsky, Eugenia, M.D et al., Radiocontrast Nephropathy: Identifying the High-Risk Patient and the Implications of Exacerbating Renal Function, Rev Cardiovasc Med. 2003, vol. 4, Supp. 1, 2003 MedReviews, LLC, pp. S7-S14. |
| Non-Final Office Action; U.S. Appl. No. 10/408,665; dated Mar. 21, 2006, 14 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/129,765; dated May 18, 2007, 10 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/129,765; dated Sep. 10, 2007, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/129,765; dated Oct. 6, 2006, 30 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/133,925; dated Oct. 8, 2008, 41 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/144,173; dated Apr. 5, 2007, 33 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/144,173; dated Sep. 10, 2007, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/144,298; dated Oct. 29, 2009, 8 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/144,298; dated Apr. 5, 2007, 33 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/144,298; dated Sep. 10, 2007, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/144,298; dated Dec. 29, 2008, 7 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/145,122; dated Apr. 11, 2007, 33 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/145,122; dated Sep. 10, 2007, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/189,563; dated May 28, 2009, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/233,814; dated Jun. 17, 2008, 12 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/252,462; dated Feb. 22, 2010, 6 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/266,993; dated Jul. 8, 2009, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/266,993; dated Dec. 30, 2008, 7 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/363,867; dated Sep. 25, 2008, 10 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/368,553; dated May 18, 2010, 4 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/368,553; dated Oct. 7, 2009, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/368,809; dated Dec. 3, 2009, 4 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/368,949; dated Jun. 11, 2010, 6 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/368,971; dated Aug. 24, 2010, 9 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/451,728; dated Jun. 12, 2008, 41 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/451,728; dated Jul. 2, 2009, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/451,728; dated Dec. 28, 2009, 7 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/504,117; dated Mar. 31, 2009, 10 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/599,649; dated Mar. 30, 2009, 10 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/599,649; dated Jun. 23, 2008, 9 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/599,723; dated Jun. 26, 2009, 17 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/599,723; dated Oct. 15, 2010, 16 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/599,882; dated Jul. 6, 2009, 13 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/688,178; dated Jun. 28, 2010, 5 pgs. |
| Non-Final Office Action; U.S. Appl. No. 11/840,142; dated Apr. 3, 2009, 13 pgs. |
| Non-Final Office Action; U.S. Appl. No. 12/567,521; dated Sep. 3, 2010, 9 pgs. |
| Non-Final Office Action; U.S. Appl. No. 12/616,708; dated Sep. 16, 2010, 10 pgs. |
| Non-Final Office Action; U.S. Appl. No. 12/725,375; dated Oct. 12, 2010, 14 pgs. |
| Nozawa, T. et al., Effects of Long Term Renal Sympathetic Denervation on Heart Failure After Myocardial Infarction in Rats, Sep. 22, 2001, Heart Vessels, 2002, 16, Springer-Verlag 2002, pp. 51-56. |
| O'Hagan, K.P. et al., Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension, Am J Hypertens., 1990, 3:62-64. |
| Onesti, G et al., Blood pressure regulation in end-stage renal disease and anephric man, Circ Res Suppl., 1975, 36 & 37: 145-152. |
| Osborn, et al., Effect of renal nerve stimulation on renal blood flow autoregulation and antinatriuresis during reductions in renal perfusion pressure, in Proceedings of the Society for Experimental Biology and Medicine, vol. 168, 77-81, 1981. (Abstract). |
| Packer, Douglas L. et al., Clinical Presentation, Investigation, and Management of Pulmonary Vein Stenosis Complication Ablation for Atrial Fibrillation, Circulation: Journal of the American Heart Association. Feb. 8, 2005. pp. 546-554. |
| Page, I.H., et al., The Effect of Renal Efficiencyof Lowering Arterial Blood Pressure in Cases of Essential Nephritis, Hospital of the Rockefeller Institue, Jul. 12, 1934, 7 pgs. |
| Palmer, Biff, F., M.D., Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System, Aug. 5, 2004, The New England Journal of Medicine 2004, vol. 351;6, 2004 Massachusetts Medical Society, pp. 585-592. |
| Pappone, Carlo et al., [2005][P2-70] Safety Report of Circumferential Pulmonary Vein Ablation. A 9-Year Single-Center Experience on 6,442 Patients with Atrial Fibrillation, Abstract only. 1 page, May 2005. |
| Pappone, Carlo et al., [2004][759] Pulmonary Vein Denervation Benefits Paroxysmal Atrial Fibrillation Patients after Circumferential Ablation, Abstract only. 1 page, Jan. 5, 2004. |
| Pappone, Carol and Santinelli, Vincenzo. Multielectrode basket catheter: A new tool for curing atrial fibrillation? Heart Rhythm, vol. 3, Issue 4, pp. 385-386. Apr. 2006. |
| Peacock, J.M. and R. Orchardson, Action potential conduction block of nerves in vitro by potassium citrate, potassium tartrate and potassium oxalate, May 6, 1998, Journal of Clinical Periodontology, Munksgaard 1999, vol. 26, pp. 33-37. |
| Petersson, M. et al., Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005;26:906-13. |
| Pettersson, A. et al., Renal interaction between sympathetic activity and ANP in rats with chronic ischaemic heart failure, Nov. 25, 1988, Acta Physiol Scand 1989, 135, pp. 487-492. |
| PHCL 762 Pharmacology of the Autonomic Nervous System, Chapter 2 and 6.8 in Mosby, http://www.kumc.edu/research/medicine/pharmacology/CAI/phcl762.html, last accessed Aug. 24, 2004, 14 pgs. |
| Pitt, B. et al., Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy: The 4E-Left Ventricular Hypertrophy Study, Circulation, 2003, vol. 108, pp. 1831-1838. |
| Pliquett, U., Joule heating during solid tissue electroporation, Oct. 22, 2002, Med. Biol. Eng. Comput., 2003, vol. 41, pp. 215-219. |
| Podhajsky R.J. et al., The Histologic Effects of Pulsed and Continuous Radiofrequency Lesions at 42 C to Rat Dorsal Root Ganglion and Sciatic Nerve, SPINE, vol. 30, No. 9, 2005, Lippincott Williams & Wilkins Inc., pp. 1008-1013. |
| Pope, Jill. Fixing a Hole: Treating Injury by Repairing Cells. The New York Academy of Sciences. Jul. 6, 2006. 6 pgs. |
| Popovic, Jennifer R. and Margaret J. Hall, 1999 National Hospital Discharge Survey, Apr. 24, 2001, Advance Data, No. 319, CDC, pp. 1-17 & 20. |
| Practice Guidelines Writing Committee and ESH/ESC Hypertension Guidelines Committee, Practice Guidelines for Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines, Published in Journal of Hypertension 2003, vol. 21, No. 10: 1011-1053, European Society of Hypertension 2003, pp. 1779-1786. |
| Programmable Infusion System, Pumps and Pump Selection, Medtronic Pain Therapies, Medtronic, Inc. Sep. 5, 2001, 2 pgs. |
| Pucihar, Gorazd et al., The influence of medium conductivity on electropermeabilization and survival of cells in vitro, May 31, 2001, Bioelectrochemistry, vol. 54, 2001, Elsevier Science B.V. 2001, pp. 107-115. |
| Pulmonary Concepts in Critical Care Breath Sounds, http://rnbob.tripod.com/breath.htm, last accessed Aug. 23, 2004, 5 pages. |
| Pulmonary Function Testing, http://jan.ucc.nau.edu/˜daa/lecture/pft.htm, last accessed Aug. 23, 2004, 8 pages. |
| Purerfellner, Helmut and Martinek, Martin. Pulmonary vein stenosis following catheter ablation of atrial fibrillation. Current Opinion in Cardiology. 20; pp. 484-490. 2005. |
| Purerfellner, Helmut et al., Pulmonary Vein Stenosis by Ostial Irrigated-Tip Ablation: Incidence, Time Course, and Prediction, Journal of Cardiovascular Electrophysiology. vol. 14, No. 2, Feb. 2003. pp. 158-164. |
| Raji, A. R. M. and R. E. M. Bowden, Effects of High-Peak Pulsed Electromagnetic Field on the Degeneration and Regeneration of the Common Peroneal Nerve in Rats, The Journal of Bone and Joint Surgery Aug. 1983, vol. 65-B, No. 4, 1983 British Editorial Society of Bone and Joint Surgery, pp. 478-492. |
| Ram, C. Venkata S., M.D., Understanding refractory hypertension, May 15, 2004, Patient Care May 2004, vol. 38, pp. 12-16, 7 pages from http://www. patientcareonline.com/patcare/content/printContentPopup.jsp?id=108324. |
| Ravalia, A. et al., Tachyphylaxis and epidural anaesthesia, Edgware General Hospital, Correspondence, p. 529, Jun. 1989. |
| Renal Parenchymal Disease, Ch. 26, 5th Edition Heart Disease, A Textbook of Cardiovascular Medicine vol. 2, Edited by Eugene Braunwald, WB Saunders Company, pp. 824-825 1997. |
| Ribstein, Jean and Michael H. Humphreys, Renal nerves and cation excretion after acute reduction in functioning renal mass in the rat, Sep. 22, 1983, Am. J. Physiol., vol. 246, 1984 the American Physiological Society, pp. F260-F265. |
| Richebe, Philippe, M.D. et al., Immediate Early Genes after Pulsed Radiofrequency Treatment: Neurobiology in Need of Clinical Trials, Oct. 13, 2004, Anesthesiology Jan. 2005, vol. 102, No. 1, 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., pp. 1-3. |
| Rihal, Charanjit S. et al., Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention, Mar. 6, 2002, Circulation May 14, 2002, vol. 10, 2002 American Heart Association, Inc., pp. 2259-2264. |
| Rosen, S.M. et al., Relationship of Vascular Reactivity to Plasma Renin Concentration in Patients with Terminal Renal Failure, Proc. Dialysis Transplant Forum 1974, pp. 45-47. |
| Roth, Bradley J. and Peter J. Basser, A Model of the Stimulation of a Nerve Fiber by Electromagnetic Induction, IEEE Transactions on Biomedical Engineering, vol. 37, No. 6, Jun. 1990, pp. 588-597. |
| Rudin, Asa, M.D. et al., Postoperative Epidural or Intravenous Analgesia after Major Abdominal orThoraco-Abdominal Surgery, The Journal of the American Society of Anesthesiologists, Inc., Anesthesiology 2001, vol. 95, A-970, 1 page. |
| Rudnick, Michael R. et al., Contrast-induced nephropathy: How it develops, how to prevent it, Cleveland Clinic Journal of Medicine Jan. 2006, vol. 73, No. 1, pp. 75-87. |
| Rump, L.C., The Role of Sympathetic Nervous Activity in Chronic Renal Failure, J Clinical Basic Cardiology 2001, vol. 4, pp. 179-182. |
| Ruohonen, Jarmo et al., Modeling Peripheral Nerve Stimulation Using Magnetic Fields, Journal of the Peripheral Nervous System, vol. 2, No. 1, 1997, Woodland Publications 1997, pp. 17-29. |
| Saad, Eduardo B. et al., Pulmonary Vein Stenosis After Radiofrequency Ablation of Atrial Fibrillation: Functional Characterization, Evolution, and Influence of the Ablation Strategy, Circulation. 108; pp. 3102-3107. 2003. |
| Sabbah, Hani N., Animal Models for Heart Failure and Device Development, Henry Ford Health System. 24 slides, Oct. 17, 2005. |
| Schauerte, P et al., Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system, Journal of Cardiovascular Electrophysiology. 12(5). May 2001. Abstract only. 2 pgs. |
| Schauerte, P et al., Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation, Circulation. 102(22). Nov. 28, 2000. Abstract only. 2 pgs. |
| Schauerte, P et al., Transvenous parasympathetic nerve stimulation in the inferior vena cava and atrioventricular conduction, Journal of Cardiovascular Electrophysiology. 11 (1). Jan. 2000. Abstract only. 2 pgs. |
| Scheiner, Avram, Ph.D., The design, development and implementation of electrodes used for functional electrial stimulation, Thesis paper, Case Western Reserve University, May 1992, 220 pages. |
| Scherlag, BJ and Po, S., The intrinsic cardiac nervous system and atrial fibrillation, Current Opinion in Cardiology. 21(1):51-54, Jan. 2006. Abstract only. 2 pgs. |
| Schlaich, M.P. et al., Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-5. |
| Schlaich, M.P. et al., Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation, Hypertension, 2004, 43:169-175. |
| Schmitt, Joseph et al., Intravascular Optical Coherence Tomography—Opening a Window into Coronary Artery Disease, LightLab Imaging, Inc. Business Briefing: European Cardiology 2005. |
| Schoenbach, Karl H. et al., Intracellular Effect of Ultrashort Electrical Pulses, Dec. 26, 2000, Bioelectromagnetics, vol. 22, 2001, Wiley-Liss, Inc. 2001, pp. 440-448. |
| Schrier, Robert et al., Cardiac and Renal Effects of Standard Versus Rigorous Blood Pressure Control in Autosomal-Dominant Polycistic Kidney Disease, Mar. 23, 2002, Journal of the American Society of Nephrology, American Society of Nephrology 2002, pp. 1733-1739. |
| Scremin, Oscar U., M.D., Ph.D. and Daniel P. Holschneider, M.D., 31 & 32 . . . . An Implantable Bolus Infusion Pump for the Neurosciences, FRP, Apr. 2005, 3 pages. |
| Sensorcaine—MPF Spinal Injection, informational document, AstraZeneca 2001, 2 pgs. |
| Shah, D.C., Haissaguerre, M., Jais, P., Catheter ablation of pulmonary vein foci for atrial fibrillation: pulmonary vein foci ablation for atrial firbrillation, Thorac Cardiovasc Surg, 1999, 47 (suppl. 3): 352-356. |
| Shannon, J.L. et al., Studies on the innervation of human renal allografts, J Pathol. 1998, vol. 186, pp. 109-115. |
| Shlipak, M.G. et al., The clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514-7. |
| Shupak, Naomi M., Therapeutic Uses of Pulsed Magnetic-Field Exposure: A Review, Radio Science Bulletin Dec. 2003, No. 307, pp. 9-32. |
| Shu-Qing, Liu et al., Old spinal cord injury treated by pulsed electric stimulation, General Hospital of Beijing Command, Beijing, Dec. 6, 1990, 5 pages (full article in Chinese; abstract on last page). |
| Siegel, RJ et al., Clinical demonstration that catheter-delivered ultrasound energy reverses arterial vasoconstriction, Journal of the American College of Cardiology. 1992. 20; 732-735. Summary only. 2 pgs. |
| Simpson, B. et al., Implantable spinal infusion devices for chronic pain and spasticity: an accelerated systematic review, ASERNIP-S Report No. 42, Adelaide, South Australia, ASERNIP-S, May 2003, 56 pages. |
| Sisken, B.F. et al., 229.17 Influence of Non-Thermal Pulsed Radiofrequency Fields (PRF) on Neurite Outgrowth, Society for Neuroscience, vol. 21, 1995, 2 pages. |
| Skeie, B. et al., Effect of chronic bupivacaine infusion on seizure threshold to bupivacaine, Dec. 28, 1986, Acta Anaesthesiol Scand 1987, vol. 31, pp. 423-425. |
| Skopec, M., A Primer on Medical Device Interactions with Magnetic Resonance Imaging Systems, Feb. 4, 1997, CDRH Magnetic Resonance Working Group, U.S. Department of Heatlh and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Updated May 23, 1997, 17 pages, http://www.fda.gov/cdrh/ode/primerf6.html, (last accessed Jan. 23, 2006. |
| Slappendel, Robert et al., The efficacy of radiofrequency lesioning of the cervical spinal dorsal root ganglion in a double blinded randomized study, Jun. 26, 1997, Pain 73, 1997 International Association for the Study of Pain, Elsevier Science B.V., pp. 159-163. |
| Sluijter, M.D., Ph.D., Pulsed Radiofrequency, May 17, 2005, Anesthesiology Dec. 2005, vol. 103, No. 6, 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., pp. 1313-1314. |
| Sluijter, M.D., Ph.D., Radiofrequency Part 1: The Lumbosacral Region, Chapter 1 Mechanisms of Chronic Pain and part of Chapter 2 Spinal Pain, 2001 FlivoPress SA, Meggen (LU), Switzerland, pp. 1-26. |
| Sluijter, M.D., Ph.D., Radiofrequency Part 2: Thoracic and Cervical Region, Headache and Facial Pain, various pages from, FlivoPress SA, Meggen (LU), Switzerland, 13 pages 2002. |
| Sluijter, M.D., Ph.D., The Role of Radiofrequency in Failed Back Surgery Patients, Current Review of Pain 2000, vol. 4, 2000 by Current Science Inc., pp. 49-53. |
| Smithwick, R.H. et al., Hypertension and associated cardiovascular disease: comparison of male and female mortality rates and their influence on selection of therapy, JAMA, 1956, 160:1023-1033. |
| Smithwick, R.H., Surgical treatment of hypertension, Am J Med 1948, 4:744-759. |
| Sobotka, Paul A., Treatment Strategies for Fluid Overload, CHF Patients, CHF Solutions. Transcatheter Cardiovascular Therapeutics 2005. 20 slides. |
| Solis-Herruzo, J.A. et al., Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome, Journal of Hepatology, 1987; 5: 167-173. |
| Souza, D.R.B. et al., Chronic experimental myocardial infarction produces antinatriuresis by a renal nerve-dependent mechanism, Oct. 14, 2003, Brazilian Journal of Medical and Biological Research 2004, vol. 37, pp. 285-293. |
| Standl, Thomas, M.D., et al., Patient-controlled epidural analgesia reduces analgesic requirements compared to continuous epidural infusion after major abdominal surgery, Aug. 29, 2002, Canada Journal of Anesthesia 2003, vol. 50 (3), pp. 258-264. |
| Steffen, W. et al., Catheter-delivered high intensity, low frequency ultrasound induces vasodilation in vivo, European Heart Journal. 1994. 15; pp. 369-376. |
| Steg, PG et al., Pulsed ultraviolet laser irradiation produces endothelium-independent relaxation of vascular smooth muscle, Circulation: Journal of the American Heart Association. 1989. pp. 189-197. |
| Stone, Gregg W., M.D. et al., Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy, JAMA Nov. 5, 2003, vol. 290, No. 17, 2003 American Medical Association, pp. 2284-2291. |
| Strojek, K. et al., Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12:602-5. |
| Summary, Critical Reviews in Biomedical Engineering, vol. 17, Issue 5, 1989, pp. 515-529. |
| Sung, Duk Hyun, M.D. et al., Phenol Block of Peripheral Nerve Conduction: Titrating for Optimum Effect, Jun. 27, 2000, Arch. Phys. Med. Rehabil. Vol. 82, May 2001, pp. 671-676. |
| Taka, Tomomi et al., Impaired Flow-Mediated Vasodilation in vivo and Reduced Shear-Induced Platelet Reactivity in vitro in Response to Nitric Oxide in Prothrombotic, Stroke-Prone Spontaneously Hypertensive Rats, Pathophysiology of Haemostasis and Thrombosis. Dec. 23, 2002. pp. 184-189. |
| Taler, Sandra J. et al., Resistant Hypertension, Comparing Hemodynamic Management to Specialist Care, Mar. 12, 2002, Hypertension 2002, vol. 39, 2002 American Heart Association, Inc., pp. 982-988. |
| Tamborero, David et al., Incidence of Pulmonary Vein Stenosis in Patients Submitted to Atrial Fibrillation Ablation: A Comparison of the Selective Segmental Ostial Ablation vs. the Circumferential Pulmonary Veins Ablation, Journal of Intervocational Cardiac Electrophysiology. 14; pp. 41-25. 2005. |
| Tay, Victoria KM, et al., Computed tomography fluoroscopy-guided chemical lumbar sympathectomy: Simple, safe and effective, Oct. 31, 2001, Diagnostic Radiology, Australasian Radiology 2002, vol. 46, pp. 163-166. |
| Terashima, Mitsuyasu et al. Feasibility and Safety of a Novel CryoPlasty™ System. Poster. 1 page, Mar. 15, 2002. |
| Thatipelli et al., CT Angiography of Renal Artery Anatomy for Evaluating Embolic Protection Devices, Journal of Vascular and Interventional Radiology, Jul. 2007, pp. 842-846. |
| The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ALLHAT Research Group, JAMA, 2002, vol. 288, pp. 2981-2997. |
| Thomas, John R. and Oakley, E. Howard N. Chapter 15: Nonfreezing Cold Injury Medical Aspects of Harsh Environments, vol. 1. pp. 467-490, 2001. |
| Thompson, Gregory W., et al., Bradycardia Induced by Intravascular Versus Direct Stimulation of the Vagus Nerve, Aug. 24, 1997, The Society of Thoracic Surgeons 1998, pp. 637-642. |
| Thrasher, Terry N., Unloading arterial baroreceptors causes neurogenic hypertension, Dec. 4, 2001, Am J. Physiol Regulatory Integrative Comp Physiol, vol. 282, 2002 the American Physiological Society, pp. R1044-R1053. |
| Tokuno, Hajime A. et al., Local anesthetic effects of cocaethylene and isopropylcocaine on rat peripheral nerves, Oct. 7, 2003, Brain Research 996, 2004, Elsevier B.V. 2003, pp. 159-167. |
| Trapani, Angelo J. et al., Neurohumoral interactions in conscious dehydrated rabbit, Am. J. Physiol. 254, 1988, the American Physiological Society 1988, pp. R338-R347. |
| Trock, David H. et al., The Effect of Pulsed Electromagnetic Fields in the Treatment of Osteoarthritis of the Knee and Cervical Spine. Report of Randomized, Double Blind, Placebo Controlled Trials, Mar. 22, 1994, The Journal of Rheumatology 1994, vol. 21, pp. 1903-1911. |
| Troiano, Gregory C. et al., The Reduction in Electroporation Voltages by the Addition of a Surfactant to Planar Lipid Bilayers, May 12, 1998, Biophysical Journal, vol. 75, Aug. 1998, the Biophysical Society 1998, pp. 880-888. |
| Trumble, Dennis R. and James A. MaGovern, Comparison of Dog and Pig Models for Testing Substernal Cardiac Compression Devices, Nov. 2003, ASAIO Journal 2004, pp. 188-192. |
| Tsai, E., Intrathecal drug delivery for pain indications, technique, results, Pain Lecture presentation, Jun. 8, 2001, 31 pages. |
| Uematsu, Toshihiko, M.D., Ph.D., F.I.C.A et al., Extrinsic Innervation of the Canine Superior Vena Cava, Pulmonary, Portal and Renal Veins, Angiology—Journal of Vascular Diseases, Aug. 1984, pp. 486-493. |
| Upadhyay, Pramod, Electroporation of the skin to deliver antigen by using a piezo ceramic gas igniter, Jan. 27, 2001, International Journal of Pharmaceutics, vol. 217, 2001 Elsevier Science B.V., pp. 249-253. |
| Valente, John F. et al., Laparoscopic renal denervation for intractable ADPKD-related pain, Aug. 24, 2000, Nephrol Dial Transplant 2001, vol. 16, European Renal Association-European Dialysis and Transplant Association, p. 160. |
| Van Antwerp, Bill and Poonam Gulati, Protein Delivery from Mechanical Devices Challenges and Opportunities, Medtronic presentation, 19 pages, Jul. 2003. |
| Velazquez, Eric J., An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry, Aug. 5, 2004, European Heart Journal vol. 25, 2004 Elsevier, pp. 1911-1919. |
| Velez-Roa, Sonia, M.D. et al., Peripheral Sympathetic Control During Dobutamine Infusion: Effects of Aging and Heart Failure, Jul. 7, 2003, Journal of the American College of Cardiology, vol. 42, No. 9, 2003, American College of Cardiology Foundation 2003, pp. 1605-1610. |
| Villarreal, Daniel et al., Effects of renal denervation on postprandial sodium excretion in experimental heart failure, Oct. 29, 1993, Am J Physiol 266, 1994, pp. R1599-R1604. |
| Villarreal, Daniel et al., Neurohumoral modulators and sodium balance in experimental heart failure, Nov. 6, 1992, Am. J. Physiol, vol. 264, 1993, pp. H1187-H1193. |
| Vonend, O. et al., Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709-17. |
| Wald, Jan D., Ph.D, et al., Cardiology Update: 2003, Sep. 11, 2003, AG Edwards 2003, 120 pages. |
| Wang, Xi et al., Alterations of adenylyl cyclase and G proteins in aortocaval shunt-induced heart failure, Jul. 2004, Am J Physiol Heart Circ Physiol vol. 287, 2004 the American Physiological Society, pp. H118-H125. |
| Weaver, James C., Chapter 1 Electroporation Theory, Concepts and Mechanisms, Methods in Molecular Biology, vol. 55, Plant Cell Electroporation and Electrofusion Protocols, Edited by J.A. Nickoloff, Humana Press Inc., pp. 3-28, 1995. |
| Weaver, James C., Electroporation: A General Phenomenon for Manipulating Cells and Tissues, Oct. 22, 1992, Journal of Cellular Biochemistry, vol. 51, 1993 Wiley-Liss, Inc., pp. 426-435. |
| Weiner, Richard L., M.D., Peripheral nerve neurostimulation, Neurosurg. Clin. N. Am. vol. 14, 2003, Elsevier, Inc. 2003, pp. 401-408. |
| Weisbord, Steven D., M.D. and Paul M. Palevsky, M.D., Radiocontrast-Induced Acute Renal Failure, Jul. 10, 2004, Journal of Intensive Care Medicine 2005, vol. 20 (2), 2005 Sage Publications, pp. 63-75. |
| Whitelaw, G.P., Kinsey, D., Smithwick, R.H., Factors influencing the choice of treatment in essential hypertension: surgical, medical, or a combination of both, Am J Surg, 1964, 107:220-231. |
| Wilson, D.H. et al., The Effects of Pulsed Electromagnetic Energy on Peripheral Nerve Regeneration, Annals New York Academy of Sciences, Oct. 1974, pp. 575-585. |
| Wolinsky, Harvey, M.D. PhD and Swan N. Thung, M.D., Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery, Aug. 30, 1989, JACC 1990, vol. 15, 1990 by the American College of Cardiology, pp. 475-481. |
| Wyss, J. Michael et al., Neuronal control of the kidney: Contribution to hypertension, Apr. 8, 1991, Can. J. Physiol. Pharmacol. 1992;70: 759-770. |
| Yamaguchi, Jun-ichi, M.D et al., Prognostic Significance of Serum Creatinine Concentration for In-Hospital Mortality in Patients with Acute Myocardial Infarction Who Underwent Successful Primary Percutaneous Coronary Intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] Registry), Feb. 24, 2004, The American Journal of Cardiology vol. 93, Jun. 15, 2004, 2004 by Excerpta Medica, Inc., pp. 1526-1528. |
| Ye, Richard D., M.D., Ph.D., Pharmacology of the Peripheral Nervous System, E-425 MSB, 6 pages, Jan. 2000. |
| Ye, S et al., A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11:723-8. |
| Ye, Shaohua et al., Renal Injury Caused by Intrarenal Injection of Pheno Increases Afferent and Efferent Renal Sympathetic Nerve Activity, Mar. 12, 2002, American Journal of Hypertension, Aug. 2002, vol. 15, No. 8, 2002 the American Journal of Hypertension, Ltd. Published by Elsevier Science Inc., pp. 717-724. |
| Yong-Quan, Dong et al., The therapeutic effect of pulsed electric field on experimental spinal cord injury, Beijing Army General Hospital of People's Liberation Army, Beijing, 5 pages (full article in Chinese; abstract on last page) Mar. 30, 1992. |
| Young, James B., M.D., FACC, Management of Chronic Heart Failure: What Do Recent Clinical Trials Teach Us?, Reviews in Cardiovascular Medicine, vol. 5, Suppl. 1, 2004, MedReviews, LLC 2004, pp. S3-S9. |
| Yu, Wen-Chung et al. Acquired Pulmonary Vein Stenosis after Radiofrequency Catheter Ablation of Paroxysmal Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. vol. 12, No. 8. Aug. 2001. pp. 887-892. |
| Zanchetti, A. et al., Neural Control of the Kidney-Are There Reno-Renal Reflexes?, Clin. and Exper. Hyper. Theory and Practice, A6 (1&2), 1984, Marcel Dekker, Inc. 1984, pp. 275-286. |
| Zanchetti, A. et al., Practice Guidelines for Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines, Journal of Hypertension, vol. 21, No. 10, 2003, pp. 1779-1786. |
| Zanchetti, A.S., Neural regulation of renin release: Experimental evidence and clinical implications in arterial hypertension, Circulation, 1977, 56(5) 691-698. |
| Zimmermann, Ulrich, Electrical Breakdown, Electropermeabilization and Electrofusion, Rev. Physiol. Biochem. Pharmacol., vol. 105, Springer-Verlag 1986, pp. 175-256. |
| Zoccali, C. et al., Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-9. |
| Zucker, Irving H. et al., The origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide, Progress in Biophysics & Molecular Biology, vol. 84, 2004, Elsevier Ltd. 2003, pp. 217-232. |
| Zundert, Jan Van, M.D. FIPP and Alex Cahana, M.D. DAAPM, Pulsed Radiofrequency in Chronic Pain Management: Looking for the Best Use of Electrical Current, Pain Practice 2005, vol. 5, Issue 2, 2005 World Institute of Pain, pp. 74-76. |
| Abruzzo, Provvidenza et al., “Oxidative stress in the denervated muscle,” Free Radical Research, vol. 44, No. 5, 2010, 563-576. |
| Amsellem S. et al., “Cubilin is Essential for Albumin Reabsorption in the Renal Proximal Tubule,” J Am Soc Nephril, vol. 21, 2010,1859-1867. |
| Andres, Vicente, “Control of vascular cell pro;iferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential,” Cardiovascular Research, vol. 63, 2004, 11 pages. |
| Ankri, R. et al., “In-vivo Tumor detection using diffusion reflection measurements of targeted gold nanorods—a quantitative study,” Biophotonics, 2012, 11 pages. |
| Bengatta, S. et al., “MMP9 and SCF Protect from Apoptosis in Acute Kidney Injury,” J Am Soc Nephril, vol. 20, 2009, 787-797. |
| Bhattacharya, S. et al. “Role of p38 Protein Kinase in the Ligand-independent Ubiquitination and Down-regulation of the IFNAR1 Chain of Type I Interferon Receptor,” The Journal of Biological Chemistry, vol. 286 No 25, 2011,22069-22076. |
| Bisoffi, M. et al., “Detection of viral bioagents using a shear horizontal surface acoustic wave biosensor,” Biosensors and Bioelectronics, vol. 23, 2008, 7 pages. |
| Centi et al., “Strategies for electrochemical detection in immunochemistry,” Bioanalysis, vol. 1. No. 7, 2009, 21 pages. |
| Dange, M. et al., “Each Conserved Active Site Tyr in the Three Subunits of Human Isocitrate Dehydrogenase Has a Different Function,” The Journal of Biological Chemistry, vol. 285, No. 27, 2010, 6 pages. |
| Darisipudi, M. et al., “Dual Blockade of the Homeostatic Chemokine CXCL 12 and the Proinflammatory Chemokine CCL2 Has Addictive Protective Effects on Diabetic Kidney Disease,” The American Journal of Pathology, vol. 179, No. 1, 2011, 9 pages. |
| Dhruvajyoti, Roy et al., ““Seeing and Counting” Individual antigens Captured on a Microarrayed Soit with Force-Based Atomic Force Microscopy,” Anal. Chem. vol. 82, 2010 6 pages. |
| Dikow, Ralf et al., “In Renal Transplants With Delayed Graft Function Chemokines and Chemokine Receptor Expression Predict Long-Term Allograft Function, ”Transplantation, vol. 90, 2010, 71-776. |
| Dinish, U. et al., “Highly sensitive SERS detection of cancer proteins in low sample volume using hollow core photonic crystal fiber,” Biosens, Bioelecton, 2012, 6 pages. |
| Dorr et al., “Soluble fms-Like Tyrosine Kinase-1 and Endothelial Adhesion Molecules (Intercellular Cell Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1) as Predictive Markers for Blood Pressure Reduction After Renal Sympathetic Denervation.” Hypertension, 2014, 63, pp. 984-990. |
| Ford, M. et al., “Expression of fibroblast growth factors and their receptors in rat glomeruli,” Kidney International, vol. 51, 1997, 10 pages. |
| Fragiadaki, Maria et al., “Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo,” Matrix Biology, vol. 30, 2011, 396-403. |
| Frostick, S. et al., “Schwann Cells, Neurotrophic Factors, and Peripheral Nerve Regeneration,” Microsurgery, vol. 18, 1998, 9 pages. |
| Gaikwad, A. et al., “Epigenetic changes and alteration of Fbn1 and Col3A1 gene expression under hyperglycaemic and hyperinsulinaemic conditions,” Biochem. J., vol. 432, 2010, 10 pages. |
| Green, H., et al., “Development of ERK Activity Sensor, an in vitro, FRET-based sensor of Extracellulat Regulated Kinase activity,” BMC Chemical Biology, vol. 5, No. 1 ,2005, 8 pages. |
| Grishman, Ellen et al., “Toll-like receptors, the NLRP3 inflammasome, and interleukin-1β in the development and progression of type 1 diabetes,” Pediatric Research, vol. 71, No. 6, 2012, 7 pages. |
| Heberlein, Annemarie et al., BDNF plasma levels decrease during benzodiazepine withdrawal in patients suffering from comorbidity of depressive disorder and benzodiazepine dependence, Psychopharmacology, vol. 209, 2010, 3 pages. |
| Hervas, M. et al., “Electrochemical immunosensing on board microfluidic chip platforms,” Trends in Analytical Chemistry, vol. 31, 2012, 20 pages. |
| Higgins, J, et al., “Gene Expression in the Normal Adult Human Kidney Assessed by Complementary DNA Microarray,” Molecular Biology of the Cell, vol. 15, 2004, 649-656. |
| Hirst, E., “Bond-rupture immunosensors—A review,” Biosensors and Bioelectronics, vol. 23, 2008, 10 pages. |
| Horke, S. et al., “Paraoxonase-2 Reduces Oxidative Stress in Vascular Cells and Decreases Endoplasmic Reticulum Stress-Induced Caspase Activation,” Circulation, vol. 115, 2007, 11 pages. |
| Ihling, C. et al., “Endothelin-1 and Endothelin Converting Enzyme-1 in Human Atherosclerosis—Novel Targets for Pharmacotherapy in Atherosclerosis,” Current Vascular Pharmacology, vol. 2, 2004, 10 pages. |
| Jacobs, C. et al.,“ Review: Carbon nanotube based electrochemical sensors for biomolecules,” Analytical Chimica Acta, vol. 662, 2010, 23 pages. |
| Jin, Xinghua et al., “Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array,” Anti-Cancer Drugs, vol. 23, No. 4, 2012, 10 pages. |
| Johnson, B. et al., “Biosensing using dynamic-mode cantilever sensors: A review,” Biosensors and Bioelectronics, vol. 32, 2012, 18 pages. |
| Kasuno, Kenji et al., “Clinical Application of Urinary Redox Regulating Protein,” Thioredoxin, Rinsho Byori, vol. 59, 2011, 189-195. |
| Kerr, Heather et al., “Complement-mediated injury and protection of enforhelium: Lessons from atypical haemolytic uraemic syndrome,” Immunobiology, vol. 217, 2012, 195-203. |
| Kinoshita, Yukiko et al., “Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis,” Translational Research, vol. 158, No. 4, 2011, 15 pages. |
| Klosterhalfen, B. et al., “Influence of Heat Shock Protein 70 and Metallothionein Induction by Zinc-bis-(DL-Hydrogenaspartate) on the Release of Inflammatory Mediators in a Porcine Model of Recurrent Endotoxemia.” Biochemical Pharmacology, vol. 52, 1996, 1201-1210. |
| Kopp, “Endothelin in the Control of Renal Sympathetic Nerve Activity,” Contrib Nephrol. Basel, Karger, vol. 172, 2011, 107-119. |
| Kopp, Ulla C. et al., “Impaired Interaction Between Efferent and Afferent Renal Nerve Activity in SHR Involves Increased Activation of α2-Adrenoceptors,” vol. 57, 2011, 640-647. |
| Kourtzelis, L., et al., “Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis,” Blood, 116, No. 4, 2010 9 pages. |
| Krukoff, Teresa L. et al., “Effects of renal denervation and reinnervation on ganglionic gene expression of neurotransmitter proteins and c-fos in rat,” Molecular Brain Research, vol. 19, 1993, 6 pages. |
| Lan, Hui Yao, Transforming growth factor-β/Smad signalling in diabetic nephropathy, Clinical and Experimental Pharmacology and Physiology, vol. 39, 2012, 731-738. |
| Lantero, A. et al., “Transforming Growth Factor-β in Normal Nociceptive Processing and Pathological Pain Models,” Mol Neurobiol, vol. 45, 2012, 76-86. |
| Lechner, Stefan et al., “Regulation of neuronal ion channels via P2Y receptors,” Purinergic Signalling, vol. 1, 2004, 31-41. |
| Lee, Y. et al., “Fibromodulin Suppresses Nuclear Factor-κB Activity by Inducing the Delayed Degradation of IKBA via a JNK—dependent Pathway Coupled to Fibroblast Apoptosis,” The Journal of Biological Chemistry, vol. 286, No. 8, 2011, 9 pages. |
| Leguillon-Buffello, D. et al., “An Alternative Quantitative Acoustical and Electrical Method for Detection of Cell Adhesion Process in Real-Time,” Biotechnology and Bioengineering, vol. 108, No. 4, 2011, 16 pages. |
| Leonard, M., et al., “Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury,” The FASEB Journal, vol. 20, 2006, 3 pages. |
| Liang, W. et al., “A novel microfluidic immunoassay system based on electrochemical immunosensors: An application for the detection of NT-proBNP in whole blood,” Biosensors and Bioelectronics, vol. 31, 2012, 6 pages. |
| Liu, Bin et al., “Role of cyclooxygenase-1-mediated prostacyclin synthesis in endothelium-dependent vasoconstrictor activity of porcine interlobular renal arteries,” Am J Physiol Renal Physiol, vol. 302, 2012, F1133-F1140. |
| Liu, Y. et al., “BID Binds to Replication Protein A and Stimulates ATR Function following Replicative Stress,” Molecular and Cellular Biology, vol. 31, No. 21, 2011, 12 pages. |
| Liu, Yanxin et al., “A novel SNP ofthe ATP1A1 gene is associated with heat tolerance traits in dairy cows,” vol. 38, 2011, 83-88. |
| Liu, Ying et al., “Induction of KLF4 in response to heat stress,” Cell Stress & Champerones, vol. 11, No. 4, 2006, 379-389. |
| Liu, Yong et al., “Renal Medullary MicroRNAs in Dahl Salt-Sensitive Rats: miR-29b Regulates Several Collagens and Related Genes,” Hypertension, vol. 55, 2010, 974-982. |
| Lloyd-Burton, S. et al., “SPARC-Like 1 (SC1) is a Diversely Expressed and Developmentally Regulated Matricellular Protein That Does Not Compensate for the Absence of SPARC in the CNS,” The Journal of Comparative Neurology: Research in Systems Neuroscience, vol. 520, 2012, 2575-2590. |
| Lo, Denise et al., “Chemokines and their Receptors in Human Renal Allotransplantation,” Transplantation, Author manuscript; available in PMC, 2012, 14 pages. |
| Longley, C. D. et al., “Proportions of Renal and Splenic Postganglionic Sympathetic Populations Containing Galanin and Dopamine Beta Hydroxylase,” Neuroscience, vol. 55, No. 1, 1993, 9 pages. |
| Lu, X. et al., “The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities,” Current Medicinal Chemistry, vol. 17, 2010, 957-973. |
| Luo, Lin, “Gene expression profiles of laser-captured adjacent neuronal subtypes,” Nature Medicine, vol. 5, No. 1, 1999, 6 pages. |
| Ma, Frank, et al., “TGF-β1-activated kinase-1 regulated inflammation and fibrosis in the obstructed kidney,” Am J. Physiol Renal Physiol, vol. 300, 2011, 12 pages. |
| Maeshima, A. et al., “Activin A: Autocrine Regulator of Kidney Development and Repair,” Endocrine Journal, vol. 55, No. 1, 2008 9 pages. |
| Maity, Tapan et al., “Distinct, Gene Specific Effect of Heat Shock on Heat Shock Factor-1 Recruitment and Gene Expression of CXC Chemokine Genes,” Cytokine, Author manuscript, available in PMC, 2012, 14 pages. |
| Mas, Valeria et al., “Gene Expression Patterns in Deceased Donor Kidneys Developing Delayed Graft Function After Kidney Transplantation,” Transplantation, vol. 85, No. 4, 2008, 10 pages. |
| Mazanowska, O et al. “Imbalance of Metallaproteinase/Tissue Inhibitors of Metalloproteinase System in Renal Transplant Recipients With Chronic Allograft Injury.” Transplantation Proceedings, vol. 43, 2011, 4 pages. |
| Messina, G., et al., “Microfluidic immunosensor design for the quantification of interleukin-6 in human serum samples,” Analytical Biochemistry, vol. 380, 2008, 6 pages. |
| Metters, J. et al., “New directions in screen printed elctroanalytical sensors: an overview of recent developments,” Analyst, vol. 136, 2011, 10 pages. |
| Musial K., et al., “Heat shock proteins in chronic kidney disease,” Journal of the International Pediatric Nephrology Association, 2010, 9 pages. |
| Nakaya, R. et al., “Identification of proteins that may directly interact with human RPA,” J. Biochem, vol. 148, No. 5, 2010, 9 pages. |
| Nath, N. et al., “Evanescent wave fibre optic sensor for detection of L. donovani specific antibodies in sera of kala azar patients,” Biosensors & Bioelectronics, 1996, 8 pages. |
| Obeidat, Motaz A., et al., “Post-transplant nuclear renal scans correlate with renal injury biomarkers and early allograft outcomes,” Nephrol Dial Transplant, vol. 26, 2011, 8 pages. |
| Orellana G. et al., “New Trends in Fiber-Optic Chemical and Biological Sensors,” Current Analytical Chemistry, vol. 4, 2008, 23 pages. |
| Pache, G. et al., “Upregulation of Id-1 via BMP-2 receptors induces reactive oxygen species in podocytes,” Am J Physiol Renal Physiol, vol. 291, 2006, 9 pages. |
| Panini, N. et al., “Integrated microfluidoc systems with an immunosensor modified with carbon nanotubes for detection of prostate specific antigen (PSA) in human serum samples,” Biosensors and Bioelectronics, vol. 23, 2008, 7 pages. |
| Paulis, L. et al., “Novel therapeutic targets for hypertension,” Nature Reviews: Cardiology, vol. 7, 2010, 11 pages. |
| Pereira, Rui et al., “Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure,” Hemodialysis International, vol. 14, 2010, 7 pages. |
| Ransom, Richard F. et al., “Differential proteomic analysis of proteins induced by gluecocorticoids in cultured murine podocytes,” Kidney International, vol. 67, 2005, 1275-1285. |
| Reich, Heather N. et al., “Molecular Markers of Injury in Kidney Biopsy Specimens of Patients with Lupus Nephritis,” The Journal of Molecular Diagnostics, vol. 13, No. 2, 2011, 9 pages. |
| Romanenko, Alina et al., “p16INK4A and p15INK4B Gene Alteration Associated with Oxidative Stress in Renal Cell Carcinomas After the Chernobyl Accident (Pilot Study),” Diagnostic Molecular Pathology,vol. 11, No. 3, 2002, 163-169. |
| Ruotsalainen, V. et al., “Nephrin is specifically located at the slit diaphragm of glomerular podocytes,” Proc. Natl. Acad. Sci. USA, vol. 96, 1999, 6 pages. |
| Rusling, J. et al., “Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer,” Analyst, Author manuscript, available in PMC, 2010, 31 pages. |
| Rusnati, M. et al., “Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity,” Sensors, vol. 9, 2009, 33 pages. |
| Sadik, O. et al., “Status of biomolecular recognition using electrochemical techniques,” Biosensors and Bioelectronics, vol. 24, 2009, 17 pages. |
| Saito, S. et al., “Analysis of glial cell line-derived neurotrophic factor-inducible zinc finger protein 1 expression in human diseased kidney,” Human Pathology, col. 42, 2011, 11 pages. |
| Sataranatarajan, K. et al., “Regulation of Elongation Phase of mRNA Translation in Diabetic Nephropathy,” The American Journal of Pathology, vol. 171, No. 6, 2007, 10 pages. |
| Sigdel, Tara K. et al., “Shotgun Proteomics Identifies Proteins Specific for Acute Renal Transplant Rejection,” Proteomics Clin Appl. Author manuscript; available in PMC 2010, 27 pages. |
| Snigdha, Shikha et al., “Caspase-3 activation as a bifurcation point between plasticity and cell death,” Neurosci Bull, vol. 28, No. 1, 2012, 11 pages. |
| Soleimani, M., “Dietary fructose, salt absorption and hypertension in metabolic syndrome: towards a new paradigm,” Acta Physiol, vol. 201, 2011, 55-62. |
| Sonna, L. et al., “Molecular Biology of Thermoregulation Invited Review: Effects of heat and cold stress on mammalian gene expression,” J Appl Physiol, vol. 92, No. 1725, 2002, 17-42. |
| Struckmann, Kirsten et al., “Impaired Expression of the Cell Cycle Regulator BTG2 is Common in Clear Cell Renal Cell Carcinoma,” Cancer Res, vol. 64, 2004, 1632-1638. |
| Su, Y. et al., “Chromatic immunoassay based on polydiacetylene vesicles,” Colloids and Surfaces B: Biointerfaces, vol. 38, 2004, 5 pages. |
| Sun, A. et al., “Sensitive label-free electrochemical immunoassay based on a redox matrix of gold nanoparticles/Azure l/multi-wall carbon nanotubes composite,” Biochemical Engineering Journal, vol. 57, 2011, 6 pages. |
| Sun, Dong et al., “Thrombospondin-1 Short Hairpin RNA Suppresses Tubulointerstitial Fibrosis in the Kidney of Ureteral Obstruction by Ameliorating Peritubular Capillary Injury,” Kidney Blood Press Res, vol. 35, 2012, 6 pages. |
| Tiniakos, D. et al, “Ontogeny of intrinsic innervation in the human kidney,” Anat Embryol, vol. 209, 2004, 7 pages. |
| Todorov, Vladimir et al., “Differential Regulation of Cathepsin B and Prorenin Gene Expression in Renal Juxtaglomerular Cells,” Kidney Blood Press Res, vol. 24, 2001, 4 pages. |
| Trimarchi, Hernan et al., “Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis,” International Journal of Nephrology and Renovascular Disease, vol. 5, 2012, 7 pages. |
| Vivekanandan, A. et al., “Urine Glycoprotein Profile Reveals Novel Markers for Chronic Kidney Disease,” International Journal of Proteomics, 2011, 18 pages. |
| Waalkes et al., “Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer,” Cancer, vol. 10, 2010, 6 pages. |
| Wang, Bao-Ying et al., Hepatotoxicity and gene expression down-regulation of CYP isozymes caused by Yenal ischemia/reperfusion in the rat, Experimental and Toxicologic Pathology 61 (2009) 169-176. |
| Wong, Dona L. et al., “Adrenergic Responses To Stress: Transcriptional and Post-Transcriptional Changes,” Ann N Y Acad Sci. Author manuscript; available in PMC, 2009, 10 pages. |
| Wu, Huiling et al., “TLR4 activation mediates kidney ischemia/reperfusion injury,” The Journal of Clinical Investigation, vol. 117, No. 10, 2007, 2847-2859. |
| Xie, Chaoqin, “Ablation of Transient Receptor Potential Vanilloid 1 Abolishes Endothelin-lnduced Increases in Afferent Renal Nerve Activity: Mechanisms and Functional Significance,” Hypertension, vol. 54, 2009, 1298-1305. |
| Xie, Chaoqin, Interdependent Regulation of Afferent Renal Nerve Activity and Renal Function: Role of Transient Receptor Potential Vanilloid Type 1, Neurokinin 1, and Calcitonin Gene-Related Peptide Receptors, The Journal of Pharmacology and Experimental Therapeutics, vol. 325, No. 3, 7 pages. |
| Yoshino, Jun et al., “Leukemia Inhibitory Factor is Involved in Tubular Regeneration after Experimental Acute Renal Failure,” J Am Soc Nephrol, vol. 14, 2003, 3090-3101. |
| Yuan, B. et al., “Gene expression reveals vulnerability to oxidative stress and interstitial fibrosis of renal outer medulla to nonhypertensive elevations of ANG II,” Am J. Physiol Regul Integr Comp Physiol, vol. 284, 2003, 12 pages. |
| Zager, Richard et al., “Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and “end-stage” kidney disease,” Am J Physiol Renal Physiol, vol. 301, 2011, 12 pages. |
| Zeisberg, Michael, “Bone morphogenic protein-7 and the kidney: current concepts and open questions,” Nephrol Dial Transplant, vol. 21, 2006, 6 pages. |
| Zerega, Barbara et al., “Expression of NRL/NGAL (neu-related lipocalin/neutrophil gelatinase-associated lipocalin) during mammalian embryonic development and in Inflammation.” European Journal of Cell Biology, vol. 79, 2000 8 pages. |
| Zhang, Weiru et al. “Interleukin 6 Underlies Angiotensin II—Induced Hypertension and Chronic Renal Damage,” Hypertension, vol. 59, 2012, 136-144. |
| Zhao, Hongcheng et al., “Activation of the Transcription Factor Oct-1 in Response to DNA Damage,” Cancer Res, vol. 60, 2000, 6 pages. |
| Staal, S.S., et al., “A Prefilled, Ready-to-Use, Electrophoresis-Based Lab-on-a-Chip Device for Monitoring Ions in Blood and Urine.” 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Oct. 3-7, 2010, Groningen, The Netherlands. 3 pages. |
| Rusling, James F., “Nanomaterials-Based Electrochemical Immunosensors for Proteins.” The Chemical Record, 12 (1), Feb. 2012. 13 pages. |
| Yanase, Yuhki, et al., “Development of an Optical Fiber SPR Sensor for Living Cell Activation.” Biosensors and Bioelectronics, 25 (5), Jan. 15, 2010. 16 pages. |
| Chinushi et al., “Blood Pressure and Autonomic Responses to Electrical Stimulation of the Renal Arterial Nerves Before and After Ablation of the Renal Artery.” Hypertension, 2013, 61, pp. 450-456. |
| Pokushalov et al., “A Randomized Comparison of Pulmonary Vein Isolation With Versus Without Concomitant Renal Artery Denervation in Patients With Refractory Symptomatic Atrial Fibrillation and Resistant Hypertension.” Journal of the American College of Cardiology, 2012, 8 pages. |
| Extended European Search Report for Application No. 17208077.2, dated Jun. 4, 2018, 11 pages. |
| Examination Report from Canada Application No. 2,865,242, dated Aug. 13, 2021, 3 pages. |
| International Preliminary Report on Patentability from PCT App. No. PCT/US2013/030041, dated Sep. 9, 2014, 12 pages. |
| Wisniewski, Jack R., “Mass Spectrometry-Based Proteomics, Principles, Perspectives, and Challenges”, Arch Pathol Lab Med—vol. 132, Oct. 2008, 4 pages. |
| “Relative Quantitation Using Comparative CT Getting Started Guide”, Applied Biosystems 7300/7500/7500 Fast Real-Time PCR System, 2006 (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 2006, is sufficiently earlier than the effective U.S. filing date, so that the particular month of publication is not in issue), 120 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20180042535 A1 | Feb 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61608625 | Mar 2012 | US | |
| 61608626 | Mar 2012 | US | |
| 61746528 | Dec 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15296925 | Oct 2016 | US |
| Child | 15667901 | US | |
| Parent | 13791681 | Mar 2013 | US |
| Child | 15296925 | US |
